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ABSTRACT  
Aspartic Proteases are proteolytic enzymes involved in a large number of biological 
processes, playing an essential role in several important diseases. Their inhibitors 
have emerged as useful drugs in the treatment of cancer, parasitic, fungal and viral 
infections as well as inflammatory, immunological, respiratory, cardiovascular and 
neurodegenerative disorders.  
Acquired Immunodeficiency Syndrome (AIDS) and Alzheimer Disease (AD) are 
controlled by aspartic proteases, HIV-Pr and BACE-1 respectively. HIV-Pr plays an 
essential role in the replication and maturation of the Human Immunodeficiency 
Virus, while BACE-1 is involved in the production and deposition of amyloid--
peptide (A), recognized as a possible cause for AD.  
Aspartic proteases inhibitors can be classified into the two major categories of 
peptidomimetic and nonpeptide inhibitors. The former, designed to emulate their 
natural substrates, are oligopeptides containing a not-hydrolizable dipeptide isostere. 
Currently, many designed potent and selective protease peptidomimetic  inhibitors 
of the human immunodeficiency virus protease (HIV-1 Pr) are used in the treatment 
of AIDS as they efficiently slow down or halt disease progression.  
Even very potent in vitro peptidomimetic  BACE-1 inhibitors were developed but 
their poor pharmacokinetic profile has prevented them from being further developed 
to oral bioavailable CNS drug. Thus, more recent attempts have been directed 
towards the discovery of small non peptidic inhibitors, that have higher blood brain 
barrier penetration and are capable to efficiently bind the active site of the enzyme 
lowering the production of A protein. 
This thesis is divided in two parts.  
In the frame of a research activity aimed at the design and synthesis of 
peptidomimetic HIV-Pr inhibitors, the first part of this work is focused on the 
synthesis of chiral optically pure -allylamines as key intermediates for the 
stereoselective synthesis of dipeptidic isosters. In particular, in chapter 2 the 
development of a revised version of Julia olefination is described, that allowed the 
obtainment of a small library of -aminoalkenes derived from Ala, Ileu, Leu, Phe, 
Pro, Tyr, Val with good yields and exccellent e.e.s. With respect to the original Julia 
 reaction, in this modified version -aminoesters derived from aminoacids are 
employed as the starting material,  this avoiding the use of the aminoaldehydes 
normally used in the classical olefination methods, whose reproducibility is often 
affected by the low configurational and chemical stability of -chiral parent 
aldehydes.  
The second part of the thesis deals with the synthesis and biological evaluation of 
functionalized 3,4-dihydropyrimidines (DHPMs) as BACE 1 inhibitors. This 
heterocyclic scaffold is present in many biologically and pharmacologically active 
compounds and it possesses the requisite features for an effective inhibitory activity 
against BACE-1, as shown by our preliminary studies run (Chapter 4) on a group of 
3,4-dihydropyrimidinones (X = O) e 3,4-dihydropyrimidinthiones (X = S), with 
measured affinities in the micromolar range. 
 
With the aim of obtaining inhibitors with improved potency, the study was extended 
to 2-iminoDHPMs having a guanidine group embedded in the heterocyclic scaffold, 
due to the structural features of the guanidine moiety, suitable for an optimal 
interaction with BACE-1 active site. The library of DHPMs was obtained by 
Biginelli reaction in which  a variety of different aliphatic and aromatic aldehydes, 
were reacted -dicarbonylic compounds  and with urea, thiourea and guanidine.   
Molecular docking experiments (Chapter 5) assisted the choice of the most 
appropriate substituents to append on the heterocyclic scaffold; inhibitory activity 
was determined measuring IC50 values (Chapter 5), with fluorimetric assays using 
the FRET technique. 
In chapter 5 we describe some preliminary approaches to the obtainment of DHPM 
as single enantiomers, through resolution techniques or chiral auxiliary based 
stereoselective synthesis.  
  
ABSTRACT 
Le proteasi aspartiche sono enzimi proteolitici coinvolti in un gran numero di 
importanti processi biologici e svolgono un ruolo chiave in  diverse importanti 
patologie.  La loro inibizione è una strategia che si è rivelata utili nel trattamento di 
malattie fra cui alcuni tipi di tumore, infezioni fungine, parassitiche e virali, nonché 
malattie infiammatorie, immunologiche, respiratorie cardiovascolari e 
neurodegenerative.  
Sia l’AIDS (Sindrome da Immunodeficienza Acquisita) che il morbo di Alzheimer 
(AD) sono regolati da proteasi aspartiche, rispettivamente l’HIV-proteasi e la BACE-
1. La prima è coinvolta nel processo di maturazione e replicazione del virus da HIV, 
mentre BACE-1 è alla base dello sviluppo di placche amiloidi, costituite da 
oligopeptidi di tipo A, e considerate una possibile causa di AD. 
Inibitori delle proteasi aspartiche possono essere classificati in due categorie 
principali, quella dei peptidomimetici e dei non-peptidici. I primi sono piccoli 
oligopeptidi che mimano il substrato naturale dell’enzima in quanto contengono un 
isostere  dipeptidico non idrolizzabile.  Attualmente diversi inibitori di questo tipo 
sono usati con successo nel trattamento dell’AIDS, per la loro capacità di rallentare o 
bloccare il progresso della malattia. Al contrario, la strategia basata su inibitori 
peptidomimetici si è rivelata non produttiva nel caso della BACE-1, in quanto alcuni 
di questi, pur essendo molto potenti in vitro, sono risultati inefficaci  in vivo a causa 
del loro elevato peso molecolare e scarso profilo farmacocinetico. L’attenzione si è 
perciò in questo caso spostata su piccole molecole a carattere non peptidico, in grado 
di oltrepassare la barriera ematoencefalica e quindi di abbassare la produzione di 
proteina A anche in vivo. 
La prima parte di questa tesi di dottorato si sviluppa all’interno di un progetto più 
ampio rivolto alla progettazione e sintesi di inibitori peptidomimetici dell’HIV-
proteasi e riguarda la sintesi di -allilammine chirali otticamente pure come 
intermedi chiave nella sintesi stereoselettiva di isosteri dipeptidici.  
In particolare nel capitolo 2 è descritta la messa a punto di una variante della 
reazione di olefinazione di Julia. che ha consentito di ottenere una piccola libreria di 
-amminoalcheni derivati da Ala, Ileu, Leu, Phe, Pro, Tyr, Val con buone rese e 
 eccellenti eccessi enantiomerici. La modifica rispetto alla versione originale della 
reazione è consistita nell’impiegare -amminoesteri derivati da amminoacidi naturali 
come substrati, al posto delle -amminoaldeidi normalmente usate nelle reazioni di 
olefinazione, la cui affidabilità e riproducibilità sono spesso condizionate dalla 
instabilità configurazionale e chimica dei precursori aldeidici con chiralità in 
posizione alfa. 
Nella seconda parte della tesi è descritta la sintesi e valutazione biologica di 3,4-
diidropirimidine (DHPMs) funzionalizzate come inibitori di BACE-1. Questo 
scaffold eterociclico, opportunamente funzionalizzato, è presente in molti sistemi 
biologicamente e farmacologicamente attivi ed ha le caratteristiche  richieste per 
un’efficace inibizione della BACE 1, come mostrato dai nostri  studi preliminari 
(Capitolo 5) condotti su una libreria di 3,4-diidropirimidinoni (X = O) e 3,4-
diidropirimidintioni (X = S) che hanno evidenziato affinità nell’ordine del 
micromolare. 
 
Con l’obiettivo di aumentare l’attività inibitoria abbiamo poi modificato la struttura 
di questi composti introducendo nello scaffold diidropirimidinico un motivo 
guanidinico, individuato come unità in grado di interagire più efficacemente con il 
sito attivo dell’enzima.  
L’approccio sintetico utilizzato si basa sulla reazione di Biginelli,  in cui oltre che 
l’urea e la tiourea è stata usata guanidina cloridrato, e come partners di reazione  
aldeidi alifatiche e aromatiche, e composti -dicarbonilici..  
La scelta dei diversi sostituenti da introdurre sullo scaffold eterociclico è stata 
supportata da esperimenti di docking molecolare (capitolo 5) mentre l’ attività 
inibitoria è stata valutata tramite misure di IC50 eseguite mediante saggi enzimatici di 
fluorescenza basati sulla tecnica FRET 
Nel capitolo 5 sono descritti anche alcuni preliminari approcci all’ottenimento delle 
DHPMs in forma enantiomericamente pura, attraverso risoluzione delle miscele 
raceme che risultano dalla reazione o attraverso sintesi stereoselettiva mediata da 
ausiliarichirali. 
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Introduction 
1. Proteases  
Proteases are a class of enzymes that selectively catalyze the hydrolysis of peptide 
bonds in proteins and polypeptides. The human genome encodes over 500 proteases, 
making this class one of the largest families of enzymes.
1
  
Proteases play a crucial role in physiological as well as in pathological 
processes related to important diseases. As a consequence, protease inhibitors are 
emerging as useful drugs in the treatment of cancer, parasitic, fungal and viral 
infections (e.g. schistosomiasis, malaria, C.albicans, AIDS, hepatitis, herpes), 
inflammatory, immunological, respiratory, cardiovascular and neurodegenerative 
disorders including Alzheimer's disease
2
. 
Proteases can be classified into four classes: aspartic, serine, cysteine and 
metalloproteases.
3
 While cysteine and serine hydrolases use the nucleophilic side 
chain of an aminoacid residue for the catalytic reaction, in aspartic and 
metalloproteases the nucleophile attacking the scissile peptide bond is a water 
molecule which is activated directly, as in aspartic peptidases, or by binding to one 
or two metal ions, as in the metallopeptidases. Typically, each protease has a 
dipeptide target (Table 1) and the knowledge of their specific sequences can be an 
excellent starting point for the design of new inhibitors.
4
  
  
                                                 
1 H.V Motwani, M. De Rosa; L.R. Odell, A. Hallberg, M. Larhed, Eur. J. Med. Chem., 2015, 90, 
462. 
2 a. B. Schmidt, ChemBioChem 2003, 4, 366; b. M. S. Craik and C. Debouck, in Perspectives in 
Drug Discovery and Design,: J. H. McKerrow and M. N.G. James, Eds, ESCOM, Leiden,1995, 
Volume 2, pp 1–125, c. C. Seife, Science, 1997, 277, 1602. 
3 O. Kohei, J. Biochem., 2012, 151, 13. 
4 N. D. Rawlings, G. Salvesen, Handbook of Proteolytic Enzymes, Elsevier, 2013. 
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Protease Type Dipeptide target 
BACE1  
(β-site APP cleaving enzyme 1) 
Aspartic human Leu-Ala 
HIV-PR 
(Human Immunodeficiency Virus 
Protease) 
Aspartic viral Phe-Pro 
Gastricsin Aspartic human Tyr/Ala, Leu, Ser, Thr 
Papain Viral cysteine Hydrophobic aa-Arg/Lys 
uPA urokinase Serine human Arg/Val 
Table 1. Target sequences for representative proteases 
 
1.1 Aspartyl Proteases 
Aspartyl proteases are so named because they use two aspartic acid residues (Asp) to 
activate the scissile amide bond and a water molecule in the active site, thus 
promoting the catalytic cleavage of the peptide substrate. These proteases represent 
the smallest class of peptidases, comprising only 15 members, and they can be 
classified into two main groups AA and AD according to their tertiary structure. The 
AA group can be further divided into two families: the A1 family, which includes the 
classic aspartic proteases (BACE1, BACE2, cathepsin D, cathepsin E, pepsin, pepsin 
C, renin and napsina), and A2 family, including HIV-PR, which can be integrated in 
the human genome by retroviruses. The AD group is constituted by presenilin and by 
other peptidases capable of hydrolysing peptide bonds within a transmembrane 
region.
5
  
Enzymes belonging to the A1 family are monomeric bilobed, with the active 
site located between the lobes, and an Asp residue on each lobe. The peptidases of 
the A2 family are homodimers with a single lobe bearing one catalytic Asp. These 
proteases are active only in dimeric form and the active site is located between the 
two monomeric units (Figure 1). 
 
                                                 
5 J. Eder, U. Hommel, F. Cumin, B. Martoglio and B. Gerhartz, Current Pharmaceutical Design, 
2007, 13, 271. 
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Figure 1.Schematic structure of monomeric aspartyl proteases (a: renin; b: plasmepsin) and dimeric 
proteases (c: HIV-1 Pr; d: EIAV protease) 
 
All aspartic proteases have two triads Asp-Thr/Ser-Gly which form the 
catalytic site through a network of hydrogen bonds called “fireman’s grip”. Inside 
the active site, aspartic proteases generally bind 6-10 aminoacids of their 
polypeptide substrates.
6
 The side chains of the polypeptide substrate are hosted 
within subsites of the protease catalytic site. According to the nomenclature of 
Schechter and Berger,
7
 the amino acid residues at the N-terminus of the scissile bond 
are indicated with P1 ... Pn, which correspond to the protease’s subsites S1 ... Sn; the 
residues at C-terminus are indicated with P1 '... .Pn', corresponding to subsites S1'... 
Sn' (Figure 2).  
 
Figure 2. Schechter and Berger’s nomenclature for describing the protease subsites and the side 
chains of the substrates (the scissile bond is indicated in green). 
                                                 
6 M. N. G. James, A. R. Sielecki, Biological Macromolecules and Assemblies: Active Sites of  Enzymes; 
John Wiley & Sons: New York, 1987, Volume 3, 413. 
7 I. Schechter, A Berger. Biochem. Biophys. Res. Commun., 1967, 27, 157.  
a b 
c 
d 
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Furthermore, some aspartic proteases also have one or more flaps that close down 
on top of the bound substrate interacting with it and increasing the basis for 
selectivity. 
 
1.1.1  Hydrolysis Mechanism 
The accepted mechanism for aspartic proteases is a general acid-base mechanism 
involving the coordination of a water molecule between the two aspartate residues. 
One aspartate activates water by abstracting a proton, enabling the water to attack the 
carbonyl carbon of the substrate scissile bond, generating a tetrahedral oxyanion 
intermediate whose rearrangement mediated by the protonated Asp residue finally 
results in the amine and carboxylic acid fragments
8
 (Scheme 1).  
Several aspartic proteases are known to be involved in pathological disorders 
caused by dysfunctions of their proteolytic activity, such as for example BACE 1 
whose overexpression is related to the onset of Alzheimer’s disease;9  others are 
included in viruses that once in the human body alter the normal regulation of 
biological processes, as for example HIV-PR that is involved in the proliferation and 
maturation of HIV-virus, the causative agent of AIDS.
10
  
 
                                                 
8R. Mannhold, H. Kubinyi, G. Folkers, Wiley-VCH, Aspartic acid proteases as therapeutic targets, 
2010, 29. 
9 R. Vassar, B. D. Bennett, S. Babu-Khan, S. Kahn, E. A. Mendiaz, P. Denis, D. B. Teplow, S. 
Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M. A. Jarosinski, 
A. L. Biere, E. Curran, T. Burgess, J. Louis, F. Collins, J. Treanor, G. Rogers, M. Citron, 
Science, 1999, 286, 735. 
10 A. M.J. Wensing, N. M. van Maarseveen, M. Nijhuis, Antiviral Research, 2010, 85, 59. 
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Scheme 1. Hydrolytic mechanism of aspartyl proteases 
 
1.2 Human Immunodeficiency Virus (HIV) and AIDS 
Acquired Immune Deficiency Syndrome (AIDS) is a severe immunological disease 
caused by HIV virus, resulting in a defect in cell-mediated immunity that is 
manifested by increased susceptibility to opportunistic infections and to development 
of rare cancers, which increases with the progression of the disease. There are many 
different strains of HIV virus, but HIV-1 is the most common type found worldwide.  
HIV-1 belongs to the class of retroviruses, in which the genetic information is 
enclosed in single strands of RNA. The virus has a spherical structure with a 
diameter of about 130 nm and is constituted by a lipid bilayer membrane and a core; 
each viral particle contains 72 glycoprotein complexes integrated into the lipid 
membrane. The core is a proteic capsid consisting, containing two identical strands 
of RNA and three enzymes involved in the viral replication, i.e. reverse transcriptase 
(RT), integrase (IN) and protease (PR). 
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Three genes encode for the viral proteins: Gag encodes for the proteins of the 
virion core, Pol for the three fundamental enzymes, and Env for the outer envelope 
proteins (Figure 3).
11
 
 
   
Figure 3. HIV replication cycle 
 
Helper T lymphocytes are the host cells for HIV virus. They possess CD4 
receptors on the outer membrane, which bind the gp120 glycoprotein of the viral 
membrane. Subsequently the viral and the cell membrane merge and the core of the 
virus is released into the host.
12
  
Currently there is no cure for AIDS; however, therapies based on the treatment 
with HIV-PR inhibitors (nelfinavir, ritonavir, and indinavir, etc) in combination with 
RT inhibitors, have changed the nature of the disease from a terminal illness to a 
manageable one. Nonetheless, the onset of drug resistance due to mutant viral strains 
                                                 
11a. F. Barré-sinoussi, A. L. Ross and J. Delfraissy, Nat. Rev. Microbiol., 2013, 11, 877; b. V. W. 
Pollard M. H. Malim, Annu. Rev. Microbiol., 1998, 52, 491.  
12 D. C. Chan and P. S. Kim, Cell, 1998, 93, 681. 
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makes the development of new inhibitors still a strong priority for pharmaceutical 
research.
10 
 
1.2.1 HIV Protease (HIV-PR) 
HIV-PR plays an essential role in the replication cycle of the HIV-1 virus. HIV-PR 
cleaves polyproteins PR55gag and PR160gag/pol (expressed by gag and pol genes) 
allowing maturation of a new viral particle. Since HIV-PR is a common target for 
anti-HIV therapy, it has become one of the most studied enzymes in terms of 
function and structure. 
HIV-PR in its active form is a C2 symmetric homodimer. The monomers, 
containing 99 amino acid residues, assemble to form a long tunnel closed by two 
flexible regions (flaps). The active site is located at the centre of the tunnel, with the 
catalytic Asp residues (Asp25 and Asp25’) at the bottom of the cavity.13 The stability 
of the dimer mostly depends on a network of intermolecular hydrogen bonds 
between β sheets located in the proximity of the N- and C-terminals of the two 
monomers. 
The carboxylate groups of the catalytic Asp residues located on each chain 
are nearly coplanar and show close contacts between two oxygen atoms (2.8-3 Å), 
indicating the presence of a bridging acidic proton. A water molecule also bridges 
the carboxylate residues, within hydrogen bond distance to the oxygen atoms of 
both. Similar water molecules are found also in nonviral proteases and are likely to 
be the catalytic water in this family of enzymes. 
In the presence of a substrate, the flaps open and wrap around the substrate’s 
protein chain, holding it tightly in the tunnel, through interactions responsible for the 
selectivity observed in catalysis (Figure 4, Figure 5).
14
  
                                                 
13 D. R. Davies, Annu. Rev. Biophys. Biophys. Chern, 1990, 19, 189. 
14 A. Wlodawer and J. Vondrasek, Annu. Rev. Biophys. Biomol. Struct., 1998, 27, 249. 
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Figure 4. Crystal structures of HIV-1 PR in the closed and open (PDB 1HVR and 1TW7) 
conformations. In red the “flaps”, in blue the hinge loop, cyan sticks are the catalytic aspartates. 
 
 
Figure 5. Schematic diagram of the hydrogen bonds between the active site and the polyprotein 
 
1.2.2 HIV-PR inhibitors 
HIV-PR is among the most studied enzymes in terms of function and structure, and 
due to its essential role in the maturation and replication cycle of the HIV-1 virus it 
has become one of the most important therapeutic targets for the treatment of AIDS. 
HIV-PR active site, as for the majority of aspartic proteases, does not contain 
groups that can be chemically modified by irreversible inhibitors. Only strong 
electrophiles, such as epoxides, can alkylate the catalytic Asp groups, but they are 
cytotoxic.
15
 Therefore, reversible inhibitors were designed and developed with 
                                                 
15 B. Said, D. C. Matsumoto, A. K. Hamade, R. C. Shank, Biochem, Biophys, Res. Commun., 1999, 
261, 844. 
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groups that interact with the active site through non-covalent interactions, so as to 
have higher affinity for the proteolytic site than its natural substrate.   
A successful approach to the design of efficient inhibitors, according to 
Pauling’s principle, 16  is based on peptidomimetic structures containing a non-
hydrolysable isoster of the scissile dipeptide that mimics the stereo-electronic 
features of the tetrahedral TS for amide bond hydrolysis (transition state analog).
17
 In 
Figure 6 are shown several transition-state analogs that have been successfully used 
in the design of aspartic protease inhibitors.
18
  
 
 
Figure 6. Some dipeptide isosters 
                                                 
16 L. Pauling, Chem. Eng. News., 1946, 24, 1375. 
17 A. Brik and C-H. Wong Org. Biomol. Chem., 2003,1, 5. 
18 a. A. Wlodawer, J. W. Erickson, , Annu. Rev. Biochem., 1993, 62, 543; b. J. A. Martin, S. 
Redshaw, G. J.Thomas, Progress in Medicinal Chemistry, 1995, 32, 239; c. C. A. Chen, S. M. 
Sieburth,; A. Glekas, G. W. Hewitt, G. L. Trainor, S. E. Vitanen,; S. S. Garber, B. Cordova; S. 
Jeffry, R. M.Klabe, Chem. Biol., 2001, 8, 1161; d. J. M. Ahn, N. A. Boyle, M. T. MacDonald, K. 
D. Janda, , Mini Rev. Med. Chem., 2002, 2, 463. 
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HIV-PR selectively performs hydrolysis of peptide bonds between two 
hydrophobic residues and a bond between an amino acidic residue containing an 
aromatic ring and a proline is cleaved in three of the nine sites of proteolytic 
cleavage on the viral polyprotein (Figure 7).
19
 The ability to hydrolyze amide bonds 
to proline (Prolylpeptidase class of enzymes) is a peculiarity of viral proteases; 
eukaryotic proteases do not have this ability and this has made Phe-Pro and Tyr-Pro 
isosters good candidates for the selective inhibition of viral proteases.
20
  
 
 
Figure 7. Cleavage sites of viral polyproteins 
 
Several representative examples of HIV-PR inhibitors approved by FDA for 
anti HIV-therapy are shown in Figure 8. It can be seen that the presence of a 
hydroxylated dipeptide isoster is a peculiar characteristic of many inhibitors. In 
Saquinavir, Nelfinavir and Indinavir this structural motif is associated to a Phe-Pro 
dipeptide isoster, in which proline is replaced by larger heterocyclic groups 
(decahydroisoquinoline in Saquinavir and Nelfinavir; piperazine in Indinavir), that 
provide better  interactions with the  protease’s S1' sub-site.  
 
                                                 
19a. P. L. Darket, R. F. Nutt, S. F. Brady, V. M. Garsky, T. M. Ciccarone, C. Leu, P. K. 
Lumma, R. M. Freidinger, D. F. Veber and I. S. Sigal, Biochem Biophys Res Commun, 1988, 156, 
297; b. L. Pearl, W. Taylor, Nature, 1987, 328, 482. 
20 N.A. Roberts, J. A. Martin, D.Kinchington, A.V. Broadhurst, J.C. Craig, I.B. Duncan, S.A. 
Galpin, B.K. Handa, J. Kay, A. Krohn, R.W. Lambert, J.H. Merrett, J.S. Mills, K.E.B. Parkes, 
S. Redshaw, A.J. Ritchie, D.L. Taylor, G.J. Thomas, P. Machin, Science, 1990, 248, 358. 
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Figure 8. HIV-Pr inhibitors 
 
Peptidomimetic inhibitors of HIV-PR contain multiple chiral centres, some of which 
are located on the central isoster (see, for example, Figure 8). The observation that 
the absolute configuration of these stereocentres has an important impact on the 
inhibitor’s activity 21  has fostered the development of methodologies for the 
stereoselective synthesis of hydroxylated dipeptide isosters.
22
  
Chiral, enantiomerically pure, 1,4-diaminoalkenes (b, Scheme 2) are 
interesting in this respect because many methods exist for the stereoselective 
hydroxylation and dihydroxylation of alkenes
23
 which, in this case, would lead to 
hydroxyethylene(c) and dihydroxyethylene(c’) dipeptide isosters, as shown in 
Scheme 2. Cross-metathesis of chiral allylamines is, in turn, an attractive approach to 
                                                 
21 a. K.-H. Budt, A. Peyman, J. Hansen, J. Knolle, C. Meichsner, A. Paessens, D. Ruppert, B. 
Stowasser, Bioorg. Med. Chem. 1995, 5, 559; b. M. V. Hosur, T. N. Bhat, D. J. Kempf, E. T. 
Baldwin, B. Liu, S. Gulnik, N. E. Wideburg, D. W. Norbeck, K. Appelt, J. W.Erickson, J. Am. 
Chem. Soc. 1994, 116, 847; c. Vondràsˇek, M. Hradıìlek,, M. Soucek, I. Pichovà, P. Majer, P. 
Strop, J. Sedlàcek, A.-M. Heuser, H. Kottler, H.-G. Kräusslich, Eur. J. Biochem. 1997, 250, 559. 
22 A. Tossi, F. Benedetti, S. Norbedo, D. Skrbec, F. Berti, D. Romeo, Bioorg. Med. Chem. 2003, 
11, 4719; F. Benedetti, F. Berti, G. Garau, I. Martinuzzi and S. Norbedo Eur. J. Org. Chem. 2003, 
1973. F. Benedetti, F. Berti, S. Budal, P. Campaner, F. Dinon, A. Tossi, R. Argirova, P. 
Genova, V. Atanassov, and A. Hinkov, J. Med. Chem. 2012, 55, 3900. 
23  a. A. K. Ghosh, G. Bilcer, G.Schiltz, Synthesis 2001, 2203; b. H. C. Kolb, M.S. 
VanNieuwenhze, K. B. Sharpless Chem. Rev., 1994, 94, 2483; c. D. J. Ager, I. Prakash, and D. R. 
Schaad, Chem. Rev. 1996, 96, 835. 
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the synthesis of 1,4-diaminoalkenes
24
 (Scheme 2) and is currently being 
investigated.
25
 
 
 
Scheme 2. Retrosynthesis analysis of hydroxyethylene and dihydroxyethylene dipeptide isosters 
 
A prerequisite for the approach outlined in Scheme 2 is the availability of reliable 
and affordable methods for the synthesis of chiral allylamines in enantiomerically 
pure form, which will be the subject of the first part of this thesis (chapter 2). Chiral 
allylamines, however, are valuable compounds per se. For this reason the subject 
will be briefly reviewed in the following chapter. 
 
1.3  Chiral allylamines 
Allylamines are of significant interest as synthetic intermediates and compounds of 
biological interst.
 26,27,28
 The allylamine fragment is present in natural products
29,30,31
 
and other biologically-active compounds,
32,33,34
 including drugs for the treatment of 
                                                 
24 a. H.E. Blackwell, D.J. O'Leary, A.K. Chatterjee, R.A. Washenfelder, D.A. Bussmann, and 
R. H. Grubbs, J. Am. Chem. Soc., 2000, 122, 58; b. S.J. Connon, S. Blechert, Angew.Chem. Int. 
Ed. 2003, 42, 1900; c. R. H. Grubbs, Tetrahedron , 2004, 60, 7117; d. C. Deraedt, M. d’Halluin 
and D. Astruc, Eur. J. Inorg. Chem. 2013, 4881. 
25 a. A. Ostric, Università di Trieste Tesi di Dottorato XXIII Ciclo; b. V. Sinisi, unpublished work. 
26 E.M. Skoda, G.C.Davis, P.Wipf, Org. Process Res. Dev. 2012, 16, 26. 
27 S. Nag, S.Batra, Tetrahedron 2011, 67, 8959. 
28 M. Johannsen, K.A. Jørgensen, Chem. Rev. 1998, 98, 1689. 
29 C. Dai, C.R. Stephenson, J. Org. Lett. 2010, 12, 3453. 
30 Y. Nakamura, A.M.Burke, S. Kotani, J.W.Ziller, S.D. Rychnovsky, Org. Lett. 2009, 12, 72. 
31 Z. Ali, I.A. Khan, Phytochemistry 2008, 69, 1037. 
32 Z. Ye, T.F.Brust, V.J Watts, M.Dai, Org. Lett. 2015, 17, 892. 
33 J.S. Foot, M.Deodhar, C.I. Turner, P. Yin, E.M.Van Dam, D.G. Silva, A. Olivieri, A.Holt, 
I.A. McDonald, Bioorganic Med. Chem. Lett. 2012, 22, 3935. 
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mycosis (terbinafine, naftifine),
35
 depression (zimelidine),
36
 motion sickness 
(cinnarizine),
37
 migraine and epilepsy (flunarizine)
38
(Figure 9).  
 
 
Figure 9. Bioactive allylamines 
 
Furthermore, chiral allylamines are valuable organic building blocks for 
the synthesis of optically active compounds, due to the participation of their 
characteristic bifunctional unit into a wide range of different transformations 
(aminations, oxidations, metathesis, etc. (Scheme 3).
26,29,39,40 
  
                                                                                                                                          
34  N. Kitahata, S.-Y.Han, N.Noji, T.Saito, M. Kobayashi, T. Nakano, K.Kuchitsu, K. 
Shinozaki, S. Yoshida, S. Matsumoto, M. Tsujimoto, T.Asami, Bioorg. Med. Chem. 2006, 14, 
5555. 
35 A. Stütz, Angew. Chem. Int. Ed. Engl. 1987, 26, 320. 
36 A. Carlsson, Science 2001, 294, 1021. 
37 G.Towse, J. Laryngol. Otol. 1980, 94, 1009. 
38 M. Bebin, T.P.Bleck, Drugs 1994, 48, 153–171. 
39a. S. B. D. Jarvis, A. B. Charette, Org. Lett. 2011, 13, 1830; b. T. Moriwake, S. Hamano, S. 
Saito, S. Torii, S. Kashino J. Org. Chem. 1989, 54, 4114; c. R. Jumnah, J. M. J. Williams, A.C. 
Williams, Tetrahedron Lett.1993, 34, 6619; d. J. F. Bower, R. Jumnah, A. C. Williams and J. M. 
J. Williams, J. Chem. Soc., Perkin Trans. 1, 1997, 19, 1411; f. K. Burgess, L.T. Liu, B. Pal J. 
Org.Chem. 1993, 58, 4758. 
40 a. J. R. Luly, J. F. Dellaria, J.J. Plattner, J.L. Soderquist, N. Yi Org. Chem. 1987, 52,1487; b. 
A. Albeck, R. Persky, J. Org. Chem. 1994, 59, 653.  
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Scheme 3. Synthetic transformations of allylamines 
 
The asymmetric synthesis
 
of α-chiral allylamines has been the subject of many 
studies
41,42
 resulting in the development of several approaches, among which the 
transition metal-catalyzed asymmetric allylic amination has been extensively 
documented.
41,43,44
  
Other methods include the asymmetric vinylation of imines,
42
 the Overman 
rearrangement of allylic imidates,
45
 the asymmetric hydrogenation of dienamines,
46
 
the transition metal-catalyzed asymmetric allylic C-H amination
47
 and the nitroso-
ene reaction.
48
 Despite the recent advances in asymmetric synthesis, the olefination 
of α-amino aldehydes derived from the chiral pool still remains a valuable synthetic 
                                                 
41 J.F. Hartwig, L.M. Stanley, Acc. Chem. Res. 2010, 43, 1461. 
42 M.T. Robak, M.A. Herbage, J.A. Ellman, Chem. Rev. 2010, 110, 3600. 
43 C.C. Marvin, Comprehensive Organic Synthesis, 2nd ed.; Knochel, P., Molander, G.A., Eds; 
Elsevier: Amsterdam, The Netherlands, 2014; Volume 6, pp. 34. 
44 G. Helmchen, In Iridium Complexes in Organic Synthesis; Oro, L.A., Claver, C., Eds.; Wiley-
VCH: Weinheim, Germany, 2009; pp. 145. 
45 L.E. Overman, N.E. Carpenter, Org. React. 2005, 66, doi:10.1002/0471264180.or066.01. 
46 T.-L. Liu, C.-J. Wang, X. Zhang, Angew. Chem. Int. Ed. Engl. 2013, 52, 8416. 
47 T.A. Ramirez, B. Zhao, Y. Shi, Chem. Soc. Rev. 2012, 41, 931. 
48 M. Baidya, H. Yamamoto, Synthesis 2013, 45, 1931. 
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method as the starting materials can be obtained from the corresponding -
aminoacids.
49,50,51
 The synthesis of chiral allylamines by the Wittig,
52,53,54
 Julia
55,56,57
 
and Peterson
58
 olefination of α-amino aldehydes has been reported, but these 
approaches are often limited by the chemical and configurational instability of α-
amino aldehydes.
50
 
  
                                                 
49 D. Gryko, J. Chalko, J. Jurczak, Chirality 2003, 15, 514. 
50 J. Jurczak, A. Gołebiowski, Chem. Rev. 1989, 89, 149. 
51 M.T. Reetz, Chem. Rev. 1999, 99, 1121. 
52 P. Stallforth, S. Matthies, A. Adibekian, D.G. Gillingham, D. Hilvert, P.H. Seeberger, Chem. 
Commun. 2012, 48, 11987. 
53 Z.-Y. Wei, E.E. Knaus, Synthesis 1994, 1463. 
54 W.S. Saari, T.E. Fisher, Synthesis 1990, 453. 
55 S. Mirilashvili, N. Chasid-Rubinstein, A. Albeck, Eur. J. Org. Chem. 2008, 2008, 3461. 
56 O. Shirota, K. Nakanishi, N. Berova, Tetrahedron 1999, 55, 13643. 
57 M.K. Gurjar, S. Pal, A.V. Rama Rao, Tetrahedron 1997, 53, 4769. 
58 G. Wei, T. Cohen, Synlett 2011, 2011, 2697. 
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2. Results and Discussion 
Allylamines are versatile building blocks in organic synthesis, because their 
characteristic bifunctional unit can undergo a wide range of chemical 
transformations.
26
 Chiral allylamines, in particular, are valuable intermediates for the 
synthesis of a variety of chiral, enantiomerically-pure bioactive compounds.
59,60,61,62 
 Among the methods available for their obtainment, the olefination of α-
aminoaldehydes derived from aminoacids by Wittig,
52,53,54
 Julia
55,56,57
 and Peterson
58
 
olefination, is a procedure of choice. Unfortunately these approaches are often 
limited by the chemical and configurational instability of the the α-amino aldehydes 
starting material.
50
 
In the classical Julia reaction
63,64
 (Scheme 4), a lithiated aryl alkyl sulfone is 
added to an aldehyde to give the corresponding α-hydroxysulfone A (pathway a). 
This, in turn, is converted into the target alkene by in situ acetylation and treatment 
of the resulting α-acetoxysulfone with sodium or magnesium amalgam65 or SmI2.
66
 
The same α-hydroxysulfone A, however, can be obtained in two steps by the 
acylation of the lithiated phenylalkylsulfone with an ester, followed by the reduction 
of the corresponding α-ketosulfone (Scheme 4, pathway b). Chiral allylamines may 
thus be obtained starting from readily-available α-amino esters that are chemically 
and configurationally more stable than α-amino aldehydes. 67  Furthermore, the 
additional step of pathway b is not a limitation, as the latter compounds are generally 
prepared from the corresponding esters in at least one step.
49
 
                                                 
59 P. Szcześniak, S. Stecko, RSC Adv. 2015, 5, 30882.  
60  S. Fustero, A.C. Cuñat, S.Flores, C.Báez, J. Oliver, M.Cynamon, M. Gütschow, M.D. 
Mertens, O.Delgado, G. Tresadern, A.A.Trabanco, Chem. - Eur. J. 2011, 17, 14772.  
61 A.J. Blacker, M.Roy, S. Hariharan, C. Headley, A.Upare, A. Jagtap, K. Wankhede, S.K. 
Mishra, D. Dube, S. Bhise, S. Vishwasrao, N. Kadam, Org. Process Res. Dev. 2011, 15, 331.  
62 R. Martín, M.Alcón, M.A. Pericàs, A.Riera, J. Org. Chem. 2002, 67, 6896. 
63 M. Julia, J.-M.Paris, Tetrahedron Lett. 1973, 14, 4833. 
64 I.E. Markó, J. Pospíšil, In Science of Synthesis; de Meijere, A., Ed.; Thieme: Stuttgart, Germany; 
New York, NY, USA, 2009; Volume 47a; pp. 105. 
65 G.H. Lee, H.K. Lee, E.B. Choi, B.T. Kim; C.S. Pak, Tetrahedron Lett. 1995, 36, 5607. 
66 G.E. Keck, K.A. Savin, M. A. Weglarz, J. Org. Chem. 1995, 60, 3194. 
67 A.R. Katritzky, D. Cheng, J. Li, J. Org. Chem. 1998, 63, 3438. 
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Scheme 4. Julia olefination. 
 
This variant of the Julia reaction has been used in the synthesis of E-alkene 
dipeptide isosteres,
68 , 69
 but its wider scope and general applicability is still 
unexplored. In this study, we have demonstrated that the α-aminoester Julia 
olefination is a convenient method for the synthesis of terminal and disubstituted 
allylamines (Scheme 5).  
  
                                                 
68 C. Charrier, L. Ettouati, J. Paris, Tetrahedron Lett. 1999, 40, 5705.  
69 B. Lygo, Synlett 1992, 793. 
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 R
 
R
1
 R
2
 
a H Me H 
b H CH(Me)2 H 
c H CH2CHMe2 H 
d H CHMeEt H 
e H CH2Ph H 
f H CH2pC6H4OTBDMS H 
g               (CH2)3 H 
h H CH2Ph Me 
i (CH2)3 R Me 
a: PhSO2CH3(2a) or PhSO2CH2CH3(2b), nBuLi, THF, -78°C; b: NaBH4, MeOH, 0°C; c: Ac2O, DMAP, Et3N, 
CH2Cl2, 0°C; d: Meth. A Mg, cat HgCl2, EtOH and THF (3:1), 25°C, Meth. B Na(Hg), EtOH, -15°C. 
Scheme 5. Julia olefination of chiral α-amino esters. 
2.1 Synthesis of α-Chiral allylamines by a modified Julia olefination 
reaction  
The synthesis started with the reaction between N-Boc amino esters 1 and 
lithiated phenylmethylsulfone 2a, giving the corresponding ketosulfones 3. The 
experimental conditions for this key step were initially optimized, with respect to 
yields and ee, using N-Boc alanine methyl ester 1a as the substrate (Table 2).
70
 
  
                                                 
70 As it was not possible to separate the enantiomeric ketosulfones 3, the ee were measured after 
conversion of 3 into the corresponding allylamine 6 (Scheme 5Scheme 4), except for 3f whose ee 
was determined by chiral HPLC. 
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Entry 2a (eq.) Base (eq.) T (°C) Yield 
a 
% ee 
a,b 
% 
1 1 n-BuLi (2) −78 55 <70 
2 1 n-BuLi (2) −30 66 <70 
3 1 n-BuLi (3) −78 86 <70 
4 2 n-BuLi (4) −78 89 65 
5 2 n-BuLi (4) −30 42 <70 
6 2 n-BuLi/TMEDA (4) −78 - - 
7 2 KHMDS −78 - - 
8 2 NaH −78 - - 
9 2 n-BuLi (4) −78 89 
c
 95 
c
 
a By addition of 1a to lithiated 2a; b ee determined after conversion to the allylamine 6a; c By the 
reverse addition of a suspension of lithiated 2a to 1a. 
Table 2 Optimized synthesis of the first step of revisited Julia: ketosulfone 
 
Addition of 1a to one equivalent of lithiated phenylmethylsulfone 2a, even in the 
presence of two equivalents of n-BuLi as originally suggested by Lygo,
69,70, 71
 
resulted in a partial conversion into the ketosulfone 3a (Table 2, Entries 1 and 2). 
The low yields are likely due to the presence of ionizable protons, both in the starting 
amino ester (NHBoc) and in the ketosulfone product (methylene) that can exchange 
with lithiated 2a. The yield improved when an excess of BuLi and 2a was employed 
(Entries 4 and 5); under these conditions, however, the enantiomeric purity of the 
ketosulfone 3a was modest. The use of TMEDA in association with butyllithium
72
 
(Entry 6) and of other base systems (Entries 7, 8) was not successful. The best results 
were eventually obtained with two equivalents of sulfone and four equivalents of 
butyl lithium,
73,74
 with the resulting yellow suspension added to the amino ester 1a, 
at −78 °C under argon. In this case, complete conversion into the ketosulfone 3a was 
                                                 
71 B. Lygo, C.N. Rudd, Tetrahedron Lett. 1995, 36, 3577. 
72 L. Řehová, I. Císařová, J. Ullrich, Eur. J. Org. Chem. 2014, 1461. 
73 R. Rönn, Y.A Sabnis, T. Gossas, E. Akerblom, U.H. Danielson, A. Hallberg, A.Johansson, 
Bioorg. Med. Chem. 2006, 14, 544.  
74 D. Severi, L. Ettouati, J. Paris, Lett. Pept. Sci. 2002, 9, 11. 
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achieved, which was isolated in excellent yield and enantiomeric purity (Entry 9). It 
had been suggested that, under similar conditions, the dilithiated sulfone 8 is formed 
and is the reactive nucleophile.
73,74
 It seems more likely, however, that the 
monolithiated species 9 is formed following H/Li exchange with the protected 
aminoester (Scheme 6) and is the actual nucleophile. A second equivalent of 8 is 
then required for a further H/Li exchange giving the dilithiated product 12, in 
agreement with the observed stoichiometry. 
 
 
Scheme 6. Reactions of mono- and bis-lithiated sulfones. 
 
The optimized reaction conditions were then applied to the N-Boc-amino esters 
1b–f (Table 3), giving the corresponding ketosulfones 3 in good to excellent yields 
and ee, with the only exception of the protected tyrosine methyl ester 1f; repeated 
attempts under several reaction conditions invariably led to a significant loss in 
enantiomeric purity for this compound (e.e.: 80%). The e.e.s of 3b-f were determined 
via HPLC on a Lux5ucell2  and  a Lux5ucell3 column, respectively. Results are 
reported in Table 3. 
With L-proline methyl ester 1g (Entry 7), where no ionizable protons are 
present, the best optical purity, albeit at the expenses of a lower yield, was obtained 
by using two equivalents of PhSO2Me and BuLi with respect to the aminoester, 
whereas racemization was observed by employing the usual conditions. This further 
confirms that the reactive nucleophile in the reaction with the amino esters is the 
monolithiated species PhSO2CH2Li, as suggested above (Scheme 6). 
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Entry Sulfone Aminoester R2 Yield(%) e.e % Producta 
1 1a Ala (1a) H 89 95 3a 
2 1a Val (1b) H 85 97 3b 
3 1a Leu (1c) H 89 99 3c 
4 1a Ile (1d) H 86 99 3d 
5 1a Phe (1e) H 94 95 3e 
6 1a Tyr (1f)b H 78 80 3f 
7 1a
c
 Pro (1g) H 60 n.d. 3g 
8 1b Phe (1e) Me 77 n.d.
d 
3h 
9 1b
c
 Pro (1g) Me 80 n.d.
e 
3i
 
a Reactions were carried out as for entry 9, Table 2; b Protected as O-TBDMS; c With 2 equivalents of 
sulfone; d 3:2 mixture of diastereoisomers; e 55:45 mixture of diastereoisomers. 
Table 3. Reactions between amino esters 2 and lithiated sulfones 1
a
 
 
Finally, the same conditions were applied to the reaction of amino esters 1e and 
1g with phenylethylsulfone 2b (Table 3, Entries 8 and 9), giving the corresponding 
ketosulfones 3h and 3i, as mixtures of diastereoisomers, in excellent yield.  
The ketosulfones 3a–g thus obtained were reduced with NaBH4 (Scheme 5), 
giving quantitatively the α-hydroxysulfones 4a–g as mixtures of syn (S,S) and anti 
(S,R) diastereoisomers in ratios from approximately 10:1 for branched compounds 
4b–d (Val, Leu, Ile) to 3:1 for compounds having linear side chains 4a,e,f (Ala, Phe, 
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Tyr) to 1.5:1 for 4g (Pro), in agreement with previous findings.
75
 No attempts were 
made to optimize the stereoselectivity, as the newly-formed stereogenic center is lost 
in the final step of the synthesis. Not surprisingly, complex mixtures containing all 
four possible diastereoisomers were obtained in the reduction of ketosulfones 3h and 
3i. 
Conversion of hydroxysulfones 4 into the allylamines 6 followed the standard 
protocol of the Julia reaction. Thus, the alcohols 4 were acetylated with acetic 
anhydride and DMAP, and the corresponding acetoxysulfones 5 were converted to 
the target aminoalkenes 6 in the final reductive elimination, promoted by sodium 
amalgam
63
 or in situ generated magnesium amalgam
65
 (Scheme 5, Table 4). The two 
methods were shown to proceed with comparable yields and ee, except for 5f: in this 
case, sodium amalgam caused the deprotection of the phenol group, leading directly 
to the allylamine 6f′, while the O-protected product 6f was smoothly obtained with 
magnesium amalgam. 
  
                                                 
75 F. Benedetti, S. Miertus, S. Norbedo, A. Tossi, P. Zlatoidzky, J. Org. Chem. 1997, 62, 9348. 
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 Allylamine Methoda Yield b % ee c % 
6a 
 
A (1h) 68 (60) 95 
6b 
 
A (2h) 60 (50) >99 
6c 
 
A (2h) 67 (62) >99 
6d 
 
A (3h) 69 (59) >99 
6e 
 
A (2h) 68 (64) >99 
B (4h) 71 (67) >99 
6f 
 
A d,e (2h) 65 (52) 80e 
6f′ 
 
B d (4h) 71 (57) ND 
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6g 
 
B (2h) 84 (50) >99 
6h 
 
B (4h) 71 f (55) ND 
6i 
 
B (12h) 65 g (52) ND 
a Method A: Mg powder (2.5 eq), HgCl2 (0.1 equiv.), EtOH/THF (3:1), 25 °C; Method B: 5% Na/Hg 
(3 equiv.), EtOH, −15 °C; b Final yields from amino esters 1 in brackets; c By chiral HRGC; d From 
O-TBDMS protected sulfone 5f; e By chiral HPLC; f 80:20 mixture of E and Z isomers; g 85:15 
mixture of E and Z isomers.  
Table 4. Synthesis of allylamines. 
 
The enantiomeric excess of (S)- allylamines 6a-e has been determined via chiral high 
resolution gas-chromatography carried out on β- or  γ-cyclodextrin capillary column 
and were found to be always higher than 99%.  
The e.e. of compound 6f was determined via HPLC on a Lux5ucell 3 column. 
The Julia reaction is known to favor the formation of the E isomer, when leading 
to disubstituted alkenes.
63,64
 Accordingly, when substituted acetates 5h,i were 
subjected to reductive elimination with Na(Hg), the corresponding allylamines 6h,i 
were obtained as 4:1 mixtures of E and Z isomers, as determined by NMR. A 
complete list of the allylamines synthesized in this study with overall yields and 
enantiomeric excess is reported in Table 4. 
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2.2 Conclusions 
In this first part of the thesis we have described a general procedure for the 
synthesis of α-chiral allylamines from readily available α-amino esters, by a simple 
modification of the Julia olefination reaction. While retaining all of the advantages of 
the original Julia reaction, this approach avoids using amino aldehydes as precursors 
in favor of the more readily-available and chemically and configurationally more 
stable amino esters. Epimerization at the chiral center, which is a frequent problem in 
the standard Julia and Wittig olefination of N-protected α-amino aldehydes, is thus 
prevented, and the desired allylamines were obtained in excellent yield and 
enantiomeric excess. The approach described here for the synthesis of allylamines is 
quite general and should provide a useful alternative to the classical Julia reaction 
whenever the starting aldehyde is unstable or, otherwise, not readily accessible. 
Moreover, its scope might be further expanded by replacing the phenyl alkyl 
sulfones of this work with benzotriazolylalkyl sulfones or other heteroarylalkyl 
sulfones, as in the Julia–Kocienski reaction, 76 , 77  where the intermediate 
hydroxysulfones directly collapse to alkenes, thus avoiding the final reduction step. 
                                                 
76 P.R. Blakemore, J. Chem. Soc. Perkin Trans. 1 2002, 2563. 
77 E. Pfund, T. Lequeux, D. Gueyrard, Synthesis 2015, 47, 1534. 
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Introduction 
3.  Alzheimer’s disease (AD) 
Alzheimer's Disease (AD) is a chronic neurodegenerative disease, affecting people in 
presenile and senile age, resulting in severe cognitive deficits due to loss of neurons 
and ultimately leading to death. According to the World Health Organization, 48 
million individuals suffer from this condition worldwide, and this number is 
expected to dramatically grow to 115 million by 2050, due to an increase in the 
average age of the population.
78
  
AD was described for the first time in 1906 by the German psychiatrist and 
neuropathologist Alois Alzheimer, assisted by the Italian neurologist Gaetano 
Perusini.
79
 The disease is characterized by a progressive cognitive and functional 
deterioration manifesting with short-term memory loss, accompanied by 
concentration and orientation problems. These early symptoms are often mistaken 
with those due to aging or stress, and gradually convert into difficulties in the 
language (aphasia), perception (agnosia) and execution of complex movements 
(apraxia). Finally, the person loses the ability to interact with the environment and to 
control his movements, becoming completely dependent on those who provide care. 
The leading causes of death are the physical deterioration and the action of external 
agents, to which the patient is completely exposed during the final stage of the 
disease. 
The main neuropathological hallmarks of AD are the presence of 
extracellular amyloid- (A) plaques and intracellular neurofibrillary tangles in the 
brain. Neurofibrillary tangles are insoluble bundles of fibres that locate in the 
perinuclear cytoplasm and are generally composed of phosphorylated tau protein.
80
 
Neuritic amyloid plaques are spherical lesions that contain extracellular aggregates 
of amyloid- protein (A) and are likely to be the primary lesion in AD.81 It has been 
suggested that the appearance of tangles in the AD brain could be due to neuronal 
                                                 
78 C. Reitz, R. Mayeux, Pharmacology, 2014, 88, 640. 
79 A. Alzheimer, Allgemeine Zeitschrift für Psychiatrie und Psychish-Gerichtliche Medizin, 1907, 64, 
146.  
80 a. D. J. Selkoe, Physiol. Rev., 2001, 81, 741;b. KS. Kosik, C.L. Joachim, D.J. Selkoe Proc. Natl. 
Acad. Sci. USA 1986, 83, 4044. 
81 D. J. Selkoe, JAMA, J. Am. Med. Assoc., 2000, 283, 1615. 
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responses to the formation of plaques.
82 ,80a
 Current therapies are aimed at the 
management of symptoms and, to date, no disease altering treatment exists for 
Alzheimer’s patients. Currently, Aß peptides and tau proteins are the main 
therapeutic targets for the treatment of Alzheimer (Figure 10).
83
  
 
 
Figure 10. Comparison between a healthy (left) and an AD affected brain tissue (right). 
 
The processes that lead to aggregation of the proteins and to neurodegeneration are 
not yet entirely clear.
78
 Distinctive signs of Alzheimer's appear in the peripheral 
regions of the cortex, centre of cognitive functions such as memory, perception and 
language, and they are constituted by an enlargement of the ventricles and by a 
thinning of the cerebral cortex and of the hippocampus (Figure 11).
84
  
  
                                                 
82 D. J. Selkoe, Nature, 1991, 354, 432. 
83 P. Tiraboschi, L. A. Hansen, L. J. Thal, and J. Corey-Bloom, Neurology, 2004, 62, 1984. 
84 a. N. Schuff, N. Woerner, L. Boreta, T. Kornfield,L. M. Shaw, J. Q. Trojanowski, P. M. 
Thompson, C. R. Jack, Jr, M. W. Weiner, and the Alzheimer's; Disease Neuroimaging 
Initiative,, Brain, 2009, 132, 1067; b. www.brightfocus.org/alzheimers/infographic/brain-
alzheimers-disease. 
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Figure 11. Brain cross-section of a normal (l) and an AD (r) patient. 
 
The cause of the atrophy of the brain areas affected by Alzheimer's is the loss of 
dendrites and axons, which in the beginning undergo a reduction of myelin and at the 
end lead to the death of neurons.
85
 The hippocampus region of a healthy person 
contains around nine million neurons, while in AD terminal stages more than 80% of 
these neurons have disappeared and the volume of the brain reduced to less than 
half.
86
 A decrease of the thickness of the medial temporal lobe in AD can be shown 
by modern imaging techniques, such as MRI (Magnetic Resonance Imaging) and 
PET (Positron Emission Tomography), that also reveals the presence of β-amyloid 
fibres (Figure 12).
87
 AD affected patients suffering from language dysfunction 
display a significant reduction in metabolism in the left, frontal, temporal and 
parietal lobes (blue). 
 
                                                 
85 a. X. Hu, C. W. Hicks, W. He, P. Wong, W. B. Macklin, B. D. Trapp and R. Yan, Nature 
Neurosci. 2006, 9, 1520. b. S. Barão, D. Moechars, S. F. Lichtenthaler, and B. De Strooper, 
Trends in Neurosciences, 2016, 39, 158 
86 A.D. Smith, Proc. Natl. Acad. Sci. USA, 2002, 99, 4135. 
87 a. R. S. Desikan, H. J. Cabral, C. P. Hess, W. P. Dillon, C. M. Glastonbury, M. W. Weiner, 
N. J. Schmansky, D. N. Greve, D. H. Salat, R. L. Buckner and B. Fischl, Brain, 2009, 132; 2048; 
b. A.P. Jr Carpenter , M.J. Pontecorvo , F.F.Hefti, D.M. Skovronsky, Q J Nucl Med Mol Imaging. 
2009, 53, 387. 
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Figure 12. PET images of a normal (left) and an AD affected(right) brain. 
 
3.1 Hypotheses for AD pathogenesis  
The observation of neurofibrillary tangles and neuritic plaques in the brain of AD 
patients has led to two theories for the onset of AD, namely the tau and amyloid 
hypotheses.
88
 According to the tau hypothesis, the development of AD is caused by 
the hyperphosphorylation of the tau proteins as a result of an imbalance in the 
activity of kinases and phosphatases. The tau proteins are a class of proteins 
particularly abundant in neurons of the central nervous system; they are linked to 
microtubules that help to keep the network of interconnections between neurons. 
Hyperphosphorylation causes the destruction of the network of microtubules, leading 
to their self-assembly into a β-sheet structure organized into paired helical filaments, 
which eventually gives rise to neurofibrillary tangles in the perinuclear cytoplasm of 
the neuron. This causes an alteration of the regular functions of the neuronal 
transport system, since the biochemical communication between neurons is 
prevented, thus leading to cellular death (Figure 13).
89
 
The hyperphosphorylated tau proteins seem to be in excess in the brain of patients 
affected of Alzheimer disease than in the healthy people.  
 
                                                 
88V. H. Finder, J. Alzheimers Dis., 2010, 22, 5. 
89 a. W. H. Stoothoff, G. V.W. Johnson, Biochim. Biophys. Acta, 2005, 1739, 280; b. G. V. W. 
Johnson and W. H. Stoothoff, J.Cell Sci., 2004, 117, 5724. 
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Figure 13. Hyperphosphorylation of tau proteins. 
 
This hypothesis has been criticized because other neurodegenerative diseases 
caused by hyperphosphorylation of tau proteins are known (Pick's disease, Lateral 
Amyotrophic Sclerosis, etc.),
90
 and from recent studies it emerged that 
hyperphosphorylation follows the formation of β-amyloid aggregates and not the 
contrary.
91
The most accredited hypothesis for the pathogenesis of AD is the β-
amyloid hypothesis that correlates neurodegeneration to the formation of plaques 
composed of β-amyloid peptides A (Figure 14). The hypothesis is based on the 
observation that neuron plaques seem to be the primary lesions in order of time in 
AD. The formation of these plaques initiates a cascade of degenerative processes that 
eventually result in dementia.
83
 
 
 
Figure 14. Schematic cascade of the formation of extracellular Aβ plaques.92 
                                                 
90 C. Ballatore, V.M. Lee, J.Q. Trojanowski, Nat. Rev. Neurosci., 2007, 8, 663.   
91 J. Hardy and D. J. Selkoe, Science, 2002, 19, 297, 353. 
92 C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, E. Jones, The lancet, 2011,377, 
1019. 
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The hyperproduction of β-amyloid peptide is due to an alteration of metabolism 
of Amyloid Precursor Protein (APP); in the amyloidogenic pathway, Aβ peptide is 
produced following the sequential cleavage of APP in neurons by two proteases, 
BACE 1 and γ-secretase.93 Appropriate choices for a rational approach to the cure of 
AD are the inhibition of the accumulation of β-amyloid peptide and the selective 
disaggregation of Aβ plaques, and therefore many research efforts in medicinal 
chemistry are based on this hypothesis. 
 
3.1.1  Amyloidogenic hypothesis 
APP is a bitopic transmembrane protein consisting of 695 to 770 residues (Figure 15) 
produced in different tissues of the human body, mainly in brain and kidneys.
94
 The 
physiological function of this protein is still not known with precision, but it has 
been shown that APP and its derivatives contribute to cell-cell and cell-matrix 
interactions, adhesion and the regulation of intracellular calcium levels within the 
cells themselves.
94
 
 
 
Figure 15. APP structure. 
                                                 
93 Cole, S.L.; Vassar, R. Mol.Neurodeg., 2007, 2, 22.  
94 A.K. Ghosh and H. Osswald, Chem. Soc. Rev., 2014, 43, 6765. 
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Upon arrival of the stimulus to the cell, the signal peptide carries the APP in 
the endoplasmic reticulum (ER), where it is linked to the membrane by the 
hydrophobic domain. Proteolysis of APP can take several pathways that give rise to a 
variety of soluble and membrane fragments. The enzymes responsible for these 
activities are proteases, called α-secretase, β-secretase and γ-secretase (Figure 16). 
Cleavage of APP by α-secretase governs the non-amyloidogenic pathway, leading to 
the formation of the fragment soluble in the matrix (sAPPα) and the C83 C-terminal 
fragment.  Alternatively, APP can undergo a first proteolysis by the β-secretase, 
which hydrolyses the peptide bond in the extracellular region of APP, 16 aa down 
from the α-secretase site, releasing the soluble fragment sAPPβ and the C99 C-
terminal fragment. The fragments C83 and C99 are further processed by γ-secretase, 
which acts in the transmembrane region of APP (Figure 16).  
 
 
Figure 16. APP proteolytic pathways. Left: amyloidogenic; right: non amyloidogenic. 
 
Processing of the C83 fragment by γ-secretase releases the 3 kDa, non-
amyloidogenic peptide p3. The action of γ-secretase on the C99 peptide results in the 
formation of a heterogeneous mixture of A peptides, predominantly 40 and 42 
amino acids in length. The latter (A42) is more hydrophobic and particularly prone 
to aggregation,
93
 forming oligomers that accumulate in the brain and initiate a 
cascade of events resulting in neuronal disfunctioning, neurodegeneration and 
neuronal fatality. Normally, γ-secretase activity favours the formation of less 
aggregating Aβ40 peptides, but mutations of this enzyme (and mutations of the so-
called presenilins, which can modulate the activity of γ-secretase, or behave like γ-
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secretase) lead to massive formation of Aβ42. Accordingly, Aβ plaques are also 
observed in healthy subjects, but these are completely asymptomatic.
93
 
Typical symptoms of AD can also emerge when there is an overexpression of 
the gene encoding APP. For example, since the gene just mentioned is encoded 
within the chromosome 21, subjects suffering from trisomy-21 (or Down syndrome) 
may show signs of neuritic plaques as early as 12 years old, as the accumulation of 
Aβ begins from birth, this AD being known as Familial AD.80a These gene mutations 
can affect the location of hydrolysis for γ secretase, leading to the formation of an 
excess of Aβ42. 
 
3.2  BACE 1: β-site APP cleaving enzyme 1 
β-Secretase (BACE-1) represents the first protease involved in the APP degradation 
process, leading to production of β-amyloid (Aβ). Silencing BACE-1 can reduce 
A42 production thus slowing or stopping disease progression and therefore it 
represents a viable therapeutic strategy for AD.  
BACE 1 is a type 1 transmembrane aspartic protease with a bilobate 
structure, made of 501 aa. It is built in the Golgi apparatus from modification and 
cleavage of the immature glycosylated polypeptide pro-BACE1 in the endoplasmic 
reticulum. BACE 1 exhibits optimum proteolytic activity between pH 4 and 5, 
suggesting that this enzyme does not act at the cell surface but in the endosomes, on 
the way to the cell surface.
94,95
 
BACE 1 can assume two thermodynamically stable conformations, the open 
flap and closed flap conformation (red and blue, respectively, in Figure 17). The free 
enzyme preferentially assumes the open flap conformation, in which the active site is 
exposed to accommodate the substrate. When it is bound to the substrate, the enzyme 
adopts the closed flap conformation.
96
 
 
                                                 
95 C. Venugopal, C. M. Demos, K. S. J. Rao, M. A. Pappolla, and K. Sambamurti, Neurol Disord 
Drug Targets, 2008, 7, 278. 
96 L. Hong, J. Tang, Biochemistry, 2004, 43, 4689. 
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Figure 17.BACE1 conformations: open flap (red) and closed flap (blue). 
 
The conformational shift open - closed flap is accompanied by the breaking 
of several hydrogen bonds. This destabilization, however, is compensated by 
interactions between the enzyme and the substrate, as well as by interactions between 
the side chains.
94
 The two catalytic aspartates (Asp32 and Asp228) are located in the 
center of the proteolytic pocket and are surrounded by a network of hydrogen bonds. 
In the presence of a substrate their carboxylate groups are not perfectly coplanar.
97
 
While BACE 1 inhibition is a promising approach to fight Alzheimer’s 
disease, one must be aware of several possible adverse effects: 
1. there is another enzyme (BACE 2) with a sequence similar to BACE 1 
(68% homology) and with the same structural organization, but differing 
in the tissue distribution, localization and substrate specificity.
95
 While 
BACE 2 function is not completely understood, its activity, considering 
the structural similarities, might be affected by BACE 1 inhibitors.  
2. Another function of BACE 1 is the proteolytic processing of Neuregulin 
1 that regulates axon myelination in the peripheral nervous system.
85
 
3. Amyloid β peptide appears to participate in the activation of kinase 
enzymes,
98
 regulation of cholesterol transport,
99
 protection against 
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oxidative stress,
100
 and others, but especially it may fight other 
syndromes.
101
 
Therefore the degree of BACE 1 inhibition is a matter of great importance, 
depending on the advancement of the disease. In vivo tests allow to estimate that 
50% inhibition may circumvent mechanism-based side effects and, yet, provide 
sufficient Aβ reduction for therapeutic efficiency. 102 
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3.2.1 BACE 1 inhibitors 
The crystal structure of BACE 1 co-crystallized with different ligands reveals the 
basic requirements and the key features needed for enzyme inhibition.  
Following a well-established approach to protease inhibition, in earlier 
attempts, peptidomimetic BACE-1 inhibitors were designed mimicking the 
conformation of the transition state for hydrolysis of the substrate.
103
 In this 
approach, a hydroxyl group on the transition state isostere displaces the catalytic 
water molecule and forms tight hydrogen bonds with the catalytic aspartic acid 
residues, thus precluding catalytic activity. Peptidomimetics containing statine, 
hydroxyethylene, and hydroxyethylamine transition states isosters were extensively 
investigated and their properties optimized. Their major drawback is related to the 
poor pharmacokinetic profile, limited specificity and pharmacological properties in 
vivo, such as blood brain barrier crossing, oral bioavailability, susceptibly to 
transport P-glycoprotein, which have prevented them from being further developed 
to orally bioavailable CNS drugs.  
 
The most detailed study on the complex BACE1-inhibitor was reported by Shimzu, 
with the highly peptidic inhibitor OM99-2.
104
  
The authors have obtained the structures of active and inactive forms of the enzyme. 
The maximum catalytic activity and the maximum binding of OM-99-2 occur both at 
pH 5, and the analysis of the crystal structures of the enzyme from crystallizations 
carried out at different pHs reveal that a major conformational change can also be 
identified by raising or lowering the pH. The crystal structure at pH 5 can therefore 
be used to map the binding subsites of the proteases, and to set a reference 
interaction scheme (Figure 18). 
                                                 
103 A.K. Ghosh, M. Brindisi, J. Tang, J. Neurochem., 2012, 120, 71. 
104 H. Shimizu, A. Tosaki, K. Kaneko, T. Hisano, T. Sakurai, N. Nukina, Mol Cell Biol. 2008, 28, 
3663. 
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a
b 
Figure 18. a: side and b: top views of the complex of BACE-1 with the pseudopeptide inhibitor 
OM99-2. 
 
The substrate analogue inhibitor is hosted by a channel in contact with eight 
aminoacid residues spanning from P4’ to P4, and the catalytically active aspartyl 
residues 32 and 228 are buried inside the catalytic site. In the empty enzyme they 
interact with the conserved water residues, which lies in the same position occupied 
by the hydroxyl group of the pseudopeptide moiety of the inhibitor. A large flap 
made by an antiparallel b-sheet strand and by its loop covers the catalytic site in the 
empty enzyme, while a major conformational change occurs in the complex, where 
the flap is shifted towards the P2 residue of the inhibitor. This allows the interaction 
of the pseudopeptide at all the binding channel subsite. A map of such interactions is 
reported in Figure 19. 
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a 
b 
Figure 19. a: map of the interactions of the pseudopeptide inhibitor OM99-2 at the S4’ ÷ S4 subsite 
level; b: view of the subsite from the crystallographic structure (pdb id. 2ZHR). 
 
The binding mode is highly unsymmetrical, and most of the interactions are found at 
the P1-P4 side. S1 is a large a well-defined site, where the P1 isoleucine is in contact 
with four hydrophobic side chains (Leu30, Phe 108, Trp 115, Ile 118). Conversely, 
S1’ is smaller and less accessible, and no hydrophobic contacts are clearly identified 
for the alanine residue at P1’. S2 is a very polar and cationic subsite, as it shares Arg 
235 with S4, and this residue interacts on one side with the asparagine side chain of 
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P2 and with the carboxyl terminus on the other side. On the contrary, S2’ is small 
and hydrophobic. Polar S2 is followed by the very hydrophobic subsite S3, where 
interactions take place with P3 valine, while hydrophobic S2’ is followed by the very 
polar S3’ subsite, where Arg 128 binds P3’ glutamate. The last polarity inversion is 
then found at S4 (very polar to bind P4 aspartate) and S4’ (hydrophobic to bind P4’ 
isoleucine). 
 
More recent attempts have been directed towards the discovery of non peptidic, 
small molecule BACE-1 inhibitors,
105
 designed to have optimal interactions with the 
enzyme, higher metabolic stability, and higher blood-brain-barrier penetration 
ability.
102
 
Recently, a significant number of these 2
nd
 generation BACE-1 inhibitors has 
been developed as small-molecule candidates possessing drug-like features.  
While no one of those have has been approved for clinical use as yet, 
however some of them have gone through various stages of clinical trials, as shown 
in Table 5. AZD3293 and MK-8931 are currently at an advanced state of clinical 
sperimentation. 
 
Company Compound Clinical trial phase  
AstraZeneca/Lilly AZD3293 Phase 2/3 
CoMentis CTS-21166 Phase 1 
Eisai/Biogen Idec E2609 Phase 2 
High Point HPP854 Phase 1 
Merck MK-8931 Phase 2/3 
Pfizer PF-05297909 Phase 1 
Takeda TAK-070 Phase 1 
Vitae/Boehringer 
Ingelheim 
VTP-37948 Phase 1 
Table 5. Phases of clinical sperimentation of BACE1 inhibitors. 
 
MK-8931 (Verubecestat)
106
 developed by Merck, was tested for safety and 
tolerability as well as pharmacokinetic and pharmacodynamic properties in moderate 
                                                 
105 R. Silvestri, Med Res Rev., 2009, 29, 295 
106 R. Yan, Transl. Neurodegen. 2016, 5, 13. 
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to mild symptomatic AD patients. The core of the molecule is a 3-aminothiadiazine 
group (Figure 20). 
 
 
Figure 20. MK-8931 (left) and AZD- 3293 (right). 
 
MK-8931 reduces Aβ40 peptides in cells with IC50 = 13 nM and Ki =7.8 nM. This 
inhibitor showed positive results in the 1 and 1b clinical phase; the combined phases 
2 and 3 will be concluded in the 2018. 
AZD3293, also known as LY3314814, has been shown in Phase 1 studies to reduce 
levels of amyloid-beta in the cerebro-spinal fluid of Alzheimer's patients and healthy 
volunteers. A pivotal Phase 2/3 clinical trial started in 2014 and is planned to end in 
June 2019. 
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4. Small molecules as non peptidomimetic inhibitors for BACE1 
 
Several chemical scaffolds have been proposed in the design of BACE 1 inhibitors 
(Figure 21), all of which contain structural motifs that can establish efficient 
hydrogen bond interactions with the catalytic aspartates.
107
 The synthesis and 
biological evaluation of inhibitors based on a different heterocyclic scaffold, namely 
the dihydropyrimidinone scaffold, is described in the second part of this thesis. 
 
 
Figure 21. Scaffolds for BACE-1 inhibitors. 
 
4.1 3,4-Dihydropyrimidin-2(1H)-ones  (DHPMs) and their 2-thia and 2-
aza analogues 
Recently, interest in multifunctionalized 3,4-dihydropyrimidin-2(1H)-ones, 
(DHPMs) has surged rapidly, owing to the biological and pharmacological properties 
associated with this heterocyclic scaffold. 
  Properly functionalized DHMPs derivatives have been identified, for 
example, as excellent calcium channel modulators,
108
 mitotic Kinesin inhibitors, 
adrenergic receptor antagonists, antibacterials, antivirals, as extensively reviewed.
109
. 
                                                 
107 a. S. J. Stachel, J Drug Develop. Res. 2009, 70, 101; b. Y. Niu, H. Gao, F. Xu, C. Wang, P. Liu, 
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108 a. K.S. Atwal, B.N. Swanson, S.E. Unger, D.M. Floyd, S. Moreland, A. Hedberg, B.C. 
O’Reilly, J. Med. Chem., 1991, 34, 806; b. G. C. Rovnyak, K. S. Atwal, A. Hedberg, S. D. 
Kimball, S. Moreland, J. Z. Gougoutas, B. C. O’Reilly, J. Schwartz, M. F. Malley, J. Med. Chem. 
1992, 35, 3254. 
109 C. O. Kappe, Eur. J. Med. Chem. 2000, 35, 1043–1052 
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Figure 22. The DHMP scaffold and two medicinally relevant dihydropirimidinones. 
 
Nitractin (Figure 22) has excellent antiviral activity against the viruses of the 
trachoma group. The same compound also exhibits modest antibacterial activity.
110
  
The aminopropyl-4-arylpiperidine group attached via a C-5 amide to the 2-thio 
DHPM scaffold, as for compound (S)-L-771688 (Figure 22), has proved to be an 
excellent template for selective α1A receptor subtype antagonists for the treatment of 
benign prostatic hyperplasia.  
Besides, (S)-Monastrol (Figure 22) has been identified as an inhibitor of a mitotic 
kinesin Eg5 and a potential new lead compound for the treatment of cancer.
111
  
Moreover, Atwal and co-worker demonstrated that the compound SQ 32926, 
(Figure 22) has antihypertensive properties in vivo.
108a 
The interest in DHMPs is also related to their easy accessibility by the well 
known three component Biginelli reaction,
112
 and the possibility of structural 
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modifications introducing various chemical substituents in different positions of the 
ring, this providing remarkable changes in pharmacological profile.  
 
4.2 Biginelli Reaction 
The Biginelli reaction is one of the first examples of multicomponent reactions 
(MCRs), a class of increasing importance in organic and medicinal chemistry.
113
 The 
convergent approach characteristic of MCRs offers significant advantages over 
conventional linear-type synthesis and can provide products with the diversity 
needed for the discovery of new lead compounds using combinatorial chemistry 
techniques.  
In 1893, the Italian chemist Pietro Biginelli reported the acid catalyzed 
cyclocondensation reaction of ethyl acetoacetate, benzaldehyde, and urea.
112
 The 
reaction was carried out in refluxing ethanol in the presence of a catalytic amount of 
HCl. The product of this one-pot, three-component reaction was identified as ethyl 6-
methyl-4-phenyl-3,4-dihydropyrimidin2(1H)-one 5-carboxylate (Scheme 7). 
 
Scheme 7. Biginelli reaction. 
While the early examples of the Biginelli reaction were limited to the use of aromatic 
aldehydes, urea and a -ketoester, the scope of the reaction has been significantly 
extended by variation of all three reaction partners, giving access to a broad range of 
different dihydropyrimidine compounds of the type A0 (Figure 23). 
 
                                                 
113 J. Zhu, H. Bienayme, Multicomponent Reaction, WILEY-VCH, 2005. 
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Figure 23. The DHPM scaffold (A0). 
 
Variations in the aldehyde component have been explored extensively. The reaction 
generally tolerates well aromatic aldehydes, substituted in all position of the aromatic 
rings by electron withdrawing or donating groups, and also with heteroaromatic 
aldehydes derived from furan, thiophene, and pyridine. With aliphatic aldehydes 
lower yields are observed under the classical conditions but better results were 
achieved by the use of Lewis acids and solvent free conditions.  
Regarding the 1,3-dicarbonyl compound, in addition to alkyl acetoacetates 
also other types of 3-oxoalkanoic esters or thioesters were employed successfully.
114
 
Primary, secondary and tertiary acetoacetamides can be used to afford pyrimidine-5-
carboxamides.
115
 Linear and cyclic 1,3-diketones,
 116
 and nitroacetone have also been 
used.
117
 
The urea component is the most limiting in terms of structural variations 
allowed. Monosubstituted ureas have been employed in regiospecific reactions 
affording the N-1 substituted DHPMs. Isomeric N-3 substituted derivatives are not 
obtained with monoalkyl ureas under Biginelli conditions, and N,N’-disubstituted 
ureas do not react.
118
 With thiourea and monosubstituted thioureas similar results are 
observed leading to the formation of the corresponding thiopyrimidinones.
 119
  
Biginelli reactions with guanidine and protected guanidine have been reported,
119
 
giving access to 2-iminoDHPMs (Scheme 8). The optimized reaction conditions were 
decribed by Kappe,
 120
 with guanidine hydrochloride, in DMF at 80°C, in the 
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presence of NaHCO3 for 3hrs. The reaction times can be further reduced by the 
recent use of ultrasonic irradiation.
121
 
 
Scheme 8. Biginelli-type reaction with guanidine. 
 
More recent developments of the Biginelli reactions are in the field of solid phase 
synthesis, combinatorial chemistry and the synthesis of natural products.
122
 
A great variety of experimental conditions have been reported for this reaction, 
exploring the use of different solvents, acidic catalyst and temperature, as 
extensively reported  in the published reviews.
118
 
 
4.2.1 Mechanistic studies  
Starting from the early work of Johnoson and Folkers,
123
 the mechanism of the 
Biginelli condensation has been extensively investigated and three possible 
mechanisms have been proposed (iminium, enamine and Knoevenagel).
124
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123 K. Folkers, T.B. Johnson, J. Am. Chem. Soc., 1933, 55, 3781 
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Folkers and Johnson privileged the “enamine mechanism” (Scheme 9) that 
involves the condensation between ethylacetoacetate (A1) and urea (A2), in the first, 
rate determining step, followed by addition to the aldehyde.  
 
 
Scheme 9. The Enamine-based mechanism for the Biginelli reaction. 
 
Interestingly, in 2007 Cepanec and coworkers
125
 presented a series of 
experiments showing that the three components reaction proceeds via the enamine 
mechanism when catalysed by SbCl3 and other Lewis acids in anhydrous aprotic 
solvents.  
The so-called Knoevenagel mechanism (Scheme 10) is based on the findings 
of Sweet and Fissekis,
126
 and it postulates that a Knoevenagel adduct, formed by the 
condensation between benzaldehyde and ethyl acetoacetate is the key intermediate. 
Although the Knoevenagel-based mechanism is still accepted, further evidences 
indicate other preferred reaction pathways in most cases. 
 
                                                 
125 I. Cepanec, M. Litvic, M. Filipan-Litvic, I. Grungold, Tetrahedron, 2007, 63, 11822 
126 F. Sweet, J.D. Fissekis, J. Am. Chem. Soc., 1973, 95, 8741. 
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Scheme 10. Knovenagel mechanism for the Biginelli reaction. 
 
In 1997 Kappe
127
 reported a detailed re-investigation of the mechanism of the 
Biginelli reaction using 
1
H and 
13
C NMR spectroscopy and trapping experiments, 
providing strong evidences for the iminium mechanism (Scheme 11). This is based 
on the formation of an N-acyliminium intermediate from the acid-catalyzed reaction 
of the aldehyde (A3) and urea (A2) which is intercepted in the following step by the 
enol form of the dicarbonyl component, giving an open chain ureide precursor of the 
Biginelli compound (Scheme 11). The reaction mechanism can therefore be 
classified as -amidoalkylation.  
 
                                                 
127C. O. Kappe, J. Org. Chem. 1997, 62, 7201. 
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Scheme 11. Iminium mechanism of Biginelli reaction. 
 
The elucidation of the mechanism of the Biginelli reaction prompted a 
renewed interest in improving the efficiency of this process and a great variety of 
experimental conditions have been reported for this reaction, exploring the use of 
different solvents and acid catalyst as extensively reported.
128
 Solvent-free 
procedures 
129 130
 as well as microwave enhanced protocols,
131
 and solid-phase 
methods suitable for combinatorial chemistry have also been described.
132
 
 
4.3 Chiral, enantioenriched dihydropyrimidines 
4-Substituted-dihydropyrimidines arising from the Biginelli reaction are chiral 
molecules and, not surprisingly, the absolute configuration at C-4 was found to 
                                                 
128  C.O. Kappe, A. Stadler Org.Reactions, 2004, vol. 63, chapt. 1, The Biginelli 
Dihydropyrimidine Synthesis, Ed.by L.Overman et al., Published by John Wiley & Sons.,  
129 A. Shaabani, Bazgir and F. Teimouri, Tetrahedron Lett. 2003, 44, 857. 
130H. G. O. Alvim, T. B. Lima, A. L. de Oliveira, H. C. B. de Oliveira, F. M. Silva, F. C. Gozzo, 
R. Y. Souza, W. A. da Silva, and B. A. D. Neto J. Org. Chem. 2014, 79, 3383. 
131 M. Nuchter, B. Ondruschka, Mol. Diversity 2003, 7, 253. 
132 a. P. Wipf, A. Cunningham, A. Tetrahedron Lett. 1995, 36, 7819; b. A. Studer, P. Jeger, P. 
Wipf, D.P. Curran, J. Org. Chem. 1997; 62, 2917-2924; c. C. O. Kappe, Bioorg. Med. Chem. Lett. 
2000, 10, 49, d. J. J. Vanden Eynde, N. Labuche, Y. Van Haverbeke, L. Tietze, Arkivoc 2003, 15, 
22. 
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greatly influence their pharmacological properties. For example, the (R)-enantiomer 
of the calcium channel blocker SQ 32926 exhibits >400-fold more potent 
antihypertensive activity in vitro than the (S)-enantiomer (Figure 22).
108a
  
 
Similarly, the (S)-enantiomer of the well-known antitumor lead compound monastrol 
(Figure 22) has been found to have a considerably higher activity than the (R)-
enantiomer, both in vitro and in vivo.
133
 The (S) enantiomer of L-771,688 ( Figure 
22), an α1A-adrenoceptor antagonist active against benign prostatic hyperplasia 
(BPH), is 100-fold more potent and selective than its enantiomer.
134
 
 
Due to their important biological and pharmaceutical properties, access to 
optically pure DHPMs is in great demand. Although still lacking a broad application 
scope, several approaches have been developed, based either on the resolution of 
racemic mixtures or on asymmetric synthesis; these have been mainly applied to the 
synthesis of enantioenriched 2-oxo or 2-thiapyrimidinones, while, to our knowledge, 
a single example of optically pure aza analogs has been reported to date.
135
  
 
4.3.1 Resolution 
Initially, optically pure dihydropirimidinones were obtained only by the fractional 
crystallization of diastereoisomeric salts of chiral amines,
136
 or by separation of 
covalently bonded diastereoisomeric compounds.
137 , 138
, For instance, the chiral 
resolution of racemic Monastrol was carried out on a preparative scale (ca. 100 mg), 
                                                 
133 Y. Yan,V. Sardana, B. Xu,C. Homnick, W. Halczenko, C.A. Buser, M. Schaber, G.D. 
Hartman, H.E. Huber, L.C. Kuo, J. Mol. Biol., 2004, 335, 547. 
134 J. C. Barrow, P. G. Nantermet, H. G. Selnick, K. L. Glass, K. E. Rittle, K. F. Gilbert, T. G. 
Steele, C. F. Homnick, R. M. Freidinger, R. W. Ransom, P. Kling, D. Reiss, T. P. Broten, T. W. 
Schorn, R. S. L. Chang, S. S. O'Malley, T. V. Olah, J. D. Ellis, A. Barrish, K. Kassahun, P. 
Leppert, D. Nagarathnam, and C. Forray J. Med. Chem. 2000, 43, 2703. 
135 N. Li, X-H. Chen, J. Song, S.-W. Luo,W. Fan and Z. Gong, J. Am. Chem. Soc. 2009, 131, 
15301. 
136 C. O. Kappe, G. Uray, P. Roschger, W. Lindneq, C. Kratky, and W. Keller, Tetrahedron, 
1992, 48, 5473 
137 A. Dondoni, A. Massi and S. Sabbatini, Tetrahedron Lett., 2002, 43, 5913. 
138 K. Singh , K. Singh, H. Kaur, Tetrahedron 2012,68,6169. 
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through the separation of diastereomeric N-3 ribofuranosyl amides. These were 
obtained from the regioselective acylation of the racemic substrate with the chloride 
of the -linked C-glycosyl carboxylic acid (8c,Scheme 12). After chromatographic 
separation of the diastereoisomeric amides and N-3 deprotection, the individual 
stereoisomers of monastrol were isolated wit >97% optical purity and good total 
yield. CD spectra proved the absolute C-4 configuration of each enantiomer.
137
  
 
 
Scheme 12. Separation of Monastrol enantiomers. 
 
More recently
139
 Singh reported the chemical resolution of some DHPMs by 
appending an enantiopure chiral auxiliary derived from phenylalanine at the N-1 or 
N-3 positions of the heterocycles, leading to the formation of two diastereomers that 
were separated by chromatography to obtain both enantiomers of DHPMs, after 
removal of the auxiliary, with ee up to 99.9%. However, although being efficient in 
the reported cases, these methods turned out to be of limited general applicability.  
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 Biocatalytic kinetic resolution of a precursor of (S)-L-771,668 was 
performed
139
 employing subtilisin for the  selective hydrolysis of C-5 (R)-methyl 
ester, leading to the recovery of the desired (S)-enantiomer in 80-90% chemical yield 
and high (98%) enantioselectivity. Similarly, the preparation of optically pure 
DHPMs by a lipase-catalyzed kinetic resolution of the corresponding N-3-
acetoxymethylated derivatives has been reported by Kappe (Scheme 13).
140
 
 
 
Scheme 13. Lipase catalyzed kinetic resolution of racemic DHMPs. 
 
On the analytical scale, the separation of DHMP derivatives was achieved by 
HPLC on a variety of different chiral stationary phases,
141
 and also by capillary 
electrophoresis
142
 with chiral modifiers and buffers. 
                                                 
139 D. R. Sidler, N. Barta, W. Li, E. Hu, L. Matty, N. Ikemoto, J.S. Campbell, M. Chartrain, K. 
Gbewonyo, r. Boyd, E. Corley, R.G. Ball, R.D. Larsen, P. Reider,  J. Can. J. Chem. 2002, 80, 
646. 
140 B. Schnell, W. Krenn, K. Faber and C. O. Kappe, J. Chem. Soc. Perkin Trans. 1, 2000, 4382 
141 O.P. Kleidernigg, C.O. Kappe Tetrahedron: Asymmetry 1997, 8, 2057.  
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4.3.2 Asymmetric synthesis 
The asymmetric version of the Biginelli reaction has not been available until 
recently. Complementarily to the resolution procedures described above, direct 
asymmetric version of the Biginelli reaction using chiral starting materials or 
auxiliaries have been developed. (-)-Menthyl acetoacetate
136
 and glycosylated 
aldehydes (hexoses or pentoses)
143
 have been used as chiral reactants, providing 
DHPMs, albeit with poor stereoselectivities.  
A breakthrough in the catalytic asymmetric Biginelli reaction came in 2005 
when Zhu and co-workers
144
 found that a novel, recyclable chiral ytterbium catalyst 
provided efficient  control on the enantioselectivity of Biginelli reactions involving 
different aldehydes, -ketoesters and urea/thiourea, yielding DHPMs with good to 
excellent chemical and optical yields.  Later, a 1-glycyl-3-methyl imidazolium 
chloride copper (II) complex was reported to promote the three-component reaction 
of different benzaldehydes, ethyl acetoacetate and urea under solvent-free conditions, 
although its application scope was limited to a few urea-derived DHPMs.
145
 
The very fast progress of organocatalysis as a powerful tool in asymmetric 
synthesis has provided significant advances also in the enantioselective Biginelli 
reaction, which were reviewed in 2013
146
 and 2014.
147
 The first organocatalytic 
highly enantioselective Biginelli reaction was reported by Gong and co-workers in 
2007 using a BINOL-derived phosphoric acids as catalyst.
148
 Different aryl/alkyl 
aldehydes, alkyl acetoacetates, and thiourea/urea were used allowing a broad range 
                                                                                                                                          
142 Wang, F.; Loughlin, T.; Dowling, T.; Bicker, G.; Wyvratt, J.  J. Chromatogr. A., 2000, 872, 
279. 
143 A. Dondoni, A. Massi, E. Minghini, S. Sabbatini, V.  Bertolasi, V. J.Org. Chem. 2002, 67, 
6979. 
144 Y. Huang, F. Yang, C. Zhu, J. Am. Chem. Soc., 2005, 127, 16386. 
145 P. Karthikeyan, S. A. Aswar, P. N. Muskawar, P. R. Bhagat, S. S. Kumar, J. Organometal. 
Chem., 2013, 723, 154. 
146 M.M. Herawi, S. Asadi, B:M. Lashkariani, Mol. Divers. 2013, 17, 389. 
147 J.-P. Wan, J. Lin, Y. Liu, Current organic chemistry 2014, 18, 687. 
148 X.-H. Chen, X.-Y. Xu, H.Liu, L.-F. Cun, and L.-Z. Gong, J. Am. Chem. Soc. 2006, 128 , 
14802. 
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of functionalized DHPMs to be synthesized with good to excellent enantioselectivity. 
Further development on the use of chiral Brønsted acids led to the enantioselective 
synthesis of MCH1-R inhibitor SNAP-7941 with 91%e.e and 96% yield (Figure 
24).
149
 
 
Figure 24. SNAP-7941. 
 
An alternative approach was based on the use of proline-derived secondary 
amines
150
 in combination with achiral Brønsted acids as catalysts to promote the 
Biginelli reaction, with enantioselectivities controlled by a dual activation protocol 
involving the enamine-type activation (via the condensation of the chiral amine and 
the β-keto ester) and the Brønsted acid-catalyzed formation of urea-based imines.151 
A broad range of secondary amines has been employed in the organocatalytic 
Biginelli rection.
147
 Later, chiral primary amines, especially of the cinchona alkaloid 
class, have also attracted great interests. In 2010, the Zhao
152
 and Lai
153
 groups 
reported the enantioselective Biginelli reaction via dual activation using chiral 
primary amines with an acid as additive to activate the enamine intermediate. 
Recently, Wang and co-workers used a derivative of cyclohexane-1,2-diamine for 
the synthesis of enantiomerically enriched DHPMs via the Biginelli reaction.
154
  
                                                 
149 J. M. Goss, S. E. Schaus, J. Org. Chem. 2008, 73, 7651.  
150a. J. G. Xin, L. Chang, Z. R. Hou, D. J. Shang, X. H. Liu, X. M. Feng, Chem.Eur.J. 2008, 14, 
3177; b. R. Gonzalez-Olvera, P. Demare, I. Regla, E. Juaristi, Arkivoc 2008, 4, 61. 
151 a. J. H. Sohn, H. M. Choi, S. Lee, S. Joung, H.Y. Lee,  Eur. J. Org. Chem. 2009, 3858; b. Y.Y. 
Wu, Z. Chai, X.Y. Liu, G. Zhao, S.W. Zhao, Eur. J. Org. Chem. 2009, 904. 
152 D. Ding, C.-G. Zhao, Eur. J. Org. Chem., 2010, 3802. 
153 Y.-F. Cai, H.-M. Yang, L. Li, K.-Z. Jiang, G.-Q. Lai, J.-X. Jiang, L.W. Xu, Eur. J. Org. Chem. 
2010, 4986. 
154 D.-Z. Xu, H. Li, Y. Wang, Tetrahedron, 2012, 68, 7867. 
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Chiral thioureas have been developed as another major class of 
organocatalysts; their ability to induce enantioselectivity in a variety of different 
reactions has been mainly attributed to the ability to form strong hydrogen bonds 
with reactants and/or intermediates. The use of thioureas in enantioselective Biginelli 
reaction has been investigated, among others, by Miao and Chen
155
 they reported that 
a gluco-2-aminocyclohexylthiourea (BPAT(I)), combined with with tert-
butylammonium trifluoroacetate ((t-BuNH2)·TFA) as a Brønsted acid additive, in 
dichloromethane at room temperature, provided DHPMs with (R)- configuration via 
the transition state proposed in Scheme 14.  
 
 
Scheme 14. Mechanism of the BPAT(I)-catalyzed Biginelli reaction. 
 
The opposite (S) enantiomers of the same DHMPs were produced by the 
stereoisomeric catalyst BPAT(II), differing in the configuration at the cyclohexyl 
stereogenic carbon atoms (Figure 25). Later the same authors discovered that the 
same bifunctional thiourea-amine-TfOH system could be used in aqueous solution, 
as a chiral phase transfer catalyst. 
 
                                                 
155 Y. Wang, H. Yang, J. Yu, Z. Miao, R. Chen, Adv. Synth. Catal. 2009, 351, 3057. 
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Figure 25. Thiourea catalysts BPAT(I) and BPAT(2). 
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Results and Discussion 
5. Biginelli reaction with urea and thiourea 
The synthesis of 3,4-dihydropyrimidin-2-(1H)-ones (O1-O16) and thiones (S1-S8), 
was run following a very simple, inexpensive, solvent free method, reported in the 
literature in 2003 as a "green" version of the Biginelli reaction.
129
 The reaction was 
carried out by heating at 100 °C for three hours the reactants in the absence of 
solvent, with ammonium chloride as the catalyst. This protocol is reported to give the 
products in good yields, avoiding the problems associated with the use of solvents, in 
shorter reaction times compared with the traditional methods. Moreover at the 
reaction temperature of 100°C, water by-product evaporates.  
Highest yields were obtained with a 0.5:1:1:1.5 ratio of ammonium chloride, 
aldehyde, 1,3-dicarbonyl compound and urea or thiourea. 
The work-up simply involves addition of water in which the DHPMs precipitate and 
subsequent isolation of the products by filtration.  
Under these conditions a series of aldehydes, acetoacetic esters and acetoacetamide 
were reacted with urea and thiourea for 3hrs to give the corresponding DHPMs. 
Good yields were achieved with aromatic aldehydes, either unsubstituted or bearing 
electron-withdrawing (entries 5, 14, 20) and donating groups (entries 6, 7), and with 
heteroaromatic aldehydes (entries 8, 9, 12, 13, 21).  
Even the reaction of aliphatic aldehydes (entries 1 and 2) which normally proceeds to 
give the products in extremely poor yields under classical conditions, furnished the 
final heterocyclic products in 50 and 60% yields respectively. 
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Entry X R
1 
R
2
 Product Yield (%) 
1 O Methyl EtO O1 60 
2 O Butyl EtO O2 50 
3 O Phenyl EtO O3 92 
4 O Phenyl MeO O4 90 
5 O 4-fluoro-phenyl EtO O5 70 
6 O 
4-hydroxy-3-
methoxyphenyl 
EtO O6 78 
7 O 4-methoxyphenyl EtO O7 72 
8 O Benzothiophen-2-yl EtO O8 85 
9 O 3-benzothiophenyl EtO O9 73 
10 O 2-Naphtyl EtO O10 87 
11 O 1-Naphtyl EtO O11 89 
12 O 2-thiophenyl EtO O12 61 
13 O 3- thiophenyl EtO O13 58 
14 O 2-(2-NO2- thiophenyl) EtO O14 50 
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15 O Phenyl BnO O15 90 
16 O Phenyl NH2 O16 47 
17 S Phenyl EtO S1 85 
18 S Phenyl MeO S2 87 
19 S Phenyl BnO S3 85 
20 S 4-fluoro-phenyl EtO S4 68 
21 S Benzothiophen-2-yl EtO S5 73 
22 S 2-Naphtyl EtO S6 88 
23 S 1-Naphtyl EtO S7 87 
24 S Phenyl (-)MenthylO S8 54 
Table 6. “Solvent free” Biginelli reaction.  
 
All the reaction products were isolated as pure crystalline solids and characterized by 
NMR spectroscopy. They show in the 
1
H NMR spectrum the peak of the hydrogen 
linked to the C-4 that typically resonates in the range 5.0 - 5.5 ppm (Figure 26). Only 
in O1-O2, carrying an alkyl substituent at C-4, the same signal is moved upfield, 
around 4.0 ppm. In O11 on the contrary, it resonates at 6.06 ppm.  
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Figure 26. 
1
H-NMR spectra of compounds O3/O4/O6/O8/O10 in the region from 3.9 to 5.7 ppm. In 
the red box is shown the peak of H-4 for each compound. 
 
The signal of the C-6 methyl group resonates near 2.25 ppm. Furthermore, from the 
correlation with H-4 in the COSY spectra, it is possible to identify the characteristic 
peak of the hydrogen N(3)-H which usually resonates between 7.3-8.0 ppm in the 
pyrimidinones and is shifted downfield in the range 9.6-9.9 ppm in the case of 
thiopyrimidinones.  
Moreover, from O15 the corresponding carboxylic acid O17 was derived by 
hydrogenolysis carried out in MeOH over 10% Pd/C, at room temperature under H2 
atmophere. 
In turn, the carboxylic acid  O17 was employed as the starting material for the 
synthesis of  amides O18, O19 (Figure 27), by  reaction with piperidine or n-
propilamine, under standard amide coupling conditions (TBTU  and DIPEA (N, N-
diisopropylethylamine)). 
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Figure 27. Compounds O17, O18, O19. 
 
5.1 Biological activity assays 
The in vitro BACE 1 inhibitory activity was  determined by enzymatic Fluorescence 
Resonance Energy Transfer (FRET) assay.  
The principle of the BACE 1 FRET assay is as follows: the protease substrate is a 
decapeptide connecting a fluorescence donor group (EDANS, 5- (2-
aminoethylamino) naphthalene-1- sulfonic acid; Ass. 345 nm, Em. 505 nm) and a 
fluorescence acceptor (DABCYL, 4 - ((4-aminophenyl) diazenil) benzoic acid, abs. 
505 nm), Figure 28. 
 
 
Figure 28. Peptide substrate of the β-secretase. Scissile bond is in red. 
 
The distance between these two groups has been selected so that upon light 
excitation, the donor fluorescence energy is significantly quenched by the acceptor 
through resonance energy transfer. Upon cleavage by the protease, the fluorophore is 
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separated from the quenching group, restoring the full fluorescence yield of the 
donor. The increase in fluorescence is linearly related to the rate of proteolysis (blue 
line, Figure 29).  
Upon addition of the inhibitor N3 the fluorescence intensity stops increasing and 
remains constant over time. (green line, Figure 29).  
 
Figure 29. Fluoresence intensity variation, Blue line: substrate + enzyme; green line: substrate + 
enzyme + inhibitor. 
 
The rate of the hydrolysis reaction is obtained by linear interpolation of the 
fluorescence curves and it is represented by the slope of these curve. From the 
relationship between the rate of the inhibited (green line) and not-inhibited reaction 
(blue line) is derived the residual enzyme activity, allowing the determination of the 
IC50 (the half maximal inhibitory concentration). 
 
5.1.1 Inhibition results 
The IC50 values were measured for the 2-oxoDHPMs (O2-O14 and O16-O18) and 2-
thioDHPMs (S1, S2 and S4-S7). All these compounds were found to be active as 
BACE 1 inhibitors. Among them, O4, O10, S4 and S7 were found to be the most 
active agents, with IC50 ranging from 0.20 – 0.50 µM. The others all showed IC50 in 
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the micromolar range with exception of the compounds O7, O9 and O17 that were 
two order of magnitude less active. 
 
Scaffold Product X R
1 
R
2
 IC50( µM) 
 
O2 O Butyl EtO 2.26±0.18 
O3 O Phenyl EtO 2.81±0.10 
O4 O Phenyl MeO 0.32±0.06 
O5 O 4-fluoro-phenyl EtO 1.72±0.38 
O6 O 
4-hydroxy-3-
methoxyphenyl 
EtO 0.65±0.03 
O7 O 4-methoxyphenyl EtO 46.00 
O8 O Benzothiophen-2-yl EtO 1.35±0.09 
O9 O Benzothiophen-3-yl EtO 71.00 
O10 O 2-Naphtyl EtO 0.51±0.05 
O11 O 1-Naphtyl EtO 3.07±0.45 
O12 O 2-thienyl EtO 2.20 
O13 O 3-thienyl EtO 3.20 
O14 O 2-(2-NO2-thienyl) EtO 1.20 
O16 O Phenyl NH2 1.60±0.03 
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Table 7. Determined IC50 for 2-oxoDHPMs (O2-O14 and O16-O18) and 2-thioDHPMs (S1, S2 and 
S4-S7). 
An important structural variation at the DHPM scaffold is represented by the 
introduction of a guanidine unit in the heterocyclic ring. Guanidine functional groups 
are found in numerous biologically active natural products, several drugs and drug 
candidates
156 , 157
 that include cardiovascular, antihistamine, anti-inflammatory, 
antidiabetic, antibacterial, antiviral, and antineoplastic drugs. The diversity in 
activity of these compounds likely derives, in part, from the ability of guanidinium 
cations to recognize receptors by a variety of noncovalent interactions, including 
hydrogen-bonding, electrostatic, and π-stacking associations.  
                                                 
156 J. V. Greenhill, P. Lue, Prog. Med. Chem. 1993, 30, 203. 
157 R. G. S. Berlinck, M. H. Kossuga, Nat. Prod. Rep. 2005, 22, 516.  
Scaffold Product X R
1 
R
2
 IC50( µM) 
 
O17 O Phenyl OH 34.00±0.82 
O18 O Phenyl (CH2)5N 1.60±0.08 
S1 S Phenyl EtO 1.48±0.36 
S2 S Phenyl MeO 0.85±0.03 
S4 S 4-fluoro-phenyl EtO 0.24±0.05 
S5 S Benzothiophen-2-yl Ethoxy 0.67±0.11 
S6 S 2-Naphtyl Ethoxy 1.09±0.04 
S7 S 1-Naphtyl Ethoxy 0.34±0.08 
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The guanidine-containing six-member heterocyclic structural subunit is present for 
example in Rosuvastatin (member of the drug class of statins), the anticancer agent 
Imatinib, the antibiotic sulfadiazine, and trimethoprim
158 , 159
 (TMP). This latter 
compound, initially considered as an antimalarial agent, is now known as highly 
effective against bacterial infections, especially in synergistic combination with 
sulfamethoxazole.  
Also marine natural alkaloids possessing guanidine functionalities embedded in 
complex structural architectures are known, displaying a considerable array of 
biological activity and not surprisingly have attracted considerable synthetic 
interest.
160
  
 
5.2 Biginelli reaction with guanidine 
The condensation of guanidine, an aldehyde, and a -ketoester to form the 
corresponding substituted 2-imino-3,4-dihydropyrimidines, is much less documented 
than the classical Biginelli reaction involving urea and thiourea.  
Examples of Biginelli adducts of this type were described by Cho
161
 and Atwal
162
 as 
resulting from the reactions between the Knoevenagel product of ethyl acetoacetate 
and 3-nitrobenzaldehyde with guanidine or methylguanidine, although in low yields 
(14-25%).  
Milcent in 1997
163
 showed that yields could be improved by replacing acetyl- with 
benzoyl acetate PhCOCH2CO2Et as the -ketoester. He afforded a series of 4-aryl-
                                                 
158 I.M. Lagoja Chem Biodivers 2005, 2, 1. 
159 a. M. Watanabe, H. Koike, T. Ishiba, T. Okada, S. Seo, K. Hirai Bioorg Med Chem 1997, 5, 
437; b. R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter Nat Rev Drug Discov 2002, 1, 
493.  
160 L. Heys, C.G. Moore and P.J. Murphy Chem. Soc. Rev. 2000, 29, 57 
161 H. Cho, K. Shima, M. Hayashimatsu, Y. Ohnaka, A. Mizuno, Y.Takeuchi, J. Org. Chem. 
1985, 50, 4227. 
162 K. S. Atwal, G. C. Rovnyak, J. Schwartz, S. Moreland, A. Hedberg, J. Z. Gougoutas, M. F. 
Malley, D. M. Floyd, J. Med. Chem. 1990, 33, 1510. 
163 R. Milcent, J.-C. Malanda, G. J. Barbier, Heterocycl. Chem. 1997, 34, 329. 
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3,4-dihydro-2-imino-6-phenylpyrimidines-5-carboxylate by reacting guanidine 
hydrochloride with the Knoevenangel adduct resulting from the other two carbonylic 
partners, in the presence of NaHCO3 and reaction times ranging from 8 to 48 hrs 
(Scheme 15).  
 
Scheme 15. Synthesis of 4-aryl-3,4-dihydro-2-imino-6-phenylpyrimidines-5-carboxylates proposed by 
Milcent. 
 
However, in these reactions the formation of double Biginelli adducts [diethyl-
2,4,6,8-tetraaryl-4,6-dihydro-1H-pyrimido-[1,2a]pyrimidine-3,7-dicarboxylates], 
arising from a competitive Michael type condensation between two molecules of 
ester and guanidine was observed (Figure 30).  
 
Figure 30. Diethyl-2,4,6,8-tetraaryl-4,6-dihydro-1H-pyrimido-[1,2a]pyrimidine-3,7-dicarboxylates. 
 
Kappe in 2001
120
 reported optimized microwaves and solvent-free conditions to use 
guanidine in a traditional three-component Biginelli reaction to give the 
cyclocondensation compounds in satisfactory yields while avoiding byproducts, but 
the authors claimed that the presence of the phenyl group on the ketone carbonylic 
function of the -ketoester was an essential condition. 
2-Imino-5-carboxy-3,4-dihydropyrimidines were described to be obtained in high 
yield even working with alkyl acetoacetates by the method proposed by Overman in 
2006.
164
 He reported a four step sequence utilizing pyrazole carboxamidine as a 
                                                 
164 B. L. Nilsson and L.E. Overman, J.Org. Chem. 2006, 71, 7706. 
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masked guanidine reactant, smoothly reacting in a Biginelli-type condensation  with 
aldehydes and -ketoesters.  
After N-3 Boc protection, these products were subjected to ammonolysis and acidic 
deprotection to generate 2-imino-3,4-dihydropyrimidines in good yields (Scheme 
16).  
 
Scheme 16. Synthesis of Biginelli-type products using the procedure proposed by Overman.
164
 
 
In 2009 an improved Biginelli reaction using urea/thiourea/guanidine was described 
using a phase transfer catalysis method.
165
 Finally, multistep Biginelli/ammonolysis 
strategies in which isoureas or isothioureas are used as guanidine precursors to 
access 2-imino-3,4-dihydropyrimidines after treatment with ammonia have been 
described in the literature by Atwal
166
 and later modified by Kappe,
167
 who prepared 
2-imino-3,4-dihydropyrimidines by ammonolysis of resin-bound isothiourea 
Biginelli adducts. 
 
                                                 
165B. Ahmeda, R.A. Khanb, Habibullah, M. Keshari  Tetrahedron Letters 2009, 50 2889.  
166a. D.A. Arnold, M.G. LaPorte, S.M. Anderson, P. Wipf Tetrahedron 2013, 69, 7719; b. K. S. 
Atwal, G.C. Rovnyak, B.C. O’Reilly, J. Schwartz, J. Org. Chem. 1989, 54, 5898. 
167 C. O. Kappe, Bioorg. Med. Chem. Lett. 2000, 10, 49. 
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Scheme 17. Synthesis of 2-imino-3,4-dihydropyrimidines through the procedure proposed by 
Kappe.167 
 
In our hands, and contrarily to what reported in the literature,
120 
ethyl acetylacetate 
(or 1,3-dicarbonyl compound) reacted smoothly with guanidine hydrochloride and 
different aromatic aldehydes under the conditions (DMF, 70°C, excess NaHCO3) 
Kappe had reported  for the reaction of ethyl 2-benzoylacetate, to give the 
corresponding 2-imino-dihydropyrimidines (Scheme 18) 
120
 with very good yields, 
provided the reaction time did not exceeded three hours.  
 
 
Scheme 18. Biginelli reaction with guanidine hydrochloride (R
1
 and R
2
 are summarized in Table 8). 
More prolonged reaction times infact resulted in the formation of the double adducts 
(Figure 30) thus limiting the yield of the process. 
Under these conditions we prepared a library of 2-imino-dihydropyrimidines N1-
N14, that were obtained with the yields reported in Table 8, and whose structure was 
confirmed by spectroscopic analysis.  
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Product R
1 
R
2
 Yield 
N1 Phenyl Ethyl 83 
N2 Benzothiophen-2-yl Ethyl 80 
N3 2-Naphtyl Ethyl 71 
N4 Phenyl Methyl 80 
N5 Phenyl Isobutyl 73 
N6 Phenyl Benzyl 47 
N7 Methyl Ethyl 40 
N8 Butyl Ethyl 53 
N9 4-fluoro-phenyl Ethyl  
N10 1-Naphtyl Ethyl 76 
N11 Biphen-4-yl Methyl 74 
N12 4-(pyridin-2-yl) phenyl Methyl 58 
N13 Benzyl Ethyl 69 
N14
* Phenyl Ethyl 80 
*R3= Phenyl 
Table 8 Yields and IC50 values of 2-iminoDHPMs (N1-14)(R
3= Methyl). 
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Similarly to what described for the urea- and thiourea analogs, the 
1
H-NMR spectra 
(recorded in DMSO-d6) showed characteristic peaks relative to the H-4 proton 
around 5.5 ppm, and the singlet of the CH3 near 2.17-2.24 ppm. A single broad peak 
between 6.00 and 6.50 ppm is attributed to the N(3)-H and the hydrogen of the 
C=NH imino group.
120
  
The carboxylic acid N15 (Figure 31) was obtained by hydrogenolysis of the 
benzylester N6, under the reaction conditions described above for compound O17.  
 
 
Figure 31. Compounds N15, N16, N17. 
 
The amide N16 could not be obtained by the Biginelli reaction of acetoacetamide 
with benzaldehyde and guanidine as under the usual conditions only the 
corresponding double adduct was formed quantitatively (Figure 32).  
 
Figure 32. Double adduct. 
For this reason we used the indirect procedure proposed by Atwal,
166b
 involving the 
conversion of a 2-thio Biginelli cicloadduct into a 2-imino analog through a S-
methylation/ammonolysis reaction (see chapter 5.7.1, d). 
On the contrary, the piperidine amide N17 could be obtained under microwave 
irradiation, at 120°C for ten minutes in ethanol (N17, Figure 31), in the presence of 
NaHCO3. 
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A preliminary comparative screening run on a small series of analog 2-oxo (O3, O8, 
O10), 2-thio (S1, S5, S6) and 2-iminopyrimidines (N1, N2,N3), having the same 
substitution pattern revealed that the latter compounds have the highest inhibitory 
activity. The results are reported in Table 9, in which the IC50 values determined by 
fluorimetric assay for the DHPMs with R
1
 = Ph (O3, S1, N1), R
1
 = benzothiophenyl 
(O8, S5, N2) and R
1
 = 2-naphtyl (O10, S5, N2) are compared.  
 
R
1
 Scaffold 
IC50 (µM): X 
O S N 
Phenyl 
 
2.81±0.10(O3) 1.48±0.36(S1) 0.53±0.09(N1) 
Benzothiophen-2-
yl 
1.35±0.09(O8) 0.67±0.11(S5) 0.30±0.05(N2) 
2-Naphtyl 0.51±0.05(O10) 1.09±0.04(S6) 0.19±0.05(N3) 
Table 9. Comparison of IC50 values between the 2-oxo,2- thio and 2-iminoDHPMs. 
 
Even in these cases, the inhibition values are all in a sub-micromolar range (N1, N2, 
N3, Table 9). 
The behaviour of the oxygen and sulphur compound is not linear, infact O10 (R
1
 = 2-
naphtyl, IC50 = 0.51±0.05 µM) shows a better inhibition activity than the 
corresponding 2-thioDHPMs S6 (R
1
 = 2-naphtyl;1.09±0.04 µM), but the same trend 
is not observed when comparing compounds O3 (R
1
 =Phenyl) with S1 (R
1
 =Phenyl) 
and O8 (R
1
 = Benzothiophen-2-yl) with S5 (R
1
 = Benzothiophen-2-yl) respectively  
Interestingly, it is possible to observe that in each triad the 2-iminoDHPMs are 
always more active than the oxygen and thio analogs, and in this series the 
compound N3, bearing a 2-naphthyl group at position C4 proved the most active 
(IC50 = 0.19±0.05µM). 
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5.3 Crystallographic structures of BACE1-inhibitor complexes present in 
PDB 
In order to rationalize these results we studied the crystallographic structures of non 
peptidomimetic BACE 1-inhibitor complexes present in the Protein Data Bank. This 
study was run on 302 crystallographic structures that were organized in four groups 
according to the presence of urea, thiourea, amidine and guanidine motives in their 
structure.  
No inhibitors having a thiourea unit and only 13 based on the urea group were found 
in the PDB. On the contrary, 62 molecules having the guanidine and 60 the amidine 
group have emerged by this research, and they are reported to have a higher 
inhibition activity than the oxo compounds (Figure 33). 
 
 
Figure 33. Non peptidomimetic BACE 1-inhibitosr organized in four groups according to the 
presence of urea, thiourea, amidine and guanidine motives in their structure. 
 
In the following table (Table 10) are shown some representative members belonging 
to each collection. 
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Inhibitor pdb IC50(µM) Group Subgroup 
 
3CKR 5.000 urea 2-Imidazolidinone 
 
3L5E 0.027 guanidine 
2-
Iminoimidazolidinone 
 
4B00 0.0025 amidine 2-Aminopyrrole 
Table 10 Three BACE-1 inhibitors of known BACE-1 complexes based on urea, guanidine and 
amidine unit.  
 
The crystallographic structures of these ligands, complexed with BACE 1 active site, 
showed that the amidine and guanidine motive interacts with the enzyme pocket 
through a stable network of 4 H-bonds with the catalytic aspartates. At the working 
pH of the enzyme (4-5) probably the iminic nitrogen is protonated, as well as one of 
the aspartic groups. In Figure 34 and Figure 35 are represented the weak interactions 
between the enzyme and two selected inhibitors, namely BDV and I6X 
(corresponding to the pdb file: 3L5E and 4B00, that were found to be among the 
most active (3L5E, IC50= 0.027 µM; 4B00, IC50=0.0025 µM).  
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Figure 34. BACE 1/ BDV complex (pdb file: 3LCE): H-bonds interactions in pink (guanidine group). 
 
 
Figure 35 BACE 1/ I6X complex (pdb file: 4B00): H-bonds interactions in pink (amidine group). 
 
An analogous array of hydrogen bonds is not allowed with the –NHCONH- group 
that is not protonated at the same pH value. Another structural feature of these 
inhibitors is the “butterfly shape” with two large substituents pointing towards 
opposite directions, and therefore filling the two large hydrophobic pockets of the 
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enzyme binding site. Figure 36 and Figure 37, show each the structures of five 
overlapped inhibitors having IC50  from 0.008 to 0.0003 µM. (pdb files: 4rcf 4wtu 
4rce 4b00 4frk (Figure 36) and 4djy 4frs 4h1e 4h3f 4h3g 4h3i (Figure 37). 
 
 
Figure 36 Superimposition of 5 inhibitors of BACE 1  
(PDB files 4rcf 4wtu 4rce 4b00 4frk , IC50 0.003, 0.003, 0.002, 0.003, 0.008µM)-guanidine group. 
 
 
Figure 37. Superimposition of 5 inhibitors of BACE 1 
(PDB files 4djy 4frs 4h1e 4h3f 4h3g 4h3i, corresponding IC50 0.005, 0.002, 0.003, 0.001, 0.006, 0.003 
µM)-amidine group. 
 
5.4 Structure –activity relationship: 2-iminoDHPMs and BACE1 
To gain a deeper insight into the relationship between the structure and activity of the 
2-iminoDHPMs, we extended our studies to the other 2-iminoDHPM, bearing 
different R
1
, R
2
, and R
3
 substituents.  
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Product R
1 
R
2
 Yield IC50(µM) 
N1 Phenyl EtO 83 0.50±0.1 
N2 Benzothiophen-2-yl EtO 80 0.30±0.1 
N3 2-Naphtyl EtO 71 0.20±0.1 
N4 Phenyl MeO 80 0.50±0.1 
N5 Phenyl i-PrO 73 1.06±0.19 
N6 Phenyl BnO 47 Inactive 
N7 Methyl EtO 40 / 
N8 Butyl EtO 53 1.06±0.19 
N9 4-fluorophenyl EtO 70 0.30±0.14 
N10 1-Naphtyl EtO 76 1.50±0.1 
N11 Biphen-4-yl MeO 74 4.65±0.68 
N12 4-(pyridin-2-yl) phenyl MeO 58 0.72±0.13 
N13 Benzyl EtO 69 / 
N14
* Phenyl EtO 80 0.28±0.19 
N15 Phenyl OH 50 0.69±0.05 
N16 Phenyl NH2 57 2.15±0.82 
*
 R
3
= Phenyl 
Table 11. Yields and IC50 values of 2-iminoDHPMs (N1-14). 
 
The effect of the structural variations at the heterocyclic scaffold can be synthetized 
as follows:  
a) Effect of the variation of the ester function: It is possible to observe that the 
variation at the alkoxy group of the ester function in going from methoxy 
(N4) to ethoxy (N1) to isobutoxy (N5) does not affect the inhibition activity, 
which remains in the order of sub-micromolar; by further extending the size 
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of the alkoxy group as in the benzylester N-6, no inhibitory activity was 
observed. IC50 for the carboxylic acid N15 was found to be of the same order 
as the methyl and ethylesters N1 and N4, while a lower inhibitory activity 
was measured for N16. 
b) Effect of the C4 substituent: Considering N1 as the a reference compound 
(IC50 = 0.50±0.1 µM), a decrease in the activity was shown when the phenyl 
substituent at C-4 was replaced by an alkyl group, as in N7, R1 = methyl, and 
N8, R2 = butyl. ). On the contrary an increase in the inhibitory activity was 
observed when a fluorine atom was present on the aromatic group at C4 in 
para position (N9). Larger aromatic groups, as benzothiophen-2-yl (N2), and 
2-naphtyl (N3, IC50 = 0.2µM) increased the activity but with 1-naphtyl (N10), 
biphen-4-yl (N11), 4-(pyrid-2-yl)phenyl (N12) the activity decreased. The 
difference in activity between N3 and N10 shows that the orientation of the 
large aromatic with respect to the dihydropyrimidine group plays a role, and 
the result observed with N11 and N12 suggests the presence of a tight pocket 
in which groups with larger rotational freedom are less favourably 
accommodated. 
The increased activity in going from N11 (biphen-4-yl) to N12 (4-(pyridin-2-
yl) phenyl ) indicates that the presence of the nitrogen atom on the pyridyl 
group could favour the interaction with the binding site trough additional 
hydrogen bonds.  
c) Effect of substituent at C-6: All compounds shown carry a methyl group at C-
6. A dihydropyrimidinone was synthetized with R
1
 = Ph, R
2
 = Et, and 
carrying a Ph substituent at C-6 (N14). This variation was found to not 
significantly affect the inhibitory activity that is slightly higher (IC50 0.28 
µM).  
A point of interest concerning small inhibitors of BACE 1 is the permeability 
across Blood Brain Barrier, that was estimated for some representative DHPMs by 
PAMPA test. 
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5.5 BBB Permeability test: In vitro PAMPA (Parallel Artificial  Membrane 
Permeability) assay  
The drug’s penetration into the BBB at therapeutic concentrations is one of the major 
problem in the pharmacological treatment of central nervous system (CNS) diseases. 
The BBB is a complex semipermeable barrier between blood and the CNS. It  strictly 
controls the exchanges between the brain and blood compartments.
168
 The endothelial 
cells are the main unit of this “wall”; they protect the CNS from endogenous 
materials which could damage it, and this is why they are located in such a way as to 
have tight junctions between them.
169
 The majority of CNS drugs enter the brain by 
transcellular passive diffusion, due to the tight junction structure and limited transport 
pathways. At the early drug discovery stage, evaluation of ADME (Absorption, 
Distribution, Metabolism, Excretion) properties is of crucial importance to reduce 
attrition in development process. Parallel Artificial Membrane Permeability Assay 
(PAMPA) is a high throughput technique developed to predict passive permeability 
through biological membranes. We used the PAMPA-BBB method described by Di 
et al, to determine the ability of a few compounds to penetrate into the brain.
170
 The 
assay employs a brain lipid porcine membrane. Through the equation below it is 
possible to determine the permeability of drugs (Equation 1). 
 
 
 
Equation 1 Equation for the determination of the permeability in the PAMPA assay 
      (in brakets are reported the experimental values used) 
 
                                                 
168 F. L. Cardoso, D. Brites, M. A. Brito, Brain Res. Dev., 2010, 64, 328. 
169 J. Van Asperen, U. Mayer, O. Van Tellingen, J. H. Beijnen, J. Pharm. Sciences, 1997, 86, 881 
170 L. Di, E. H. Kerns, K. Fan, O. J. McConnell, G. T. Carter Eur. J. Med. Chem., 2003, 38, 223. 
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At first, the method was validated by comparing reported permeability values of 
commercial drugs (listed in Table 12) with  experimental data. Figure 38, the shows 
the good correlation between experimental and reported values, IS (R
2
= 0.898). 
 
 
Figure 38 Linear correlation between experimental and reported permeability data, of PAMPA-BBB 
assay, of commercial drugs (reported in table). 
 
From Equation 1 and following the pattern established in the literature for BBB 
permeation prediction
171
 we could classify compounds as CNS+ when they present a 
permeability > 3.9·10
-6
 cm s
-1
 and CNS–  when they present a permeability < 2.1 ·10-
6
 cm s
-1
.  
Based on these results we can consider that compounds O10, S6 and N3 are able to 
cross the BBB by passive permeation (Table 12), with expected decreasing 
permeability in going from S10 to O10 to N3. 
  
                                                 
171 P. Crivori, G. Cruciani, B. Testa, J. Med. Chem., 2000, 43, 2204. 
y = 0.9324x + 0.1988 
R² = 0.8978 
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Compound Bibl.170 Pe (10-6 cm s-1)c Prediction 
Atenolol 0.8 0.2  0.3 CNS - 
Caffeine 1.3 0.3  0.2 CNS - 
Desipramine 12 7.0  0.4 CNS + 
Enoxacin 1.6 0.4  0.1 CNS - 
Hydrocortisone 2.4 1.0  0.3 CNS - 
Ofloxacine 0.8 1.5  0.2 CNS - 
Piroxicam 2.5 3.4  0.4 CNS +  
Promazine 8.8 9.7  1.1 CNS + 
Testosterone 17 14.9  0.6 CNS + 
Verapamil 16 18.8  0.1 CNS + 
O10 / 8.3  0.3 CNS + 
S6 / 9.8  1.0 CNS + 
N3 / 6.9  3.5 CNS + 
a
PBS:EtOH (70:30) was used as solvent. 
b
Data are an average  ± SD of two  independent 
measurments. 
Table 12 Permeability (Pe 10
-6
 cm s
-1
) in the PAMPA-BBB assay for 10 commercial drugs (used in 
the experiment validation) and O10, S6, N3 with their predictive penetration in the CNS.
a 
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5.6 Docking experiment 
Small, non-peptidic inhibitors as those that inspired our work, have only a minority 
of the interactions found on the OM99-2 complex (Chapter 4), but nevertheless, the 
affinity is fully conserved if not improved, as in the case of the 2-amino-3,4-
dihydroquinazoline described by Baxter and colleagues in 2007 (Figure 39).
 172
 
 
Figure 39. a: structure of the Baxter’s inhibitor; b: its network of interactions with the catalytic 
aspartyl residues; c: overlay of its complex with BACE-1 and the complex of OM99-2, showing that 
the N-cyclohexyl substituent lies inside the S1 subsite (pdb id. 2Q15).
172
 
The guanindine-like structure of the inhibitor allows to establish a full network of 
interactions with the catalytic aspartyl residues, both by hydrogen bonding and 
charge complementarity. In order to fill the S1 subsite, the chain connecting the core 
of the molecule with the cyclohexyl ring is folded in order to allow the hydrophobic 
end to fill into subsite S1’. No other subsites are involved in the interaction, and the 
side of the inhibitor sticks out the substrate channel forcing the flap to change its 
conformation to a more open one. 
In order to obtain a preliminary indication on the interactions of our inhibitors with 
BACE-1, we have built several computational models by a molecular dynamics – 
based docking protocol. The crystallographic structure of the BACE-1-Baxter 
inhibitor was chosen as our starting point, and several models were obtained for 
inhibitors of the guanidine series. The set comprises both the R and S enantiomers of 
the most active compound, N3, and the R enantiomers of its 6-phenyl analogue 
(N18), of the compound N10, of N1 and of its 6-phenyl analogue N14. To build the 
models, file 2Q15 was downloaded from the Protein Data Bank, and after adding all 
                                                 
172 E. W. Baxter, A. K. Conway, L. Kennis, F. Bischoff, M. H. Mercken, H. L. De Winter, C. H. 
Reynolds, B. A. Tounge, C. Luo, M. K. Scott, Y. Huang, M. Braeken, S. M. A. Pieters, D. J. C. 
Berthelot, S. Masure, W. D. Bruinzeel, A. D. Jordan, M. H. Parker, R. E. Boyd, J. Qu, R. S. 
Alexander, D. E. Brenneman, and A. B. Reitz J. Med. Chem. 2007, 50, 4261. 
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the hydrogens including the polar ones (setting the pH to 5), the structure was 
relaxed by an energy minimization of 50000 steps of steepest descent method, 
keeping first frozen the protein backbone and then allowing the whole structure to 
relax. The minimization was carried out with the OPLS3 forcefield 
173
 as 
implemented in the Schrödinger suite. 
174
 The ligands were then manually docked 
inside the enzyme and a starting geometry was obtained by superimposing the 
guanidine group of each inhibitor onto that of the Baxter inhibitor in the relaxed 
structure of its model. At least two starting models for each inhibitor were obtained 
by different superimposition ways. The starting models of each inhibitor-BACE1 
complexes were then thermalized by a molecular dynamic run carried out in the NTP 
ensemble at 300 °K for 100 ns. The dynamics outcomes were then analyzed, and the 
lowest energy conformation for each run was chosen for the final optimization of the 
complexes, carried out as described above for the initial one, but using the conjugate 
gradient optimization algorithm. Binding energies were calculated according to eq. 2. 
∆𝐸𝑏 =  𝐸𝐸𝐼 − 𝐸𝐸
0 − 𝐸𝐼
0  𝑒𝑞 2 
Where 𝐸𝐸𝐼 is the OPLS3 energy of the optimized enzyme – inhibitor complex, 𝐸𝐸
0 is 
the OPLS3 energy of the empty enzyme after relaxation down to its closest energy 
minimum (chosen as the same for each model), and 𝐸𝐼
0 is the OPLS3 energy of the 
free ligand in its absolute minimum energy conformation as obtained from a 
conformational search. In this preliminary study all the optimizations were carried 
out in vacuo and no solvation effects were carried into account. The resulting binding 
energies are reported in Table 13. 
  
                                                 
173 E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J.Y. Xiang, L. Wang, D. Lupyan, M.K. 
Dahlgren, J.L. Knight, J.W. Kaus, D.S. Cerutti, G. Krilov, W.L. Jorgensen, R. Abel, R.A. 
Friesner, J. Chem. Theory Comput., 2015, DOI: 10.1021/acs.jctc.5b00864 
174
 Schrödinger Release 2016-4: Maestro, Schrödinger, LLC, New York, NY, 2016. 
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Inhibitor 
Experimental IC50* 
(nM) 
Rel Eb** 
(Kcal mol-1) 
R-N3 
200 
0 
S-N3 5.2 
R-18 / -1.5 
R-N10 150 5.6 
R-N1 500 2.3 
R-N14 300 2.3 
Table 13.*racemic mixture. **relative to the binding energy of R-N3. 
 
 
Figure 40. overlay of the crystal structure of the complex of BACE with the Baxter inhibitor (blue) 
and the best calculated pose of R-N3 (green). 
 
Inhibitor R-N3 ranks second in binding energy within the series, and its pose inside 
the catalytic site resembles strictly that of the Baxter inhibitor (Figure 40), with the 
2-naphtyl group well placed inside S1. 
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Figure 41. the best pose of R-N3 and its interactions. Green surfaces: Connoly surface of subsite S1; 
pink surface: Connoly surface of subsite S3’; red arrow: the pro-S hydrogen of the inhibitor; yellow 
circle: the 6-methyl group of the inhibitor; brown circle: the empty area of S1’-S2’. 
The main interactions of R-N3 are shown in Figure 41. The guanidinium system 
interacts with the two aspartyl residues in a very good fashion, and a full network of 
hydrogen bonds could be established, resembling that of the Baxter inhibitor. The 2-
naphtyl group is at hydrophobic contact distance with most of the residues of S1, 
namely Phe 108, Tyr 71 on the upper flap, Leu 30, Trp 115 and Ile 118 at the bottom 
of the subsite. The ethyl ester group of the inhibitor points towards the surface of 
S3’, with some minor clashes that lead to a certain change in the local conformation 
of the flap (likely causing a decrease in the affinity).  
The S-enantiomer of the same inhibitor is predicted to bind less favorably. Actually 
none of the poses of this molecules lead to optimal interactions. The pro-S hydrogen 
of the inhibitor (red arrow in Figure 41) points towards a very unfavorable position, 
and its replacement with the 2-napthyl group leads to severe bumping with the 
bottom residues of S1. Any solution to this bumping leads to a loss in binding 
energy, either at the aspartyl residues level, either at S1 subsite which cannot be 
filled by the napthyl group in the same way as in the R-enantiomer. The observed 
activity of the racemic mixture on N3 is thus likely due to the R-enantiomer alone.  
Having therefore established that the R-enantiomer allows the better interaction, the 
analyses on the other compounds were carried out on the same configuration only.  
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The 1-naphtyl analogue of R-N3, R-N10 is about one order of magnitude less active, 
and its predicted binding energy is coherently less favorable. In this case, the 
different orientation of the aromatic system makes impossible to keep at the same 
time the interactions of the guanidinum system and those at S1 without clashes with 
Tyr 71.  
R-N1, with a phenyl ring replacing the naphtyl moiety, is found inside the catalytic 
site almost in the same pose of R-N3, and its slightly minor activity can be simply 
explained by the reduced amount of hydrophobic surface in contact with S1. 
The other two compounds in the series bear a phenyl ring at position 6, where a 
methyl group is found in R-N3 (yellow circle in Figure 41). This position points 
mostly outside, and the phenyl rings of compounds N18 and N14 remains partly 
exposed to the solvent. However, they can establish two very favorable interactions, 
namely a -stacking with Tyr 71 and a cation- stacking with Arg 128 on the other 
side, without affecting the overall pose of the molecules, and this can explain the 
good measured affinity of these compounds (Figure 42). 
 
Figure 42. the extra π-stacking and cation- π interactions of inhibitor R-N18 (red surface) with Tyr 
71 (green surface) and Arg 128 (blue surface). 
Finally, we note that it seems difficult to place on the core of our molecules some 
group capable to bring extra interactions at the S1’-S2’ level (brown circle in Figure 
41) without affecting the other interactions. It is also difficult to carry out a rational 
design to solve this problem, as the available IC50 data on the whole series of 
compounds prepared in this thesis span on a rather narrow range of affinities. This 
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makes them poorly significant as candidates for a training set, and a calibration curve 
of a quantitative model built only on the knowledge of such compounds would lead 
to very large errors in the predicted affinity of novel compounds. However, from the 
inspection of the models, it seems that the only way to reach the S1’-S2’ region 
would be via a flexible chain at C5. This could be eventually obtained by replacing 
the ester moiety with an aliphatic ketone one.  
Following this study we planned to run the synthesis  and the evaluation of the 
inhibitory activity for the individual enantiomers of DHMPs .  
 
5.7 Approaches to the synthesis of enantiomeric 2-iminoDHPMs  
Possible pathways reported for the obtainment of 2-oxo and 2-thiooxoDHPM 
enantiomers are shown in Scheme 12, Scheme 13, Scheme 14, comprising chemical 
and enzymatic resolution, use of substrate-based chiral auxiliary reaction and 
organocatalysis, that were already mentioned in the introduction.  
The obtainment of 2-iminopyrimidines in enantiomeric form is not 
documented to our knowledge, apart from a single example in which an optically 
pure thiopyrimidinone was converted into the related chiral 2-pyrrolidinoguanidine 
through S-methylation followed by ammonolysis.
175
  
In the last part of this PhD thesis, we describe some preliminary approaches 
to the  synthesis of chiral 2-iminopyrimidines as single enantiomers. 
Following what reported in the literature for the analog 2-oxo and 2-thioderivatives, 
some attempts were made to obtain  the reference compound 2-iminoDHPM N1 (R
1
 
= Ph) as a single enantiomer. 
 
5.7.1 Asymmetric substrate-based Biginelli reaction  
For the synthesis of DHMP in optically pure form, we considered first the effect of a 
chiral -ketoester on the Biginelli reaction. When (-)-menthyl and (-)-
borneylacetoacetate were reacted with guanidine hydrochloride and benzaldehyde 
under the optimized conditions described above,
120
 the expected Biginelli-type 
                                                 
175
 J.-P. Wan, Y. Lin and Y. Liu. Curr.Org.Chem. 2014, 18, 687. 
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guanidines were obtained as diastereoisomeric mixtures with 20% and 10% d.e. 
respectively, as determined by integration of the appropriate distinguishable signals 
in the 
1
H NMR spectra (Figure 43). Chiral acetylacetate were prepared by boric acid 
mediated transesterification reaction of ethyl acetoacetate with (-) – menthol  (-) - 
borneol
176
 
 
d.e. = diasteroisomeric excess 
Figure 43. Compounds N18 and N19. 
 
The diastereoisomers could unfortunately not be separated by cristallization or by 
chromatographic techniques. 
 
5.7.2 Resolution methods 
a) Classical chemical resolution by formation of diastereoisomeric 
salts  
The presence of the basic guanidine substituent was exploited for the 
formation of diastereoisomeric salts, by reaction with an optically active enantiopure 
carboxylic acid. Mandelic, acetylmandelic, Mosher, and  tartaric acid were used but 
none of them afforded the expected salts in a crystalline, separable form. 
Alternatively, we envisaged that a Biginelli compound with a free acidic group could 
serve as a suitable starting material for a resolution by reaction with a chiral amine. 
The carboxylic acid (N15, Figure 44), not described in the literature, was obtained by 
hydrogenolysis of the corresponding benzyl ester (N6) over 10% Pd/C, carried out in 
MeOH overnight at room temperature under atmospheric H2 pressure.  
 
                                                 
176 G.C.M. Kondaiah, L.A. Reddy, K.S. Babu, V.M. Gurav, K.G. Huge, R. Bandichhor, P.P. 
Reddy, A. Bhattacharya, R.V. Anand, Tetrahedron. Lett., 2008, 49, 106. 
  
94 Part 2  Results and Discussion 
 
Figure 44 Compound N15. 
 
However, subsequent reaction with (R)-(+)--phenylethylamine and (+) or (-)- 
cinchonine did not afford any product prone to crystallization. 
Alternatively, a classic chemical resolution with formation of diastereoisomeric 
compounds was tried, by the use of suitable chiral auxiliaries to append to the 2-
iminopyridines, as described in the following paragraph.  
b) Classical chemical resolution by formation of diastereoisomeric 
compounds  
Following a procedure suggested by Singh
138
 for the chemical resolution of 
enantiomers of 3,4-dihydropyrimidin-2(1H)-ones (see chapter 4), we reacted the 
enantiopure (2S)-3-phenyl-2-phthalimidylpropanoyl chloride (8a) derived from 
phenylalanine, with N1 (Scheme 19). In the literature procedure this reaction occurs, 
after lithiation with BuLi at N-1 affording N-acylated diastereomeric DHPMs, which 
after chromatographic separation and  removal of the chiral auxiliary by LiAlH4 
furnished both enantiomers of DHPMs.  
Considering the basic nature of the guanidine group we run this reaction directly on 
the substrate (N1) at room temperature, in the presence of an equimolar amount of 
Et3N. Acylation occurred at N3 with formation of the corresponding product as 
diastereoisomeric 1:1 mixture, that did not resolve on TLC nor on chromatographic 
column. 
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Scheme 19. Synthesis of NCA1. 
 
N-3 acylation was attempted on the protected guanidine (NP1), described by 
Overman.
164
 This 5-ethoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H-
pyrazol-1-yl)-imine was described to be quite easily N-Boc protected at N-3 by 
reaction with Boc2O under standard condition. This suggested us the possibility to 
employ an enantiopure acid chloride as the electrophile to acylate this position, with 
formation of diastereoisomeric derivatives. NP1 was quantitatively obtained by 
reacting the masked guanidine 1H-Pyrazole-1-carboxamidine hydrochloride in a 
Biginelli type reaction in DMF at 70°C with NaHCO3 to give NP1 quantitatively 
(Scheme 20).  
 
 
Scheme 20. Synthesis of NP1. 
 
NP1 was reacted with the three different chiral auxiliaries 8a, 8b and 8c (Scheme 
21).
137
 The reaction  of NP1 with 8a gave a diasteroisomeric mixture in a 1:1 ratio 
(NPCA1) that could unfortunately not be separated by chromatography.  
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Scheme 21 Synthesis of NPCA. 
 
On the other hand NPCA2, obtained by reaction of NP1 with 8b, lead to a 
diasteroisomeric mixture from which it was possible to separate one diasteroisomer 
with flash chromatography,  the second diastereoisomer remaining in admixture. The 
compound was fully characterized spectroscopically, and was optically active. 
([𝛼]𝐷
20= + 50.4, CHCl3, c=1). This single diasteroisomer (+)-NPCA2 was treated 
with an ammonia aqueous solution for 30min, leading to the corresponding 
deacylated compound (+)-NP1. To transform this compound into N1 in an optically 
active form it is necessary to remove the pyrazolic group as described in the 
literature, after N-Boc reprotection at N3 (see Scheme 16).
164
 These final steps are in 
due course. The opposite enantiomer could be obtained either from the second 
diastereoisomer of NPCA2 mixture, or by carrying by derivatization of NP1 with the 
opposite R enantiomer of acetilmandelic acid (R-8b). This synthesis  is currently 
under investigation.  
 
c) Enzymatic resolution  
Inspired by numerous successful examples of enzymatic resolutions via hydrolysis of 
esters with a stereogenic center in -position, we took into account this type of 
reaction as an alternative to the chemical resolution. However, when screening a set 
of commercially available hydrolases such as, for example, lipases from Aspergillus 
niger, Candida antarctica B (CAL-B), subtilisine, α-chymotripsine and PLE (esterase 
from porcine liver), we could not identify a suitable biocatalytic system  for the 
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hydrolysis at the C-5 ester function. In all cases infact the reactions stopped within 
5% conversion, that were reached after days. Due to the lack of a significant activity 
of this process, further process development has not been carried out. 
 
d) Convesion of 2-thioDHMP into 2-imino DHPM  
The conversion of 2-thioDHMPs into their 2-imino analogs is a documented 
reaction, and it occurs by a convenient one-pot S-methylation/ammonolysis 
procedure. Optimized conditions for the methylation step involve the use of methyl 
triflate in chlorobenzene as the solvent, at 100°C, under sealed tube conditions.
166a 
The following ammonolysis with NH3/NH4Cl smoothly proceeds to give the target 
guanidine with good yields, also on a multigram scale. (Scheme 22). 
Our idea, represented in Scheme 22, was to exploite this indirect method to afford 
enantiomerically pure guanidine from chiral thiopyrimidinones, whose obtainment is 
reported, at least for some specific cases (Scheme 22).
175
 
 
Scheme 22. Possible strategy for the synthesis of enantiomeric 2-imiopyrimidines  through resolution 
of DHMPs-thiones followed by methylation/ammonolysis. 
  
Possible pathways reported for the achievement of 2-thioDHPM enantiomers involve 
chemical and enzymatic resolution, use of chiral substrate-based reactions and 
organocatalysis. 
 
a) The enzymatic resolution of compound S1 was attempted as in the 
literature,
134
 by the use of subtilisine and α-chimotrypsine as the biocatalyst 
for the hydrolysis of the ester function, in aqueous phosphate buffer at pH 7.4 
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also with addition of co-solvents but the reaction did not proceed beyond very 
low conversion values.  
b) Resolution via diastereoisomeric compounds via derivatization with optically 
pure acid chlorides 8a, 8b, 8c (see Scheme 23). The chiral auxiliaries were 
reacted in refluxing toluene. With 8a compound SCA1 was obtained as a not 
separable mixture of diastereoisomers, with 8b and 8c the reactions are 
currently under investigation.  
. 
 
Scheme 23 Synthesis of diasteroisomeric compounds with optically pure active chlorides 8a, 8b, 8c. 
 
c) Asymmetric synthesis at starting from (-)-menthylacetoacetate 7a was also 
attempted, but similarly to the case of the reaction with urea, the Biginelli 
cyclocondensation with thiourea led to a 1:1 diastereoisomeric mixture that 
could not be separated.  
 
 
Figure 45. Compound S8. 
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5.8 Conclusions 
By an inexpensive and simple synthetic method, a series of functionalized 3,4-
dihydropyrimidin-2(1H)-ones, 3,4-dihydropyrimidin-2(1H)-thiones, and 3,4-
dihydropyrimidin-2(1H)-imines were obtained under Biginelli conditions, combining 
urea/thiourea/guanidine with β-ketoesters and different aromatic, heteroaromatic and 
alkyl aldehydes. They were shown to be promising inhibitors of BACE-1 with IC50 
values in the micromolar and sub-micromolar range. 
Guanidine derived DHPM-2-imines were found to be in general more active than the 
corresponding DHPM-2-ones and DHMP-2-thiones, probably due to the ability of 
the protonated guanidine residue to directly target the catalytic aspartates of the 
enzyme. This hypothesis, supported by docking experiments (Figure 41), suggested 
that the 2-imino-DHPM scaffold may represent a privileged motif for the design of 
new and efficient BACE1 inhibitors.  
It has been observed that small structural changes in the 2-iminoDHPM scaffold 
resulted in a variation of the inhibitory activity of the respective compounds. The 
best inhibition activity was observed with a 2-naphtylic substituent at C-4, as a result 
of an optimal fitting of this group into a narrow hydrophobic  pocket due to the its 
dimension and  orientation. 
Based on docking experiments indicating more favorable interactions of the (R)-
enantiomer, we have started our research on the achievement of the DHPMs in 
optically pure forms exploring so far chemical and enzymatic resolution technique 
and asymmetric synthesis with the use of a chiral -ketoester. This part will be 
developed in the future. 
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6 Instruments and materials 
IR spetra were recorded on a Nicolet Avatar FT-IR spectrometer (Thermo Fisher 
Scientific), as thin film or Nujol mull on NaCl. 
NMR spectra were obtained on a Varian 500 MHz spectrometer in CDCl3 or DMSO-
d6 or (CD3)CO2, unless otherwise stated, at 500 MHz (
1
H) and 125.68 MHz (
13
C); 
chemical shifts are in ppm (δ) with chloroform (δ = 7.26 for 1H-NMR and 77.16 for 
13
C-NMR), DMSO (δ = 2.50 for 1H NMR and 39.52 for 13C NMR), or acetone as the 
reference (δ = 2.05 for 1H-NMR and 29.84 for 13C-NMR) as the reference. Coupling 
constants J are given in hertz. 
1
H and 
13
C-NMR resonances have been assigned by a 
combination of DEPT, COSY and HSQC spectra. The resonances multiplicity is 
described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet 
of doublets), br (broad signal). 
Electrospray (ESI) mass spectra were obtained on a Bruker Daltonics Esquire 4000 
spectrometer.  
HRMS analysis were carried out in the ESI mode on a TOF-MS instrument (bruker 
Corporation). 
Chiral High Resolution GC analyses were carried out on a Shimadzu GC-14B 
instrument, the capillary columns being ChiraldexTM type G-TA, γ-cyclodextrin 
(40m X 0.25mm,carrier gas Helium, 180 KPa, split 1:100), or DiMePe β-
cyclodextrin (25m X0.25mm,carrier gas He, 110 KPa, split 1:50). 
HPLC were run on a HP 1100 series instrument with a UV detector at λ = 280 nm, 
using chiral columns (Lux5uCellulose 1 to 4) eluting with nHex/iPrOH mixture in 
different ratios as indicated, flow 1mL/min. 
M.p. (melting points) were measured on a Büchi 510 apparatus and are uncorrected 
Column chromatography were carried out with Merck silica gel 60 (230-240 
Mesh) 
TLC analysis were carried out on silica gel plates using UV light as the visualizing 
agent and KMnO4 and I2 as the developing agent. TLC were pre-coated plastic sheets 
with 0.25mm Merck silica gel 60F-254. 
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Optical rotations ([α]) were measured at 20 °C with a Jasco P-2000 polarimeter 
(Jasco Inc, Easton, MD, USA). 
Commercial reagents and solvents were purchased from Sigma-Aldrich (Milan, 
Italy); 
Anhydrous solvents: THF was distilled over sodium benzophenone ketyl under 
argon, CH2Cl2 and EtOH were distilled over CaH2 under argon. Glassware were 
oven-dried before use. 
BACE1 assays: 
Fluorescence spectra were recorded from 350 to 600 nm on a Perkin 
Elmer LS50B spectrofluorimeter in a quartz cell (optical path 5 mm).  
Human-β-secretase (1.140 mg / mL aqueous solution) was purchased from 
Sigma-Aldrich. Substrate (Arg-Glu(EDANS)-(Asn⁶⁷⁰,Leu⁶⁷¹)-Amyloid β/A4 
Protein Precursor (668-675)-Lys(DABCYL)-Arg trifluoroacetate salt) was 
purchased from BACHEM.  
PAMPA assay  
UV measurements were recorded in a 96-well plate UV reader (Tecan 
Infinite M1000).  
Ten commercial drugs, phosphate buffer saline solution at pH 7.4 (PBS), 
ethanol and dodecane were purchased from Sigma Aldrich and Alfa Aesar. 
Porcine polar brain lipid (PBL) (catalog no. 141101) was purchased from 
Avanti Polar Lipids, donor plate (a 96-well filtrate plate, Multiscreen® IP 
Sterile Plate PDVF membrane, pore size is 0.45 µM, catalog no. 
MAIPS4510), the acceptor plate (an indented 96-well plate, Multiscreen®, 
catalog no. MAMCS9610) and filter PDVF membrane units (diameter 30 
mm, pore size 0.45 μm) from Millipore. 
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6.7 Synthesis of the α-Chiral allylamines  
 
6.7.1 General method for the Synthesis of α-Ketosulfones (3a-i) 
PhSO2Me and PhSO2Et were prepared by reaction of sodium phenylsulfinate 
with appropriate iodoalkene according to the literature.
177
 
 
 
The sulfone 2a-b (2.0 mmol) was dissolved in dry THF (1.5 mL ), the 
solution was cooled to −5 °C, under Ar. Subsequently 1.6 M n-BuLi in hexane (2.5 
mL, 4 mmol for 3a–f,h; 1.25 mL, 2 mmol for 3g,i) was slowly added, and the 
mixture was stirred at −5 °C for 30 min (4 h for reactions with sulfone 2b). The 
resulting yellow suspension was transferred via a syringe to a three-necked flask, 
containing a 2.5M solution in dry THF of the N-Boc amino ester 2 (1 mmol, 1M only 
for 3h,i), at −78 °C, under an Ar atmosphere, with stirring. The mixture was stirred 
overnight and allowed to reach 25 °C, then it was partitioned between water and 
ethyl acetate. The organic phase was extracted with saturated NaHCO3 and brine, 
dried over Na2SO4 and evaporated to give a solid that was purified by flash 
chromatography (eluent AcOEt/petroleum ether from 0% to 15%). NMR spectra 
were recorded in CDCl3, unless otherwise stated.  
  
                                                 
177 S. H. Hwang and M. J. Kurth, Tetrahedron Lett. 2002, 43, 53. 
  
106 Experimental Part 
(3S)-3-(tert-Butoxycarbonylamino)-1-(phenylsulfonyl)-2-butanone (3a): 
 
Yield 89%; white solid, mp 115–117 °C, [𝛼]𝐷
25 −36 (c 0.8, CHCl3). 
IR: 3387, 1736, 1700, 1288, 1148 cm
−1
. 
1
H-NMR (500 MHz): δ 1.35 (d, J = 7.0 Hz, 3H, CH3), 1.44 (s, 9H, C(CH3)3), 4.24 (d, 
J = 14.0 Hz, 1H, CH2SO2Ph), 4.33 (m, 1H, CHNH), 4.44 (d, J = 14.0 Hz, 1H, 
CH2SO2Ph), 5.15 (br, 1H, NH), 7.58 (m, 2H, Ph), 7.69 (m, 1H, Ph), 7.90 (m, 2H, Ph) 
ppm.  
13
C-NMR (125.68 MHz): δ 16.1, 28.1, 55.9, 63.2, 80.2, 128.4, 129.3, 134.3, 139.0, 
155.3, 198.4 ppm.  
ESI-MS: m/z 350 [M + Na]
+
. 
 
(3S)-3-(tert-Butoxycarbonylamino)-4-methyl-1-(phenylsulfonyl)-2-pentanone (3b):  
 
yield 85%; white solid, mp 85–88 °C, [𝛼]𝐷
25  −34 (c 1, CHCl3). 
IR: 3372, 1709, 1506, 1323, 1160 cm
−1
. 
1
H-NMR (500 MHz): δ 0.80 (d, J = 7.0 Hz, 3H, CH(CH3)2), 0.98 (d, J = 7.0 Hz, 3H, 
CH(CH3)2), 1.44 (s, 9H, C(CH3)3), 2.29 (m, 1H, CH(CH3)2), 4.20 (d, J = 14.5, 1H, 
CH2SO2Ph), 4.25 (dd, J = 4.6, 8.7 Hz, 1H, CHNH), 4.43 (d, J = 14.5 Hz, 1H, 
CH2SO2Ph), 5.10 (d, J = 8.7 Hz, 1H, NH), 7.57 (m, 2H, Ph), 7.67 (m, 1H, Ph), 7.93 
(m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 17.0, 19.9, 28.4, 28.9, 64.0, 65.2, 80.5, 128.6, 129.4, 
134.4, 139.1, 156.0, 197.8 ppm. 
ESI-MS: m/z 378 [M + Na]
+
, 394 [M + K]
+
. 
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(3S)-3-(tert-Butoxycarbonylamino)-5-methyl-1-(phenylsulfonyl)-2-hexanone (3c):  
 
Yield 89%; white solid, mp 76–78 °C; [𝛼]𝐷
25 −43 (c 1.6, CHCl3). 
IR: 3369, 1708, 1511, 1323, 1159 cm
−1
. 
1
H-NMR (500 MHz): δ 0.93 (d, J = 6.1 Hz, 3H, CH(CH3)2), 0.94 (d, J = 6.1 Hz, 3H, 
CH(CH3)2), 1.44 (s, 9H, C(CH3)3), 1.67 (m, 2H, CH2CH(CH3)2), 4.21 (d, J = 13.9 
Hz, 1H, CH2SO2Ph), 4.28 (m, 1H, CHN), 4.49 (d, J = 13.9 Hz, 1H, CH2SO2Ph), 5.06 
(d, J = 7.1 Hz, 1H, NH), 7.58 (t, 2H, Ph), 7.67 (t, 1H, Ph), 7.94 (dd, J = 8.0, 1.5 Hz, 
2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 21.4, 23.1, 24.8, 28.2, 39.1, 58.9, 63.3, 80.5, 128.4, 
129.2, 134.2, 138.9, 155.5, 198.6 ppm. 
ESI-MS: m/z 392 [M + Na]
+
, 408 [M + K]
+
.  
Anal. Calcd. for C18H27NO5S: C, 58.51; H, 7.37; N, 3.79. Found C, 58.50; H, 7.43; 
N, 3.86. 
 
(3S,4S)-3-(tert-Butoxycarbonylamino)-4-methyl-1-(phenylsulfonyl)-2-hexanone 
(3d):  
 
Yield 86% ; white solid, mp 83–85 °C; [𝛼]𝐷
25 –0.2 (c 0.9, CHCl3). 
IR: 3368, 1708, 1504, 1323, 1156 cm
−1
. 
1
H-NMR (500 MHz): δ 0.87 (t, J = 7.1 Hz, 3H, CH2CH3), 0.95 (d, J = 6.5 Hz, 3H, 
CH3), 1.05 (m, 1H, CH2CH3), 1.27 (m, 1H, CH2CH3), 1.42 (s, 9H, C(CH3)3), 1.99 
(m, 1H, CHCH2CH3), 4.20 (d, 1H, CH2SO2Ph), 4.27 (dd, J = 5.0, 8.7 Hz, 1H, 
CHNH), 4.43 (d, J = 14.5 Hz, 1H CH2SO2Ph), 5.08 (d, J = 8.7 Hz, 1H NH), 7.56 (m, 
2H, Ph), 7.67 (m, 1H, Ph), 7.92 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 11.6, 16.1, 24.3, 28.4, 35.7, 64.1, 65.0, 80.5, 128.6, 
129.4, 134.3, 139.1, 155.9, 197.9 ppm.  
ESI-MS: m/z 392 [M + Na]
+
, 408 [M + K]
+
.  
Anal. Calcd. for C18H27NO5S: C, 58.51; H, 7.37; N, 3.79. Found C, 58.42; H, 7.40; 
N, 3.91. 
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(3S)-3-(tert-Butoxycarbonylamino)-4-phenyl-1-(phenylsulfonyl)-2-butanone (3e):
  
 
Yield 94%; white solid, mp 137–139 °C; [𝛼]𝐷
25 –22 (c 1, CHCl3). 
IR: 3386, 1732, 1691, 1295, 1147 cm
−1
. 
1
H-NMR (500 MHz): δ 1.38 (s, 9H, C(CH3)3), 2.91 (dd, J = 8.5, 14.0 Hz, 1H, 
CH2Ph), 3.16 (dd, J = 5.5, 14.0 Hz, 1H, CH2Ph), 4.22 (d, J = 14.0 Hz, 1H, 
CH2SO2Ph), 4.35 (d, J = 14.0 Hz, 1H, CH2SO2Ph), 4.47 (m, 1H, CHNH), 5.12 (d, J 
= 6.0 Hz, 1H, NH), 7.15 (m, 2H, Ph (Phe)), 7.23–7.31 (m, 3H, 1H, Ph (Phe) and 2H 
Ph (Phe)), 7.56 (m, 2H, Ph), 7.67 (m, 1H, Ph), 7.86 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 28.2, 36.3, 61.4, 63.7, 80.6, 127.1, 128.4, 128.8, 129.3, 
134.3, 136.2, 138.8, 155.4, 197.4 ppm. 
ESI-MS: m/z 426 [M + Na]
+
, 442 [M + K]
+
. 
 
(3S)-3-(tert-Butoxycarbonylamino)-4-[4-(tert-butyldimethylsilyloxy)phenyl]-1-
(phenylsulfonyl)-2-butanone (3f):  
 
Yield 78%; ee 81%; white solid, mp 111–113 °C; [𝛼]𝐷
25 −21(c 1, CHCl3). 
IR: 3369, 1709, 1609, 1584, 1511 cm
−1
. 
1
H-NMR (500 MHz): δ 0.19 (s, 6H, Si(CH3)2C(CH3)3), 0.98 (s, 9H, 
Si(CH3)2C(CH3)3), 1.39 (s, 9H, COC(CH3)3), 2.86 (dd, J = 8.6, 14.6 Hz, 1H, CH2Ph), 
3.18 (dd, J = 5.7, 14.6 Hz, 1H, CH2Ph), 4.17 (d, J = 13.9 Hz, 1H, CH2SO2Ph), 4.32 
(d, J = 13.9 Hz, 1H, CH2SO2Ph), 4.42 (m, 1H, CHNH), 5.04 (d, J = 6.4 Hz, 1H, NH), 
6.77 (d, J = 8.0 Hz, 2H, Ph(Tyr)), 7.00 (d, J = 8.0 Hz, 2H, Ph(Tyr)), 7.57 (t, J = 7.8 
Hz, 2H, Ph), 7.68 (t, J = 7.8 Hz, 1H, Ph), 7.87 (d, J = 7.8 Hz, 2H, Ph) ppm. 
13
C NMR (125.68 MHz): δ 4.4, 18.2, 25.6, 28.2, 35.7, 61.5, 63.9, 80.6, 120.4, 128.4, 
128.5, 129.2, 130.9, 134.2, 138.8, 154.8, 197.6 ppm. 
ESI-MS: m/z 556.2 [M + Na]
+
, 572 [M + K]
+
.  
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Anal. Calcd. for C27H39NO6SSi: C, 60.76; H, 7.37; N, 2.62. Found C, 60.81; H, 7.38; 
N, 2.55. 
 
1-((2S)-1-(tert-Butoxycarbonyl)-2-pyrrolidinyl)-2-(phenylsulfonyl)-1-ethanone 
(3g):  
 
Yield 60%; yellow oil; [𝛼]𝐷
25 −43.1 (c 1.6, CHCl3). 
IR: 1698, 1693, 1323, 1157 cm
−1
. 
1
H-NMR (500 MHz, mixture of rotamers): δ 1.36 and 1.43 (2s, 9H, C(CH3)3), 1.85–
1.96 (m, 2H, CH2CH2), 2.00–2.24 (m, 2H, CH2CH2), 3.46 and 3.55 (m, 2H, CH2N), 
4.18–4.42 (m, 3H, 2H CH2SO2Ph and 1H CHN), 7.58 (m, 2H, Ph), 7.67 (m, 1H, Ph), 
7.94 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz, Mixture of rotamers): δ 23.9, 24.8, 28.4 and 28.5, 47.0 and 
47.2, 62.8 and 64.1, 65.7 and 66.3, 80.6 and 81.1, 128.6, 129.3 and 129.4, 134.2 and 
134.4, 139.3, 153.7 and 155.0, 198.1 and 198.6 ppm. 
HRMS (ESI) m/z Calcd. for C17H23NNaO5S [M + Na]
+ 
376.1195, found 376.1192.  
 
(2S,4S) and (2S,4R)-2-(tert-Butoxycarbonylamino)-1-phenyl-4-(phenylsulfonyl)-3-
pentanone (3h):  
 
A 3:2 (a and b) was obtained in 77% yield; white solid. 
IR: 3390, 1737, 1700, 1286, 1150 cm
−1
. 
1
H-NMR (500 MHz, mixture of diastereoisomers): δ 1.28 and 1.37 (2d, 3H,CHCH3 a 
and b), 1.39 (s, 5.4H, b C(CH3)3), 1.44 (s, 3.6H, a C(CH3)3), 2.85 (dd, J = 9.6, 14.0 
Hz, 0.67H, a CH2SO2Ph), 3.02 (dd, J = 7.8, 13.8 Hz, 0.33H, b CH2SO2Ph), 3.22 (dd, 
J = 5.0, 13.8 Hz, 0.33H, b CH2SO2Ph), 3.33 (dd, J = 5.0, 14.0 Hz, 0.67H, a 
CH2SO2Ph), 4.40–4.55 (m, 1H, a CHNH), 4.65–4.75 (m, 1H, b CHNH), 4.97 (d, 
0.67H, a NH), 5.40 (d, 0.33H, b NH), 7.17–7.35 (m, 5H, Ph a and b), 7.52–7.77 (m, 
5H, Ph a and b) ppm. 
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13
C-NMR (125.68 MHz): δ 12.1 (b), 12.5 (a), 28.0 (a), 28.1 (b), 35.0 (a), 37.7 (b), 
61.5 (a), 61.6 (b), 65.9 (b), 66.5 (a), 80.2 (b), 80.7 (a), 126.8 (a), 127.1 (b), 128.3 
(b), 128.7, 129.1, 129.2, 129.3, 129.5, 129.6, 129.7, 134.3, 134.5, 135.9, 136.0, 
136.3, 137.3, 155.4, 155.7, 200.8, 202.2 ppm. 
ESI-MS: m/z 440 [M + Na]
+
, 456 [M + K]
+
.  
Anal. Calcd. for C22H27NO5S: C, 63.29; H, 6.52; N, 3.35. Found C, 63.23; H, 6.38; 
N, 3.38. 
 
(2S) and (2R) 1-((2S)-1-(tert-Butoxycarbonyl)-2-pyrrolidinyl)-2-(phenylsulfonyl)-
1-propanone (3i):  
 
A 55:45 mixture of two diastereoisomers (a and b) was obtained in 80% yield. 
Yellow oil. 
IR: 1700, 1689, 1322, 1157 cm
−1
. 
1
H-NMR (500 MHz, DMSO-d6, 80 °C): δ 1.30 (d, J = 7.4, 1.65H, a CH3), 1.34 (d, J 
= 7.4 Hz, 1.35H, b CH3), 1.35 (s, 4.95H, a C(CH3)3), 1.41 (s, 4.05H, b C(CH3)3), 
1.59–2.25 (m, 4H, CH2CH2, a and b), 3.28–3.45 (m, 2H, CH2N a and b), 4.55 (dd, J 
= 3.0, 8.0 Hz, 0.55H, a CHCH3), 4.67 (br, 0.45H, b CHNH), 4.73 (m, 0.45H, b 
CHCH3), 4.85 (br, 0.55H, a CHNH), 7.67 (m, 2H, Ph a and b), 7.78 (m, 1H, Ph a 
and b), 7.88 (m, 2H, Ph a and b) ppm. 
13
C-NMR (125.68 MHz, DMSOd6, 80 °C): δ 12.1 (b), 12.3 (a), 22.7 (a and b), 27.6 
(a or b), 27.7 (a or b), 46.1 (b), 46.3 (a), 64.3, 64.7, 65.7, 78.8 (a), 79.0 (b), 128.5, 
128.6 and 128.8, 133.7 (b), 133.8 (a), 137.0, 153.0, 201.6 ppm. 
HRMS (ESI) m/z Calcd. for C18H25NNaO5S [M + Na]
+
 390.1351, found 390.1342.  
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6.7.2 General method for the Synthesis of Allylamine from Ketosulfones  
 
 
 
The ketone 3a-i (1 mmol) was dissolved in MeOH (5 mL)and NaBH4 (0.04 g, 1 
mmol) was added portion-wise, at 0 °C. When the reaction was complete (TLC), the 
solvent was removed in vacuo. Aqueous workup and extraction with ethyl acetate 
gave the β-hydroxysulfones(4a-i)  as mixtures of diastereoisomers (the ratio were 
determined by NMRanalysis).  
 
 
 
In the minimum amount of dry dichloromethane, the crude mixture of 
diasteroisomeric alcohols was dissolved, 4a-i. The solution was cooled down at 0 °C 
and  2-dimethylaminopyridine (0.01 mmol), triethylamine (10 mmol) and acetic 
anhydride (5 mmol) were sequentially. The reaction mixture was stirred at room 
temperature until the formation of the product was complete (TLC: AcOEt/petroleum 
ether 2:8), extracted with 10% aqueous citric acid, saturated NaHCO3 and brine, 
dried over Na2SO4 and evaporated. If necessary, co-evaporation with toluene was 
performed to completely remove the excess anhydride. The crude acetates 5a-i were 
obtained in quantitative yield and were used in the final step without further 
purification. NMR spectra were recorded in CDCl3, unless otherwise stated. 
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6.7.3 Acetoxysulfones were transformed into the corresponding allylamines 
by two methods (6a-i).  
 
 
Method A: in a Schlenk reactor filled with Ar, sulfone 5i-f (1mmol, mixture of 
diastereoisomers) was dissolved in 3:1 EtOH/THF (0.2 M solution). Mg powder (2.5 
mmol) and HgCl2 (0.1 mmol) were added, in the order. The reaction mixture was 
stirred at room temperature monitoring the progress by TLC (petroleum ether/diethyl 
ether 8:2). To the completed reaction was added 10% aqueous citric acid, and the 
aqueous phase was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over Na2SO4 and evaporated. The crude product (6a-f) was 
purified by column chromatography using 9:1 petroleum ether/Et2O as the eluent.  
Method B: in a round-bottomed flask, under an Ar atmosphere, sulfone 5e-i (1 
mmol) was dissolved into anhydrous, degassed ethanol (0.5 M solution). 5% Na/Hg 
amalgam (3 mmol of Na) was added, at −15 °C, to the stirred solution. The reaction 
mixture was left at room temperature monitoring the progress by TLC (petroleum 
ether/diethyl ether 8:2); water was added, and the same workup as above gave the 
crude allylamines 6e, 6f’, 6g-i 
 
(3S)-3-(tert-Butoxycarbonylamino)-1-butene (6a): 
tert -butyl ( S )-3-hydroxy-4-(phenylsulfonyl)butan-2-ylcarbamate(4a) 
 
3:1 mixture of syn (s) and anti (a) diastereoisomers, pale yellow oil. 
IR: 3370, 1693, 1304, 1146 cm
−1
. 
1
H-NMR (500 MHz): δ 1.13 (d, J = 8.5 Hz, 2.25H, s CH3), 1.21 (d, J = 8.5 
Hz, 0.75H, a CH3), 1.40 (s, 9H, C(CH3)3), 3.21 (m, 1.5H, s CH2SO2Ph), 3.26 
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(m, 0.5H, a CH2SO2Ph), 3.64 (br, 2H, NHCH and OH), 4.10 (br, 1H, 
CHOH), 4.73 (br, 1H, NH), 7.59 (m, 2H, Ph), 7.69 (m, 1H, Ph), 7.92 (m, 2H, 
Ph) ppm. 
13
C-NMR (125.68 MHz): δ 15.4 (s), 18.1 (a), 28.3, 50.1, 59.8 (s), 60.5 (s), 
68.5 (s), 68.9 (s), 79.9, 127.3 (s), 127.9 (s), 129.3 (a), 129.4 (s), 133.7 (a), 
134.1 (s), 139.1, 155.5 ppm. 
ESI-MS: m/z 296 [M + Na]
+
, 368 [M + K]
+
. 
 
tert -butyl (S)-3-acetoxy-4-(phenylsulfonyl)butan-2-ylcarbamate (5a) 
 
3:1 mixture of syn (s) and anti (a) diastereoisomers, white solid, mp 110–111 
°C. 
IR: 3358, 1742, 1712, 1521 cm
−1
. 
1
H-NMR (500 MHz): δ 1.06 (d, J = 7.0 Hz, 0.75H, a CH3), 1.09 (d, J = 7.0 
Hz, 2.25H, s CH3), 1.40 (s, 6.75H, s C(CH3)3), 1.42 (s, 2.25H, a C(CH3)3), 
1.82 (s, 2.25H, s COCH3), 1.95 (s, 0.75H, a COCH3), 3.37 (m, 2H, 
CH2SO2Ph), 3.86 (br, 1H, CHNH), 4.43 (br, 0.75H, s CHOAc), 4.52 (br, 
0.25H, a CHOAc) 5.21 (br, 0.75H, s NH), 5.34 (br, 0.25H, a NH), 7.57 (m, 
2H, Ph), 7.66 (m, 1H, Ph), 7.91 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 16.3 (s), 18.1 (a), 20.6, 28.3, 48.3 (s) 49.4 (a), 
56.7 (s), 57.8 (a), 69.5 (a), 70.2 (s), 80.0, 128.3, 129.3, 133.9, 139.2, 155.1, 
169.8 ppm. 
ESI-MS: m/z 394 [M + Na]
+
. 
 
 
Method A: final yield 68%, oil, ee 95% (by GLC); [𝛼]𝐷
25
 –6.0 (c 0.45, CHCl3). 
1
H-NMR (500 MHz): δ 1.20 (d, J = 8.5 Hz, 3H, CH3), 1.44 (s, 9H, C(CH3)3), 4.22 
(br, 1H, CHNH), 4.45 (br, 1H, NH), 5.10 (m, 2H, =CH2), 5.81 (m, 1H, CH=) ppm. 
13
C NMR (125.68 MHz): δ 20.7, 28.4, 48.1, 79.3, 113.6, 140.1, 155.1 ppm. 
ESI-MS: m/z 194 [M + Na]
+
. 
  
114 Experimental Part 
 
(3S)-3-(tert-Butoxycarbonylamino)-4-methyl-1-pentene (6b): 
tert -butyl (3S)-2-hydroxy-4-methyl-1-(phenylsulfonyl)pentan-3-ylcarbamate 
(4b)  
10:1 mixture of syn (s) and anti (a) diastereoisomers, yellow oil. 
IR: 3368, 1691, 1304, 1146 cm
−1
. 
1
H-NMR (500 MHz, syn diastereoisomer): δ 0.87 (d, J = 7.0 Hz, 3H, 
CH(CH3)2), 0.90 (d, J = 7.0 Hz, 3H, CH(CH3)2), 1.40 (s, 9H, C(CH3)3), 2.18 
(m, 1H CH(CH3)2), 3.23 (m, 1H, CH2SO2Ph), 3.32 (m, 1H, CH2SO2Ph), 3.48 
(m, 1H, CHNH), 3.56 (d, J = 2.9 Hz, 1H, OH) 4.12 (m, 1H, CHOH), 4.41 (d, 
J = 9.7 Hz, 1H, NH), 7.59 (m, 2H, Ph), 7.68 (m, 1H, Ph), 7.92 (m, 2H, Ph) 
ppm.  
13
C-NMR (125.68 MHz, (2S,3S) diastereoisomer): δ 15.7, 20.0, 27.1, 28.3, 
58.5, 60.4, 67.4, 80.1, 128.1, 129.7, 134.4, 139.6, 156.7 ppm. 
ESI-MS: m/z 380 [M + Na]
+
, 396 [M + K]
+
.  
 
tert -butyl (3 S )-2-acetoxy-4-methyl-1-(phenylsulfonyl)pentan-3-ylcarbamate 
(5b) 
 
syn isomer: white solid, mp: 98–100 °C; [𝛼]𝐷
25 −5 (c 0.6, CHCl3). 
IR: 3365, 1744, 1712, 1523 cm
-1
. 
1
H-NMR (500 MHz): δ 0.86 (d, J = 8.5 Hz, 3H, CH(CH3)2), 0.90 (d, J = 8.5 
Hz, 3H, CH(CH3)2), 1.41 (s, 9H, C(CH3)3), 1.62 (m, 1H, CH(CH3)2), 1.75 (s, 
3H, COCH3), 3.33 (d, J = 18.3 Hz, 1H, CH2SO2Ph), 3.44 (dd, J = 12.5, 18.3 
Hz, 1H, CH2SO2Ph), 3.63 (m, 1H, CHNH), 4.35 (d, J = 13.0 Hz, 1H, NH), 
5.29 (m, 1H, CHOAc), 7.57 (m, 2H, Ph), 7.66 (m, 1H, Ph), 7.90 (m, 2H, Ph) 
ppm. 
13
C-NMR (125.68 MHz): δ 17.1, 19.6, 20.6, 28.3, 56.6, 57.3, 68.1, 79.9, 
127.4, 128.3, 129.1, 133.9, 139.1, 155.6, 169.7 ppm. 
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ESI-MS: m/z 422 [M + Na]
+
, 438 [M + K]
+
.  
 
 
Method A: final yield 60%, oil, ee > 99.5% (by GLC); [𝛼]𝐷
25 + 28 (c 0.85, CHCl3), 
lit. [𝛼]𝐷
25 
+25 (CHCl3). 
1
H-NMR (500 MHz): δ 0.88 (d, J = 7 Hz, 3H, CH3), 0.90 (d, J = 7 Hz, 3H, 
CH2CH3), 1.44 (s, 10H, C(CH3)3 and CH2CH3), 1.77 (m, 1H, CHCH2CH3), 3.98 (br, 
1H, CHNH), 4.50 (br, 1H, NH), 5.12 (m, 2H, =CH2), 5.73 (m, 1H, -CH=) ppm.  
13
C-NMR (125.68 MHz): δ 18.2, 18.8, 28.6, 32.4, 58.1, 79.3, 115.2, 137.5, 155.7 
ppm. 
ESI-MS: m/z 222 [M + Na]
+
, 237 [M + K]
+
. 
 
(3S)-3-(tert-Butoxycarbonylamino)-5-methyl-1-hexene (6c):  
tert -butyl (3 S )-2-hydroxy-5-methyl-1-(phenylsulfonyl)hexan-3-ylcarbamate 
(4c) 
 
7:1 mixture of syn (s) and anti (a) diastereoisomers, orange oil. 
IR: 3368, 1694, 1305, 1146 cm
−1
. 
1
H-NMR (500 MHz): δ 0.85 (d, J = 6.7 Hz, 3H, CH(CH3)2), 0.90 (d, J = 6.7 
Hz, 3H, CH(CH3)2), 1.31 (m, 2H CH2CH), 1.39 (s, 9H, C(CH3)3), 1.60 (m, 
1H, CH(CH3)2), 3.25 (m, 1.76H, s CH2SO2Ph), 3.27 (m, 0.24H, a 
CH2SO2Ph), 3.49 (br, 0.12H, a CHNH), 3.56 (br, 0.88H, s CHNH), 3.74, (br, 
0.12H, a OH), 3.78 (br, 0.88H, s OH), 4.10 (m, 1H, CHOH), 4.55 (br d, J = 
7.3 Hz, 0.88H, s NH), 4.72 (br d, J = 9.0 Hz, 0.12H, a NH), 7.57 (t, 2H, Ph), 
7.66 (t, 1H, Ph), 7.92 (d, 2H, Ph) ppm. 
13
C-NMR(125.68 MHz): δ 21.5 (s), 22.0 (a), 23.0 (a), 23.6 (s) 24.6 (s), 24.7 
(a), 28.2 (s), 28.3 (a), 38.9 (s), 41.3 (a), 52.6 (a), 52.9 (s), 59.8 (s), 60.3 (a), 
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67.8 (s), 69.4 (a), 79.6 (s), 79.8 (a), 127.9 (s), 128.0 (a), 129.4 (s), 129.5 (a), 
134.0 (a), 134.1 (s), 134.2 (a), 139.2 (a), 139.3 (s), 156.1 ppm.  
ESI-MS: m/z 394 [M + Na]
+
, 410 [M + K]
+
.  
 
tert -butyl (3 S )-2-acetoxy-5-methyl-1-(phenylsulfonyl)hexan-3-ylcarbamate 
(5c) 
 
7:1 mixture of syn (s) and anti (a) diastereoisomers, white solid. 
IR: 3372, 1745, 1707, 1519 cm
-1
 
1
H-NMR (500 MHz): δ 0.86 (d, J = 6.6 Hz, 3H, CH(CH3)2), 0.91 (d, J = 6.6 
Hz, 3H, CH(CH3)2), 1.13–1.25 (m, 2H, CH2CH), 1.41 (s, 7.9H, s C(CH3)3) 
1.43 (s, 1.1H, a C(CH3)3), 1.60 (m, 1H, CH(CH3)2), 1.78 (s, 2.6H, s CH3CO), 
1.96 (s, 0.4H, a CH3CO), 3.35 (m, 1H, CH2SO2) 3.44 (m, 1H, CH2SO2), 3.76 
(m, 0.13H, a CHN), 3.89 (br, 0.87H, s CHN), 4.33 (d, J = 10.0 Hz, 0.9H, s 
NH), 4.45 (d, J = 10.0 Hz, 0.1H, a NH), 5.18 (m, 0.9H, s CHO), 5.37 (dbt, J 
= 9.4, 2.5 Hz, 0.1H, a CHO), 7.58 (t, 2H, Ph), 7.67 (t, 1H, Ph), 7.91 (dd, J = 
8.0, 1.5 Hz, 2H, Ph) ppm.  
13
C-NMR (125.68 MHz): δ 20.6, 21.6 (s), 21.8 (a), 23.1 (a), 23.2 (s), 24.6 
(a), 24.7 (s), 28.2 (s), 28.3 (a), 39.5 (s), 41.1 (a), 50.6 (s), 52.0 (a), 56.3 (s), 
57.8 (a), 69.1 (a), 70.1 (s), 79.8 (a), 79.9 (s) 128.26 (s), 128.33 (a), 129.27 (s) 
129.33 (a), 133.8, 139.3, 155.4, 169.7 ppm.  
ESI-MS: m/z 436 [M + Na]
+
, 452 [M + K]
+
.  
 
 
Method A: final yield 67% oil, ee > 99.5% (by GLC); [𝛼]𝐷
25 +3.5 (c 1.0, CHCl3). 
1
H-NMR (500 MHz): δ 0.89 (d, J = 6.7 Hz, 3H, CH(CH3)2) 0.90 (d, J = 6.7 Hz, 3H, 
CH(CH3)2), 1.31 (m, 2H, CH2), 1.42 (s, 9H, C(CH3)3), 1.65 (sept, 1H, 
CH2CH(CH3)2), 4.12 (br, 1H, CHNH), 4.62 (br, 1H, NH), 5.03 (d, J = 9.9 Hz, 1H, 
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=CH2), 5.12 (d, J = 15.8 Hz, 1H, =CH2), 5.71 (ddd, J = 6.9, 9.9, 15.8 Hz, 1H, -CH=) 
ppm. 
13
C NMR (125.68 MHz): δ 22.0, 22.7, 24.4, 28.1, 44.7, 51.0, 79.2, 113.9, 139.4, 
155.1 ppm.  
ESI-MS: m/z 236 [M + Na]
+
. 
 
(3S,4S)-3-(tert-Butoxycarbonylamino)-4-methyl-1-hexene (6d):  
tert -butyl (3 S , 4S)-2-hydroxy-4-methyl-1-(phenylsulfonyl)hexan-3-
ylcarbamate (4d)  
94:6 mixture of syn (s) and anti (a) diastereoisomers, pale yellow oil. 
IR: 3370, 1693, 1304, 1146 cm
−1
. 
1
H-NMR (500 MHz): δ 0.85 (t, 0.18H, a CH2CH3), 0.90 (d, J = 7.0 Hz, 3H, s 
CH3), 0.92 (t, J = 7.0 Hz, 0.82H, s CH2CH3), 0.99 (m, 1H, CH2CH3), 1.39 (s, 
9H, C(CH3)3), 1.54 (m, 1H CH2CH3), 1.85 (m, 1H, CHCH2CH3), 3.27 (m, 
2H, CH2SO2Ph), 3.50 (m, 1H, CHOH), 3.58 (br, 1H, OH), 4.18 (m, 1H, 
CHNH), 4.40 (d, J = 9.5 Hz, 0.94H, s NH), 4.84 (d, J = 10.0 Hz, 0.06H, a 
NH), 7.58 (m, 2H, Ph), 7.68 (m, 1H, Ph), 7.92 (m, 2H, Ph) ppm.  
13
C-NMR (125.68 MHz): δ 11.1 (a), 11.8 (s), 15.6 (a), 16.3 (s), 23.1 (s), 25.7 
(a), 28.4, 31.0 (a) 34.2 (s), 58.8 (a), 59.0 (s), 60.4 (s), 60.7 (a), 65.2 (s), 67.2 
(s), 80.1, 127.5 (a), 128.0 (s), 129.4 (a), 129.6 (s), 133.8 (a), 134.2 (s), 139.6, 
156.6 ppm. 
ESI-MS: m/z 394 [M + Na]
+
, 410 [M + K]
+
.  
 
tert -butyl (3 S , 4 S )-2-acetoxy-4-methyl-1-(phenylsulfonyl)hexan-3-
ylcarbamate (5d) 
 
94:6 Mixture of syn (s) and anti (a) diastereoisomers, white solid, mp 108–
110 °C; [𝛼]𝐷
25 −3.8 (c 1.5, CHCl3). 
  
118 Experimental Part 
IR: 3367, 1746, 1708, 1518 cm
−1
. 
1
H-NMR (500 MHz): δ 0.84 (t, J = 7.2 Hz, 3H, CH2CH3), 0.89 (d, J = 6.5 Hz, 
3H, CH3), 1.00 (m, 1H, CH2CH3) 1.30 (m, 1H, CHCH2CH3), 1.41 (s, 8.5H, s 
C(CH3)3), 1.43 (s, 0.5H, a C(CH3)3), 1.50 (m, 1H, CH2CH3), 1.73 (s, 2.8H, s 
COCH3), 1.98 (s, 0.2H, a COCH3), 3.29 (d, J = 15Hz, 1H, CH2SO2Ph), 3.43 
(dd, J = 9.5, 15.0 Hz, 1H, CH2SO2Ph), 3.68 (m, 1H, CHNH), 4.31 (d, 1H, J = 
10.0 Hz, 0.94H, s NH), 4.55 (d, J = 10.5 Hz, 0.06H, a NH), 5.34 (dt, J = 6.3, 
1.2 Hz, 0.94H, s CHOAc), 5.55 (dt, J = 9.3, 2.2 Hz, 0.06H, a CHOAc), 7.57 
(m, 2H, Ph), 7.66 (m, 1H, Ph), 7.90 (m, 2H, Ph) ppm.  
13
C NMR (125.68 MHz, syn diastereoisomer): δ 10.8, 15.5, 20.6, 24.2, 27.9, 
35.1, 56.3, 56.4, 67.9, 80.0, 128.1, 129.1, 133.6, 139.0, 155.5, 169.7 ppm. 
ESI-MS: m/z 436 [M + Na]
+
, 452 [M + K]
+
.  
 
 
Method A: yield 69%, oil, ee > 99.5% (by GLC). [𝛼]𝐷
25 + 32 (c 1.0, CHCl3).  
1
H NMR (500 MHz): δ 0.85 (d, J = 6.5 Hz, 3H, CH3,), 0.89 (t, J = 7.5 Hz, 3H, 
CH2CH3), 1.10 (m, 1H CH2CH3), 1.43 (s, 9H, C(CH3)3), 1.40–1.53 (m, 2H, 
CH2CH3), 4.05 (br, 1H, CHNH), 4.54 (br, 1H, NH), 5.12 (m, 2H, =CH2), 5.70 (m, 
1H, CH=) ppm. 
13
C-NMR (125.68 MHz): δ 11.7, 15.0, 25.3, 28.4, 38.6, 56.9, 78.9, 115.2, 136.8, 
155.5 ppm. 
ESI-MS: m/z 236 [M + Na]
+
, 252 [M + K]
+
. 
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(3S)-3-(tert-Butoxycarbonylamino)-4-phenyl-1-butene (6e): 
tert -butyl ( S )-3-hydroxy-1-phenyl-4-(phenylsulfonyl)butan-2-ylcarbamate 
(4e)  
 
3:1 mixture of syn (s) and anti (a) diastereoisomers, white solid, mp 130–131 
°C. 
IR: 3370, 1692, 1304, 1146 cm
−1
. 
1
H-NMR(500 MHz): δ 1.30 (s, 6.75H, s C(CH3)3), 1.35 (s, 2.25H, a 
C(CH3)3), 2.78–3.01 (m, 2H, CH2Ph), 3.16–3.33 (m, 2H, CH2SO2Ph), 3.62–
3.92 (multiplets, 2H, CHNH and OH), 4.07 (br, 0.25H, a CHOH), 4.14 (br, 
0.75H, s CHOH), 4.55 (br, 0.75H, s NH), 4.93 (d, J = 9.5 Hz, 0.25H, a NH), 
7.16–7.29 (m, 5H, Ph(Phe)), 7.51 (m, 0.5H, a Ph), 7.57 (m, 1.5H, s Ph), 7.64 
(m, 0.25H, a Ph), 7.68 (m, 0.75H, s Ph), 7.82 (m, 0.5H, a Ph), 7.89 (m, 1.5H, 
s Ph) ppm.  
13
C NMR (125.68 MHz): δ 28.1 (s), 28.2 (a), 35.8 (s), 38.3 (a), (55.1 (s), 55.8 
(a), detected in HSQC only) 59.8 (s), 60.3 (a), 65.7 (a), 68.1 (s), 79.8 (s) 80.0 
(a), 126.5 (s), 126.7 (s), 127.8 (a) 127.9 (s), 128.4 (a), 128.5 (s), 129.2 (s), 
129.3 (a), 129.4 (a), 129.5 (s), 134.1 (a), 134.2 (s), 136.9, 139.1, 155.7 ppm. 
ESI-MS: m/z 428 [M + Na]
+
.  
 
tert -butyl (2 S )-3-acetoxy-1-phenyl-4-(phenylsulfonyl)butan-2-ylcarbamate 
(5e) 
 
syn isomer: white solid, mp 122–124 °C; [𝛼]𝐷
25 −7 (c 1, CHCl3). 
IR: 3336, 1732, 1705 cm
−1
. 
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1
H-NMR (syn isomer, 500 MHz): δ 1.28 (s, 9H, C(CH3)3), 1.84 (s, 3H, 
COCH3), 2.61 (m, 1H, CH2Ph), 2.84 (dd, J = 5.5, 14.0 Hz, 1H, CH2Ph), 3.41 
(m, 2H, CH2SO2Ph), 4.08 (br, 1H, CHNH), 4.40 (m, 1H, NH), 5.30 (m, 1H, 
CHOAc), 7.12–7.29 (m, 5H, Ph (Phe)), 7.52–7.57 (m, 2H, Ph), 7.66 (m, 1H, 
Ph), 7.81–7.89 (m, 2H, Ph) ppm.  
13
C NMR(125.68 MHz): δ 20.6, 28.1, 36.8, 53.5, 56.7, 69.7, 80.0, 126.8, 
128.2, 128.6, 129.0, 129.3, 133.8, 136.5, 139.3, 155.3, 169.8 ppm. 
ESI-MS: m/z 470 [M + Na]
+
, 486 [M + K]
+
.  
 
 
Method B: yield 70% white solid, mp 72–74 °C; ee > 99.5%. [𝛼]𝐷
25 + 15 (c 0.85, 
CHCl3); 
1
H-NMR ( 500 MHz): δ 1.44 (s, 9H, C(CH3)3), 2.83 (d, J = 6.3 Hz, 2H, CH2Ph), 4.47 
(br, 2H, CHNH and CHNH), 5.08 (m, 2H, =CH2), 5.80 (m, 1H,CH=), 7.17–7.29 (m, 
5H, Ph) ppm. 
13
C NMR (125.68 MHz): δ 28.3, 41.3, 53.3, 79.1, 114.5, 126.2, 128.1, 129.7, 137.1, 
137.9, 155.3 ppm. 
ESI-MS: m/z 270 [M + Na]
+
. 
 
(3S)-3-(tert-Butoxycarbonylamino)-4-[4-(tert-butyldimethylsilyloxy)phenyl]-1-
butene (6f):  
tert -butyl ( S )-3-hydroxy-1-(4-OTBDS-phenyl)-4-(phenylsulfonyl)butan-2-
ylcarbamate (4f) 
  
5:1 mixture of syn (s) and anti (a) diastereoisomers, white solid, mp 107–109 
°C.  
IR: 3369, 1693, 1610, 1511, 1256, 1145 cm
−1
. 
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1
H-NMR (500 MHz): δ 0.17 (s, 7.5H, s Si(CH3)2C(CH3)3) and 0.18 (s, 1.5H, 
a Si(CH3)2C(CH3)3), 0.97 (s, 5H, s Si(CH3)2) and 0.98 (s, 1H, a Si(CH3)2,), 
1.32 (s, 7.5 H, s C(CH3)3) and 1.35 (s, 1.5H, a C(CH3)3), 2.67–2.95 (m, 2H, 
CH2Ph), 3.14–3.35 (m, 2H, CH2SO2Ph), 3.56–3.92 (m, 2H, CHNH and OH), 
4.05 (br, 0.17H, a CHOH) and 4.11 (br, 0.83H, s CHOH), 4.51 (br, 0.83H, s 
NH) and 4.89 (d, J = 8.6, 0.17H, a NH), 6.71 (d, 0.36H, a Ph(Tyr)) and 6.75 
(d, 1.64H, s Ph(Tyr)), 7.01 (overlapping d, 2H, Ph(Tyr)), 7.61 (m, 2H, 
SO2Ph), 7.67 (m, 1H, SO2Ph), 7.83 (d, 0.36H, a SO2Ph) and 7.90 (d, 1.64H, s 
SO2Ph), ppm. 
13
C-NMR (125.68 MHz): δ −4.45, 18.2, 25.7, 28.2, 35.0 (s), 37.5 (a), 55.3 
(s), 55.9 (a), 59.9 (s), 60.4 (a) 65.7 (a), 68.1 (s), 79.7, 120.0 (a), 120.1 (s), 
127.8 (a), 127.9 (s), 129.4, 130.1, 130.4, 134.1, 139.1, 154.4 (s), 155.7 (a) 
ppm.  
ESI-MS: m/z 558.2 [M + Na]
+
, 574.2 [M + K]
+
. 
 
tert -butyl (3 S )-3-acetoxy-1-(4-OTBDS-phenyl)-4-(phenylsulfonyl) butan-2-
ylcarbamate (5f) 
 
syn isomer, white solid, mp 159–161 °C; [𝛼]𝐷
25 −6.7 (c 1.5, CHCl3). 
IR: 3369, 1747, 1705, 1609, 1512 cm
−1
. 
1
H-NMR (500 MHz): δ 0.16 (s, 6H, Si(CH3)2), 0.96 (s, 9H, 
Si(CH3)2C(CH3)3), 1.30 (s, 9H, C(CH3)3) 1.80 (s, 3H, OCOCH3), 2.45 (m, 
1H, CH2Ph), 2.84 (m, 1H, CH2Ph), 3.43 (m, 2H, CH2SO2Ph), 4.04 (br, 1H, 
CHNH), 4.48 (br, 1H, NH), 5.29–5.34 (m, 1H, CHOAc) 6.73 (d, J = 8.3 Hz, 
2H, Ph(Tyr)), 6.98 (d, J = 8.3 Hz, 2H, Ph(Tyr)), 7.56 (t, 2H, SO2Ph), 7.65 (m, 
1H, SO2Ph), 7.88 (d, J = 7.5 Hz, 2H, SO2Ph) ppm. 
13
C-NMR (125.68 MHz): δ −4.5, 18.2, 20.6, 25.6, 28.1, 35.9, 53.5, 56.6, 
69.7, 79.9, 120.1, 128.2, 129.0, 129.3, 129.9, 133.8, 139.3, 154.4, 155.3, 
169.8 ppm. 
ESI-MS: m/z 600 [M + Na]
+
, 616.2 [M + K]
+
.  
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Method A: yield 76% white solid, mp 51–53 °C; ee = 80% (by HPLC); [𝛼]𝐷
25 + 1.2 
(c 1, CHCl3). 
IR 2957, 2930, 2858, 1702, 1610, 1510 cm
−1
. 
1
H-NMR(500 MHz): δ 0.19 (s, 6H, Si(CH3)2), 0.98 (s, 9H, Si(CH3)2C(CH3)3), 1.41 
(s, 9H, C(CH3)3), 2.76 (m, 2H, CH2Ph), 4.36 (br, 1H, CHNH), 4.47 (br, 1H, NH), 
5.06 (dt, J = 10.3, 1.2 Hz, 1H, =CH2), 5.09 (dt, J = 17.4, 1.2 Hz, 1H, =CH2), 5.78 
(ddd, J = 10.3, 17.4, 5.5 Hz, 1H, CH=), 6.76 (d, 2H, Ph), 7.02 (d, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ −4.8, 18.0, 25.7, 28.4, 40.4, 79.0, 114.5, 119.9, 130.0, 
130.1, 130.4, 138.2, 154.2 ppm.  
ESI-MS: m/z 400 [M + Na]
+
.  
Anal. Calcd for C21H35NO3Si: C, 66.80; H, 9.34; N, 3.71. Found: C, 66.88; H, 9.26; 
N, 3.73. 
 
(3S)-3-(tert-Butoxycarbonylamino)-4-[4-(hydroxy)phenyl]-1-butene (6f’):  
  
Method B from 5f: 81%, white solid, mp 82–84 °C; [𝛼]𝐷
26 +21.5 (c 1.5, CHCl3). 
IR = 3339, 1683, 1615, 1516 cm
−1
. 
1
H-NMR (500 MHz): δ 1.41 (s, 9H, C(CH3)3), 2.75 (m, 2H, CH2Ph), 4.35 (br, 1H, 
CHNH), 4.50 (br, 1H, NH), 5.07 (dd, J = 10.3, 1.2 Hz, 1H, =CH2), 5.10 (dd, J = 
17.4, 1.2 Hz, 1H, =CH2), 5.60 (br, 1H, OH), 5.78 (ddd, J = 17.4, 10.3, 5.5 Hz, 1H, 
CH=), 6.75, (d, 2H, Ph), 7.01 (d, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ 28.4, 40.6, 53.7, 79.7, 114.7, 115.3, 129.0, 130.6, 138.1, 
154.6, 155.5 ppm. 
ESI-MS: m/z 286.1 [M + Na]
+
, 302 [M + K]
+
.  
Anal. Calcd for C15H21NO3: C, 68.42; H, 8.04; N, 5.32; O, 18.23; Found: C, 68.41; 
H, 8.10; N, 5.24. 
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(2S)-1-(tert-Butoxycarbonyl)-2-vinylpyrrolidine (6g):  
tert -butyl ( S )-2-(1 hydroxy-2-(phenylsulfonyl)ethyl)pyrrolidine-N-
carboxylate (4g)  
3:2 mixture of syn (s) and anti (a) diastereoisomers, pale yellow oil. 
IR: 3493, 1687, 1305, 1148 cm
−1
. 
1
H-NMR (500MHz, DMSO-d6, 80 °C): δ 1.38 (s, 5.4H, s C(CH3)3), 1.39 (s, 
3.6H, a C(CH3)3), 1.66–1.92 (m, 2H, CH2CH2), 3.08–3.40 (m, 4H, CH2N and 
CH2SO2Ph), 3.66 (m, 0.6H, s CHN), 3.80 (m, 0.4H, a CHN), 4.25 (br, 1H, 
CHOH), 4.84 (d, J = 6.0 Hz, 0.4H, a OH), 4.91 (d, J = 6.5 Hz, 0.6H, s OH), 
7.63 (m, 2H, Ph), 7.70 (m, 1H, Ph), 7.89 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6, 80 °C): δ 22.9 (a), 24.7 (s), 26.2 (s), 27.6 
(a), 27.8 (s), 30.0 (a), 46.2 (s), 46.7 (a), 58.8 (a), 59.8 (s), 60.4 (a), 60.8 (s), 
65.6 (s), 66.8 (a), 78.1 (s), 78.3 (a), 126.3 (a), 127.1 (s), 128.6 (s), 128.8 (a), 
132.8 (a), 132.9 (s), 140.26 (a), 140.27 (s), 153.5 (s), 153.8 (a) ppm. 
ESI-MS: m/z 378 [M + Na]
+
, 394 [M + K]
+
.  
 
tert -butyl ( S )- 2-(1-acetoxy-2-(phenylsulfonyl)ethyl)pyrrolidine-N-
carboxylate (5g)  
syn isomer: white solid, mp 140–143 °C; [𝛼]𝐷
25 –33.1 (c 1.25, CHCl3). 
IR: 1747, 1692, 1520 cm
−1
. 
1
H-NMR (500MHz, DMSO-d6, 80 °C): δ 1.38 (s, 9H, C(CH3)3), 1.67–1.87 
(m, 4H, CH2CH2), 1.76 (s, 3H, OCH3), 3.04 (m, 1H, CH2N), 3.31 (m, 1H, 
CH2N), 3.60, 3.65 (part AB of an ABX system, J = 4.1, 7.9, 15.0 Hz, 2H, 
CH2SO2Ph), 3.84 (br, 1H, CHN), 5.73 (m, 1H, CHOAc), 7.65 (m, 2H, Ph), 
7.74  
13
C-NMR (125.68 MHz DMSO-d6, 80 °C): δ 19.5, 22.4, 24.7, 27.2, 45.7, 
55.6, 58.8, 66.9, 78.0, 127.2, 128.2, 133.0, 139.1, 153.2, 168.1 ppm. 
ESI-MS: m/z 378 [M + Na]
+
, 394 [M + K]
+
.  
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Method B: yield 84%, oil, ee > 99.5% (by GLC); [𝛼]𝐷
25 −15 (c 0.75, CHCl3), lit. 
[𝛼]𝐷
25 −15.7 (c 0.55, CHCl3). 
1
H-NMR (500 MHz, rotamers): δ 1.43 (s, 9H, C(CH3)3), 1.69 (m, 1H, CH2CH2), 
1.77–1.79 (m, 2H, CH2CH2), 2.02 (m, 1H, CH2CH2), 3.38 (m, 2H, CH2N), 4.27 (br, 
1H, CHN), 5.04 (m, 2H,=CH2), 5.73 (m, 1H, CH=) ppm. 
13
C-NMR (125.68 MHz, rotamers): δ 22.6 and 23.2, 28.3, 31.4 and 31.8, 46.0 and 
46.4, 59.0, 79.0, 113.6, 138.8 and 139.0, 154.8 ppm. 
ESI-MS: m/z 220 [M + Na ]
+
. 
 
(4S)-4-(tert-Butoxycarbonylamino)-5-phenyl-1-butene (6h):  
tert-butyl ((2S)-3-hydroxy-1-phenyl-4-(phenylsulfonyl)pentan-2-yl) 
carbamate (4h) 
 
mixture of 4 diastereoisomers in approximately 1:1:3:3 ratio, white solid. 
IR: 3372, 1704, 1297, 1142 cm
−1
. 
1
H-NMR (500MHz): δ [1.03, 1.06, 1.20 (d, 3H, CHCH3)], [1.23, 1.29, 1.31, 
1.36 (s, 9H, C(CH3)3)], 2.75–3.15 (multiplets, 2H, CH2Ph), 3.20–3.30 (m, 
1H, CH(CH3)), [3.70, 3.85, 3.98 (multiplets, 1H, CH(NH))], [3.80, 4.06, 4.15 
(multiplets, 1H, CH(OH))], [4.38, 4.50 (br, 1H, OH)], [4.85, 4.99, 5.05 (d, 
1H, NH)], 7.20–7.30 (m, 5H, Ph(Phe)), 7.53–7.73 (m, 3H, Ph(Phe)), 7.80–
7.91 (m, 2H, Ph(Phe)). 
13
C-NMR (125.68 MHz): δ [7.1, 11.0, 11.4, 11.7 (CH3CH)], [28.0, 28.17, 
28.22, 28.25 (tBu)], [34.2, 36.8, 38.9, 39.8 (CH2)], [52.4, 52.7, 53.0, 54.8 
(CHNH)], [60.6, 63.1, 63.4, 63.6 (CHSO2Ph)], [69.1, 69.4, 70.0, 72.3 
(CHOH)], [79.4, 79.7, 79.8 (tBu)], [126.4–137.7 (CAr)], [155.1, 155.4 (CO)]. 
ESI-MS: m/z 442 [M + Na]
+
, 458 [M + K]
+
.  
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(2S)-2-((tert-butoxycarbonyl)amino)-1-phenyl-4-(phenylsulfonyl) pentan-3-yl 
acetate (5h) 
 
white solid, mixture of four diastereoisomers.  
IR: 3369, 1747, 1704, 1513 cm
−1
.  
1
H-NMR (500 MHz): δ [1.12, 1.16, 1.24, 1.28 (s, 9H, C(CH3)3), [1.17, 1.44 
(d, 3H, CH3)], [1.99, 2.02, 2.28, 2.35 (s, 3H, COCH3)], 2.45–2.90 (m, 2H, 
CH2Ph ), 3.38 (m, 1H, CHSO2Ph), 3.90–4.10 (m, 1H, CHNH), [4.64, 4.67, 
4.77, 4.82 (m, 1H, NH)], 5.25–5.40 (m, 1H, CHOAc), 7.07–7.90 (m, 5H, 
Ph(Phe)), 7.45–7.60 (m, 3H, Ph), 7.76–7.83 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz): δ [10.8, 12.0, 13.0, 14.2, 20.9, 21.2, 22.1, 22.8, 
27.9, 28.0, 28.3, 28.4 (CH3)], [36.4, 37.6, 39.8, 40.7 (CH2)], [52.3, 52.7, 53.1, 
54.6 (CHNH)], [60.2, 60.7, 61.1, 61.3 (CHSO2Ph)], [70.5, 71.7, 71.9, 73.9 
(CHOAc)], [79.8, 80.1, 80.5, (tBu)], 126.4–138.2 (CAr), [155.0, 155.4, 155.5 
(CO)], [170.0, 170.1, 170.3 (CO)] ppm. 
ESI-MS: m/z 484 [M + Na]
+
, 500 [M + K]
+
.  
 
 
Method B: 8:2 mixture of E and Z isomers, yield 60%, pale yellow oil. 
IR: 3340, 1692, 1390, 1365, 1255 cm
−1
. 
1
H-NMR(500 MHz): δ 1.40 (s, 7.2H, E C(CH3)3), 1.42 (s, 1.8H, Z C(CH3)3), 1.47 (d, 
J = 7.5 Hz, 0.6H, Z CH3), 1.65 (d, J = 7.4 Hz, 2.4H, E CH3), 2.65–2.95 (m, 2H, 
CH2Ph), 4.23–4.66 (br, 2H, CHNH and NH), 5.21 (m, 0.2 H, Z =CH2), 5.30 (m, 
0.8H, E =CH2), 5.52 (m, 1H, CH=), 7.10–7.34 (m, 5H) ppm. 
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13
C-NMR (125.68 MHz): δ 13.1 (Z), 17.7 (E), 28.36 (Z), 28.37 (E), 42.0, 53.2, 79.3, 
126.2, 126.3, 128.17 (E) 128.20 (Z), 129.6 (E), 129.7 (Z), 130.9, 137.7 (E), 137.8 
(Z), 155.0 (Z), 155.1 (E) ppm. 
HRMS (ESI) m/z Calcd, for C16H23NNaO2 [M + Na]
+
 284.1626, found 284.1628. 
 
1-[(2S)-1-(tert-Butoxycarbonyl)-2-pyrrolidinyl]-1-propene (6i):  
(2S)-tert-butyl 2-(1-hydroxy-2-(phenylsulfonyl)propyl)pyrrolidine-1-
carboxylate (4i) 
 
Mixture of diastereoisomers, yellow oil. 
IR: 3420, 1687, 1302, 1148 cm
−1
. 
1
H-NMR (500 MHz, major diastereoisomer) δ: 1.37 (d, 3H, CH3), 1.44 (s, 
9H, C(CH3)3), 1.70–1.90 (m, 3H, CH2CH2), 2.18 (m, 1H, CH2CH2), 3.30 (m, 
1H, CH2N), 3.37 (m, 1H, CHCH3), 3.50 (m, 1H, CH2N), 3.73 (m, 1H, 
CHOH), 4.40 (m, 1H, CHN), 5.18 (m, 1H, OH), 7.53 (m, 2H, Ph), 7.64 (m, 
1H, Ph), 7.93 (m, 2H, Ph) ppm. 
13
C-NMR (125.68 MHz, major diastereoisomer) δ: 13.2, 24.3, 27.8, 29.9, 
48.1, 60.1, 63.8, 77.4, 80.3, 129.0, 130.1, 134.1, 157.5 ppm. 
ESI-MS: m/z 392 [M + Na]
+
, 408 [M + K]
+
.  
 
(2S)-tert-butyl 2-(1-acetoxy-2-(phenylsulfonyl)propyl)pyrrolidine-1-
carboxylate (5i) 
 
yellow oil, mixture of diastereoisomers.  
IR: 3496, 1744, 1691 cm
−1
. 
1
H-NMR (500 MHz, major diastereoisomer): δ 1.40 (br, 12H, C(CH3)3 and 
CH3), 1.76 (s, 3H, CH3CO), 1.80–2.05 (m, 4H, CH2CH2), 3.07–3.67 (m, 3H, 
CH2N and CHSO2Ph), 4.2–4.4 (m, 1H, CHN), 5.12 (m, 1H, CHOAc), 7.53 
(m, 2H, Ph), 7.64 (m, 1H, Ph), 7.93 (m, 2H, Ph). 
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 13
C-NMR (125.68 MHz, major diastereoisomer): δ 11.9 (CH3), 21.1 
(CH3CO), 23.7 (CH2), 28.4 (tBu), 29.4 (CH2), 46.9 (CH2N), 56.9 (CHN), 
61.8 (CHSO2Ph), 73.4 (CHOAc), 79.5 (tBu), 128.8, 129.0, 133.5, 139.0, 
155.4, 170.2 ppm. 
ESI-MS: m/z 434 [M + Na]
+
, 450 [M + K]
+
.  
 
 
Method B: 85:15 mixture of E and Z isomers, yield 65%, pale yellow oil. 
IR: 1695, 1394, 1365, 1252 cm
−1
. 
1
H-NMR ( 500MHz, DMSO- d6, 80 °C): δ 1.39 (s, 7.65H, C(CH3)3), 1.40 (s, 1.35H, 
C(CH3)3), 1.51 (m, 0.15 H, CH2CH2), 1.60–1.65 (m, 0.85H, CH2CH2), 1.64 (d, 3H, 
CH3), 1.75 (m, 2H, CH2CH2), 1.94 (m, 0.85H, CH2CH2), 2.04 (m, 0.15H, CH2CH2), 
3.20–3.34 (m, 2H, CH2N), 4.14 (m, 0.85H, CHN), 4.48 (m, 0.15H, CHN), 5.30–5.50 
(m, 2H, CH= and =CHCH3). 
13
C-NMR (125.68 MHz, DMSO- d6, 80 °C): δ 12.2 (Z), 16.6 (E), 22.3 (Z), 22.8 (E), 
27.8 (E,Z), 31.3 (E), 32.0 (Z), 45.5 (E), 45.6 (Z), 53.3 (Z), 57.5 (E), 77.5 (E), 77.6 
(Z), 122.3 (Z), 123.6 (E), 131.9 (E), 132.5 (Z), 153.2 (E,Z).  
HRMS (ESI) m/z Calcd. for C12H21NNaO2 [M + Na]
+ 
234.1470, found 234.1477. 
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6.8 Biginelli Reaction: dihydropyrimidines  
6.8.1 Synthesis of β-ketoesters – transesterification (7a-c) 
 
 
 
Reagent: ROH Product name 
(1R,2S,5R)-(−)-Menthol 7a 
(−)-Ethyl-L-lactate 7b 
(-)Borneol 7c 
Table 14 synthesis of β-ketoesters 
 
To a 0.5M solution of ethylacetoacetate(1mmol) in toluene was added the 
alcohol (1.5mmol) and 10% of boric acid (0.1mmol) were added. 
The solution was heated to reflux and stirred for 6 h, ethanol was removed with a 
Dean-Stark apparatus. Once the reaction was complete (TLC, ethylacetate/PE: 
20/80). The mixture was cooled to r.t., neutralized with saturated NaHCO3 solution, 
and extracted with AcOEt . The organic layers were washed with brine, dried on 
Na2SO4, and concentrated in vacuo. The residue was purified by flash 
chromatography (siliga gel, AcOEt 10% in PE), leading to 7a-c.  
  
B(OH)3 (10 mol%) 
ROH, PhCH3 
reflux 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 3-oxobutanoate (7a)  
 
 
Yield 99%, transparent oil. 
IR: 2957, 2871, 1741, 1716, 1646, 1243, 1149 cm
-1 
1
H-NMR (500 MHz, CDCl3): δ, 0.76 (d, 3H, J = 7 Hz, CH(CH3)2 ), 0.89 (d, 3H, J = 
7.2 Hz, CH(CH3)2), 0.91 (d, 3H, J = 6.5 Hz, C(5)HCH3), 2.05-0.92 (m, 9H, C(1/2)H, 
C(3/4/6)H2), 2.26 (s, 3H, C(O)CH3), 3.42 (d, 2H, J = 2 Hz, CH2CO), 4.73 (dt, 1H, J 
= 11.1, 4.5 Hz, OC(1)H) ppm.  
13
C-NMR (125.68 MHz, CDCl3): δ 16.1, 20.7, 22.0, 23.3, 26.1, 30.0, 31.4, 34.1, 
40.7, 46.9, 50.5, 75.5, 166.7, 200.6 ppm.  
ESI-MS: (m/z) 263.4 [M+H]
+
. 
 
(S)-1-ethoxy-1-oxopropan-2-yl 3-oxobutanoate (7b)  
 
 
Yield 74%, pale-yellow oil. 
IR: 2989, 2943, 1747, 1720, 1633, 1210, 1098 cm
-1 
1
H-NMR (500 MHz, CDCl3): δ, 1.19 (t, 3H, J = 8.7 Hz, CH2CH3), 1.40 (d, 3H, J = 9 
Hz, CHCH3), 2.20 (s, 3H, C(O)CH3), 3.66 (d, 2H, J = 4 Hz, C(O)CH2C(O)), 4.13 
(qd, 2H, J = 8.8, 2 Hz, CH2CH3), 5.03 (q, 1H, J = 8.6 Hz, CHCH3). 
 13
C-NMR (125.68 MHz, CDCl3): δ, 14.4, 17.0, 30.4, 49.8, 61.5, 69.5, 167.4, 170.8, 
201.7 ppm.  
ESI-MS: (m/z) 225.4 [M+H]
+
. 
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1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 3-oxobutanoate(7c)  
 
Yield 71%, incolor oil. 
IR: 2956, 2881, 1739, 1716, 1650, 1245, 1152 cm
-1 
1
H-NMR (500 MHz, CDCl3): δ 0.84 (s, 3H, CHC(CH3)CH2), 0.87 (s, 3H, C(CH3)2), 
0.90 (s, 3H, C(CH3)2), 2.28 (s, 3H, C(O)CH3), 1.90-0.94 (m, 5H, CHCH2CH2), 2.37 
(m, 2H, CHCH2CH), 3.46 (s, 2H, C (O)CH2C(O)), 4.95 (dd, 1H, J = 10.0, 3.6 Hz, 
CHO) ppm. 
 13
C-NMR (125.68 MHz, CDCl3): δ 13.6, 19.0, 19.8, 27.2, 28.1, 30.3, 36.8, 45.0, 
48.0, 49.0, 50.6, 81.4, 167.6, 200.8 ppm.  
ESI-MS: (m/z) 260.5 [M+H]
+
. 
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6.8.2 Synthesis of 3,4-dihydropyrimidin-2(1H)-ones (O1-16) and  
3,4-dihydropyrimidin-2(1H)-thiones (S1-8).
129
 
 
 
 
Following a literature procedure a mixture of the appropriate aldehyde (1 mmol), β-
ketoester or acetoacetamide (1 mmol), urea or thiourea (1.5 mmol) and NH4Cl (0.4 
mmol) was heated at 100°C for 3 h. under stirring. The reaction mixture was allowed 
to reach r.t. and cold water was added to it (25 mL). The solid precipitated was 
filtered off and recrystallized from ethyl acetate:n-hexane (1:3). NMR spectra were 
recorded in DMSO- d6, unless otherwise stated. 
 
6.8.2.1 3,4-dihydropyrimidin-2(1H)-ones O1-11 (Table 15) 
 
R
1 
R
2
 Product name 
Methyl EtO O1 
Buthyl EtO O2 
Phenyl EtO O3 
Phenyl MeO O4 
4-fluoro-phenyl EtO O5 
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4-hydroxy-3-
methoxyphenyl 
EtO O6 
4-methoxyphenyl EtO O7 
Benzothiophen-2-yl EtO O8 
3-benzothiophenyl EtO O9 
2-Naphtyl EtO O10 
1-Naphtyl EtO O11 
2-thienyl EtO O12 
3-thienyl EtO O13 
2-(2-NO2-thienyl) EtO O14 
Phenyl BnO O15 
Phenyl NH2 O16 
a 
R
3
= methyl 
Table 15 2-oxoDHPMs synthetized
a
. 
 
5-Ethoxycarbonyl-4, 6-dimethyl-3,4-dihydropyrimidin-2(1H)-one (O1)  
 
Yield 60%, white solid, mp 192-194°C 
IR: 3265, 3110, 1704, 1651 cm
-1 
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1
H-NMR (500 MHz, DMSO-d6): δ 1.08 (d, 3H, J= 6 Hz, CHCH3), 1.18 (t, 3H, J= 7 
Hz CH2CH3), 2.14 (s, 3H, C(6)CH3), 4.07 (m, 3H, CH2CH3 and C(4)CH3) 7.19 (s, 
1H, N(3)H), 8.97 (s, 1H, N(1)H)ppm. 
13
C-NMR (100 MHz, DMSO-d6): δ 14.3, 17.7, 23.4, 46.3, 59.1, 100.5, 147.8, 152.5, 
165.3 ppm 
ESI-MS: (m/z) 199.3 [M+H]
+
. 
 
5-Ethoxycarbonyl-4- butyl-6-methyl-3,4-dihydropyrimidin-2(1H)-one (O2) 
 
Yield 50%, white solid, mp 178-183°C 
IR: 3255, 3123, 2938, 1720, 1655 cm
-1 
1
H-NMR (500 MHz, DMSO-d6): δ 0.86 (t, 3H, J= 8.5 Hz, CH2CH2CH3), 1.16 (t, 3H, 
J= 9 Hz, OCH2CH3), 1.22 (m, 4H, CH2CH2CH3), 1.36 (m, 2H, C(4)CH2), 2.14 (s, 
3H, C(6)CH3), 4.01(m, 3H, OCH2CH3 and C(4)CH3) 7.29 (s, 1H, N(3)H), 8.90 (s, 
1H, N(1)H)ppm.  
13
C-NMR (125.68 MHz, DMSO-d6): δ 14.0, 14.2, 17.7, 21.9, 25.9, 36.4, 50.0, 59.0, 
99.4, 148.3, 152.8, 165.4 ppm. 
ESI-MS: (m/z) 241 [M+H]
+
, 263 [M+Na]
+
, 279 [M + K]
+
. 
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5-Ethoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (O3)  
 
Yield 92%, white solid, mp 205-206°C 
IR: 1724, 1700, 1646, 1221, 1089 cm
-1
 
1
H-NMR (500 MHz, DMSO-d6): δ 1.09 (t, 3H, J= 10 Hz, CH2CH3), 2.24 (s, 3H, 
C(6)CH3), 3,91 (q, 2H, CH2CH3); 5.14 (d, 1H, J= 2.5 Hz, CH(4)Ph), 7.20-7.36 (m, 
5H, Ph), 7.74 (s, 1H, N(3)H); 9.20 (s, 1H, N(1)H) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 14.53, 18,24 , 54.49, 59.74, 99.87, 129,08-
126,92, 145,58, 149,09, 152.87, 166.09 ppm. 
ESI-MS: (m/z) 261.5 [M+H]
+
, 283.4 [M+Na]
+
.  
 
5-Methoxycarbonyl- 6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one(O4) 
 
Yield 90%, cream-white powder, mp 207-209°C 
IR: 1693, 1642, 1406 , 1335 , 1272 , 1228, 1088 cm
-1
.  
1
H-NMR (500 MHz, DMSO-d6):δ 2.25 (s, 3H, C(6)CH3), 3.53 (s, 3H, OCH3), 5.14 
(d, J= 1 Hz, 1H, C(4)H), 7.23-7.34 (m, 5H, Ph), 7.74 (s, 1H, N(3)H), 9.20 (s, 1H, 
N(3)H).  
13
C-NMR (125.68 MHz, DMSO-d6): δ 17.71, 50.83, 53.85, 99.30, 126.6, 127.73, 
128.90, 145.21, 149.22, 152.73, 166.45 ppm.  
ESI-MS: (m/z) 269.4 [M+Na]
+
.  
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5-ethoxycarbonyl 4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidine-2(1H)-one 
(O5)  
 
Yield 70%,  yellow solid, mp 189-191°C 
IR: 3285, 2374, 1700, 1088 cm
-1
 
1
H-NMR (500 MHz, DMSO-d6): δ 1,09 (t, 3H, J = 9.0 Hz, CH2CH3), 2.25 (s, 3H, 
C(6)CH3), 3,98 (q, 2H, J= 9.0 Hz, CH2CH3); 5.15 (d, 1H, J= 4.5 Hz, CH(4)), 7.11-
7.18 (m, 2H, Ph), 7.24-7.29(m, 2H, Ph), 7.75 (s, 1H, N(3)H); 9.22 (s, 1H, N(1)H) 
ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 14.1, 17.7, 53.4, 59.2, 99.1, 115.1(d, 
2
J = 21.0 
Hz), 128.2 (d, 
3
J = 8.0 Hz), 141.1 (d, 
4
J = 3.0 Hz), 150.3 (d, 
1
J = 345.0 Hz), 160.1, 
165.2 ppm. 
ESI-MS: (m/z) 279 [M+H]
+
.  
 
5-Ethoxycarbonyl 4-(4-hydroxy-3-methoxyphenyl)-6-methyl-3,4-
dihydropyrimidine-2(1H)-one (O6) 
 
Yield 78%, yellow solid, mp 234-236°C 
IR: 3248, 3114, 1701, 1647, 1518 cm
-1
 
1
H-NMR (500 MHz, DMSO-d6): δ 1.11 (t, 3H, J = 10.0 Hz, CH2CH3), 3.72 (s, 3H, 
OCH3), 2.23 (s, 3H, C(6)CH3), 3.99 (q, 2H, J = 9.0 Hz, CH2CH3), 5.15 (d, 1H, J= 4.0 
Hz, CH(4)), 6.55-6.83 (m, 3H, Ph), 7.62 (s, 1H, N(3)H), 8.89 (s, 1H, OH), 9.11 (s, 
1H, N(1)H) ppm. 
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13
C-NMR (125.68 MHz, DMSO-d6): δ 14.2, 17.7, 53.6, 55.6, 59.1, 99.5, 135.9, 
145.8, 147.2, 147.9, 152.2, 165.5 ppm 
ESI-MS: (m/z) 307 [M+H]
+
.  
 
5-Ethoxycarbonyl-4-(4-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one 
(O7): 
 
Yield 72%, white solid, mp 202-203°C 
IR: 3237, 3115, 1701, 1648, 1516, 1281, 1221, 1086, 786cm
-1
 
1
H-NMR (500 MHz, DMSO-d6): δ 1.15 (t, 3H, J = 7.1 Hz, CH2CH3), 2.22 (s, 3H, 
C(6)CH3), 3.70 (s, 3H, OCH3), 3.89 (q, 2H, J= 7.1 Hz, CH2CH3), 5.20 (s, 1H, 
C(4)H), 6.83 (d, 2H, J = 7.6 Hz, Ph),7.16 (d, 2H, J = 7.6 Hz, Ph), 7.63 (s, 1H, 
N(3)H), 9.20 (s, 1H, N(1)H) ppm. 
ESI-MS: (m/z) 291.5 [M+H]
+
.  
 
5-Ethoxycarbonyl-4-(benzo[b]thiophen-2-yl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-one (O8)  
 
Yield 85%, white solid, mp 260-262 °C (dec). 
IR: 3188, 3091, 2916, 1704, 1645, 1285, 1221, 1089 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 1.19 (t, 2H, J = 7.1 Hz, CH3CH2), 2.24 (s, 3H, 
C(6)CH3), 4.09 (q, 3H, J =7.1 Hz, CH3CH2O), 5.50 (d, 1H, J = 3.5 Hz, C(4)H), 7.19 
(s, 1H, thiophenyl CH=C), 7.28-7.36 (m, 2H, ArH), 7.79 (d, 1H, J = 7.2 Hz, ArH), 
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7.88 (d, 1H, J = 7.2 Hz, ArH), 8.01 (bdd, 1H, J = 1.6, 3.5 Hz, N(3)H), 9.39 (bd, J = 
1.6Hz, 1H, N(1)H);  
13
C NMR (125.68 MHz, DMSO-d6): δ 14.2, 17.7, 50.0, 59.5, 99.0, 119.9, 122.5, 
123.5, 124.2, 124.4, 138.6, 139.0, 149.2, 149.25, 152.2, 159.6, 164.0 ppm.  
ESI-MS: m/z: 317.4 [M+H]
+
. 
5-Ethoxycarbonyl-4-(3-benzothiophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-
one (O9): 
 
Yield 73%, yellow solid, mp  
1
H-NMR(500 MHz, DMSO-d6): 0.98 (t, J= 7.2 Hz, 3H, CH3CH2), 2.30 (s, 3H, 
C(6)CH3), 3.92 (q, J=7.2 Hz, 2H, CH3CH2), 5.58 (s, 1H, C(4)H), 7.39-7.35 (m, 4H, 
Ph), 7.82 (s, 1H, N(3)H), 7.99-7.97 (m, 1H, thiophenyl CH=C), 9.29 (s, 1H, N(1)H).  
13
C-NMR(125.68 MHz, DMSO-d6): δ 14.30, 18.06, 48.66, 59.70, 79.27, 98.77, 
122.37, 123.37, 124.49, 124.70, 124.79, 138.99, 140.55, 146.03, 152.44, 165.68 
ppm. 
ESI-MS: m/z:317.5 [M+H]
+
. 
 
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-2-yl)-3,4-dihydropyrimidin-2(1H)-one 
(O10)  
 
Yield 87 %, yellow solid, mp 211-213°C,  
IR: 3247, 3123, 2975, 1719, 1658, 1459, 1292, 1226, 1088 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 1.08 (t, 3H, J = 7.0 Hz, CH3CH2), 2.29 (s, 3H, 
C(6)CH3), 3.97 (q, 2H, J = 7.0 Hz, CH3CH2O), 5.32 (d, 1H, J= 3.0, C(4)H), 7.42-
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7.53 (m, 4H, ArH), 7.67 (s, 1H, ArH), 7.82( bs, 1H, N(3)H), 7.85-7.91 (m, 3H, ArH), 
9.24(s, 1H, N(1)H) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.1, 17.9, 54.3, 59.18, 99.01, 124.6, 124.9, 
125.9, 126.3, 127.5, 127.8, 128.3, 132.3, 132.7, 142.15, 148.5, 152.01, 165.3 ppm. 
ESI-MS, m/z 311 [M+H]
+ 
333.5 [M+Na]
+
. 
 
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-1-yl)-3,4-dihydropyrimidin-2(1H)-one 
(O11)  
 
Yield 89%, yellow solid , mp 251-252°C,  
IR: 3239, 3110, 2987, 2931, 1707, 1649, 1467, 1315, 1223, 1086, 793, 779 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 0.81 (t, 3H, J = 7.0 Hz, CH3CH2), 2.35 (s, 3H, 
C(6)CH3), 3.80 (q, 2H, CH3CH2O), 6.06 (d, 1H, J= 3.0, C(4)H), 7.45-7.64 (m, 1H, 
ArH), 7.80 (s, 1H, N(3)H), 7.85 (m, 2H, ArH), 7.94 (t, 2H, J = 8 Hz, ArH), 8.05 (d, 
1H, J = 8.5 Hz, ArH), 8.30 (d, 1H, J = 8.0 Hz, ArH), 9.25(s, 1H, N(1)H) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 13.8, 17.8, 49.8, 56.5, 99.1, 122.43, 123.28, 
123.42, 127.74, 128.43, 128.50, 140.4, 148.7, 151.6, 157.30, 159.53, 165.27 ppm. 
ESI-MS, m/z 311.4 [M+H]
+
 333.4 [M+Na]
+
. 
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5-ethoxycarbonyl-4-(2-thienyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (O12)  
 
Yield 61%, yellow solid. 
1
H-NMR (500 MHz, DMSO-d6): δ 1.15 (t, 3H, J= 7.2 Hz, CH2CH3), 2.20 (s, 3H, 
C(6)CH3), 4.05 (q, 2H, J= 7.2 Hz, CH2CH3); 5.40 (d, 1H, J= 3.2 Hz, C(4)H), 6.49-
6.87 (m, 2H, thyenyl), 7.35-7.33 (m, 1H, thyenyl), 7.90 (s, 1H, N(3)H); 8.31 (s, 1H, 
N(1)H) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 14.62, 18.14, 49.79, 59.85, 79.62, 100.24, 
123.99, 125.116, 127.15, 149.13, 152.72, 165.50. ppm. 
 
5-ethoxycarbonyl-4-(3-thienyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (O13)  
 
Yield 58%, yellow solid. 
1
H-NMR (500 MHz): δ 1.14 (t, 3H, J= 7.2 Hz, CH2CH3), 2.20 (s, 3H, C(6)CH3), 
4.03 (q, 2H, J= 7.2 Hz, CH2CH3); 5.19 (d, 1H, J= 3.2 Hz, C(4)H), 6.97 (d, 1H, J= 4.8 
Hz, thyenyl), 7.14 (s, 1H, thyenyl), 7.45 (t, 3H, J= 4.8 Hz, thyenyl), 7.75 (s, 1H, 
N(3)H); 9.19 (s, 1H, N(1)H) ppm. 
13
C-NMR (125.68 MHz): δ 14.50, 18.07, 49.74, 59.63, 99.83, 121.09, 126.46, 
126.99, 146.06, 148.77, 152.96, 165 ppm. 
  
  
140 Experimental Part 
5-ethoxycarbonyl-4-(2-NO2-thienyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one 
(O14)  
 
Yield 50%, yellow solid. 
1
H-NMR (500 MHz): δ 1.20 (t, 3H, J= 7.2 Hz, CH2CH3), 2.22 (s, 3H, C(6)CH3), 
4.10 (q, 2H, J= 7.2 Hz, CH2CH3); 5.43 (d, 1H, J= 3.2 Hz, C(4)H), 7.2 (s, 1H, 
thyenyl), 8.00 (d, 1H, J= 5 Hz, thyenyl), 8.18 (s, 1H, N(3)H); 9.58 (s, 1H, N(1)H) 
ppm. 
 
5-Benzyloxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (O15)
 
Yield 90 %, white solid, mp 168 – 170 °C. 
IR: 3358, 3115, 3028, 1705, 1686, 1497, 1376, 1176, 1138, 1107, 1085 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 2.27 (s, 3H, C(6)-CH3), 5.01 (d, 1H, J = 12.8 Hz, 
PhCH2), 5.05 (d, 1H, J = 12.8 Hz, PhCH2), 5.17 (d, 1H, J = 3.2 Hz, C(4)H), 7.10-
7.35(m, 10H, 2xPh ), 7.74 (bs, 2H, N(3)H), 9.25 (bs, 2H, N(1)H) ppm. 
ESI-MS, m/z: 323 [M+H]
+
. 
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6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (O16)
 
Yield 47 %, white solid, mp 220 – 222 °C. 
1
H NMR (500 MHz, DMSO-d6): δ 2.06 (s, 3H, C(6)-CH3), 5.23 (d, 1H, J = 3 Hz, 
C(4)H), 6.90 (bs, 2H, C(=O)NH2), 7.21-7.35(m, 6H, Ph), 7.49 (s, 1H, N(3)H), 
8.55(s, 1H, N(1)H) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 17.54, 55.13, 126.83, 127.61, 128.75, 139.24, 
144.88, 153.12, 168.59 ppm. 
ESI-MS, m/z: 232 [M+H]
+
. 
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6.8.2.2 3,4-dihydropyrimidin-2(1H)-thiones S1-8 (Table 16) 
Table 16 2-thioDHPMs synthesized (R
3
= methyl)  
 
5-Ethoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-thione (S1)  
 
Yield 85%, white solid, mp 206-208 °C,  
IR: 1668, 1573, 1462, 1283, 1195, 1117 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 1.10 (t, 3H, J = 7.0 Hz, OCH2CH3), 2.29 (s, 3H, 
C(6)CH3); 4.01 (q, 2H, J = 7.0 Hz, CH2CH3); 5.17 (d, 1H, J = 3.5 Hz, C(4)H); 7.21-
7.36 (m, 5H, Ph), 9.64 (s, 1H, N(3)H); 10.32 (s, 1H, N(1)H ) ppm.  
13
C NMR (125.68 MHz, DMSO-d6): δ 14.5, 18.2, 54.5, 60.0, 101.1, 128.8, 128.1, 
129.0, 143.9, 145.5, 165.6, 174.7 ppm.  
R
1 
R
2
 Product name 
Phenyl EtO S1 
Phenyl MeO S2 
Phenyl BnO S3 
4-fluoro-phenyl EtO S4 
Benzothiophen-2-yl EtO S5 
2-Naphtyl EtO S6 
1-Naphtyl EtO S7 
Phenyl (-)MenthylO S8 
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ESI-MS, m/z: 277.4 [M+H]
+
; 299.4 [M+Na]
+
.  
 
5-Methoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-thione (S2)  
 
Yield 87 %, light yellow solid, mp 220-222 °C,  
IR: 1711, 1572, 1459, 1318, 1280, 1180, 1113 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 2.29 (s, 3H, C(6)CH3), 3.56 (s, 3H, OCH3), 5.18 
(d, 1H, J = 3.5 Hz, C(4)H), 7.21-7.36 (m, 5H, Ph), 9.66 (s, 1H, N(3)H), 10.35 (s, 1H, 
N(1)H) ppm.
  
13
C NMR (125.68 MHz, DMSO-d6): δ 17.2, 51.1, 53.9, 100.4, 126.3, 127.7, 128.6, 
143.3, 145.3, 165.6, 174.25 ppm. 
ESI-MS, m/z: 263.4 [M+H]
+
; 285.4 [M+Na]
+
.  
 
5-Benzoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-thione (S3) 
 
Yield %, yellow solid, mp 157-159°C,  
1
H NMR (500 MHz, DMSO-d6): δ 2.31 (s, 3H, C(6)CH3), 5.02 (d, 1H, J = 12.5 Hz, 
PhCH2), 5.09 (d, 1H, J = 12.5 Hz, PhCH2) 5.20 (d, J = 4.0 Hz, 1H, C(4)H), 7.84-
8.36 (m, 10H, Ph), 9.63 (s, 1H, N(3)H), 10.38 (s, 1H, N(1)H) ppm.
  
ESI-MS, m/z: 339.4 [M+H]
+
.  
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5-Ethoxycarbonyl-4-(4-fluorophenyl)-6-methyl-2-thioxo-3,4-dihydropyrimidine-
2(1H)-thione (S4)  
 
Yield 68%, light yellow solid, mp 188-190°C,  
IR: 3391, 1711, 1586 cm
-1
. 
1
H NMR (400 MHz, DMSO-d6): δ 1.9 (t, 3H, J = 7.0 Hz, OCH2CH3), 2.29 (s, 3H, 
C(6)CH3), 4.00 (m, 2H, CH2CH3), 5.17 (d, 1H, J = 4.0 Hz, C(4)H), 7.11-7.29 (m, 
5H, Ph), 9.65 (s, 1H, N(3)H), 10.36 (s, 1H, N(1)H ) ppm.  
13
C NMR (100 MHz, DMSO-d6): δ 14.0, 17.2, 53.4, 59.6, 100.6, 115.3(d, 
2
J = 17.0 
Hz), 128.4 (d, 
3
J = 7 Hz), 139.8 (d, 
4
J = 2.0 Hz), 161.5 (d, 
1
J = 194.0 Hz), 165.0, 
174.2 ppm. 
ESI-MS, m/z: 295 [M+H]
+
.  
 
5-Ethoxycarbonyl-4-(benzo[b]thiophen-1-yl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-one (S5) 
 
Yield 73%, pale orange solid, mp 211-213 °C (dec). 
IR: 3272, 3167, 2978, 1705, 1558, 1310, 1182, 1100 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 1.19 (t, 2H, J = 7.1 Hz, CH3CH2), 2.30 (s, 3H, 
C(6)CH3), 4.11 (q, 3H, J = 7.1 Hz, CH3CH2O), 5.52 (d, 1H, J = 3.5 Hz, C(4)H), 7.19 
(s, 1H, thiophenyl CHC=), 7.29-7.38 (m, 2H, ArH), 7.81 (d, J = 8.2 Hz, 1H, ArH), 
7.90 (d, J = 8.2 Hz, 1H, ArH), 9.87 (s, 1H, N(3)H), 10.56 (s, 1H, N(1)H) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.1, 17.1, 50.0, 59.85, 100.5, 120.5, 122.6, 
123.7, 124.4, 124.5, 138.7, 138.9, 145.8, 147.4, 164.7, 174.9 ppm. 
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ESI-MS, m/z: 333.3 [M+H]
+
. 
 
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-2-yl)-3,4-dihydropyrimidin-2(1H)-
thione (S6) 
 
Yield 88 %, yellow solid, mp 183°C,  
IR: 3435, 3209, 3097, 2961, 1693, 1559, 1461, 1335, 1214, 1146, 1023 cm
-1
. 
1
H NMR (500 MHz, , DMSO-d6): δ 1.11 (t, 3H, J = 7 Hz, CH3CH2), 2.33 (s, 3H, 
C(6)CH3), 4.00 (m, 2H, CH3CH2O), 5.34 (d, J= 3.5 Hz, C(4)H), 7.45(m, 1H, ArH), 
7.54 (m, 2H, ArH), 7.71 (s, 1H, ArH), 7.93(m, 1H, ArH), 7.96 (m, 3H, Ph), 9.73 (s, 
1H, N(3)H), 10.37 (s, 1H, N(1)H) ppm. 
13
C NMR (125,68 MHz, DMSO-d6): δ 14.47, 17.7, 54.8, 60.03, 100.92, 125.2, 125.4, 
126.9, 126.6, 128.0, 128.3, 129.0, 132.9, 133.1, 141.2, 145.7, 165.6, 174.6 ppm. 
ESI-MS, m/z 327 [M+H]
+ 
349 [M+Na]
+
. 
  
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-1-yl)-3,4-dihydropyrimidin-2(1H)-
thione (S7) 
 
Yield 87 %, yellow powder, mp 223-225°C,  
IR: 3427, 3208, 2967, 1695, 1562, 1454, 1334, 1210, 1143, 1021 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 0.83 (t, 3H, J = 7.0 Hz, CH3CH2), 2.39 (s, 3H, 
C(6)CH3), 3.83 (m, 2H, CH3CH2O), 5.08 (d, 1H, J= 3.5 Hz, C(4)H), 7.38 (d, J = 7.0 
Hz, 1H, ArH), 7.55 (m, 3H, ArH), 7.88 (d, J = 8.0 Hz, 1H, ArH), 7.95 (d, J = 8 Hz, 
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1H, ArH), 8.37 (d, J = 8 Hz, 1H, ArH), 9.64 (s, 1H, N(3)H), 10.37 (s, 1H, N(1)H) 
ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 13.7, 17.1, 14.1, 49.7, 59.4, 100.8, 130.0, 
133.4, 139.2, 145.3, 165.0, 173.7 ppm. 
ESI-MS, m/z 327 [M+H]
+
, 349 [M+Na]
+
, 365 [M+K]
+
. 
 
(-)-Menthyl α-6-methyl-(4R,4S)-4-phenyl-3,4-dihydropyrimidin-2(1H)-thion-5-
carboxylate (S8)  
 
Yield 54%, white solid, d.e. 0% (a and b ).  
1
H NMR (500 MHz, DMSO-d6): δ 0.37 (d, a, 1.5H, J = 9.0 Hz, CHCH(CH3)2), 0.52 
(d, a, 1.5H, J = 8.5 Hz, CHCH(CH3)2), 0.67 (d, b, 1.5 H, J = 9.0 Hz, CH(CH3)2),), 
0.70 – 2.00 (m, a and b, 10.5H, CH and CH2 mentyl), 2.16 (s, b, 1.5H, C(6)-CH3), 
2.43 (s, a, 1.5H, C(6)-CH3), 4.47-4.80 (m, a and b, 2H, OCH), 5.16 (d, a, 0.5H, J = 
4.5 Hz, C(4)H), 5.17 (d, a, 0.5H, J = 4.5 Hz, C(4)H), 7.18-8.01 (m, a and b, 10H, Ph) 
ppm, 10.02 (s, a and b, 1H, NH).
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6.8.3 Synthesis of 3,4-dihydropyrimidin-2(1H)-imine derivatives (N1-19) 
Method A
120
:  
 
 
To a 0.5 M DMF solution of the appropriate aldehyde (1mmol), β-ketoester 
(1.1mmol), guanidine hydrochloride (1.5 mmol), and sodium hydrogen carbonate 
(4mmol) were added and the mixture stirred at 70°C for 3.5 hours (1.5 for N14). 
After cooling to room temperature, the mixture was poured into crushed ice. The 
solid formed was filtered, washed with cold water and finally triturated with 
diisopropyl ether or crystallized from hexane/ ethyl acetate (3:1), leading to N1-19.  
 
Method B: 
To a 0.5 M EtOH solution of the appropriate aldehyde (1mmol), were added the 1,3-
dicarbonyl compound (1.1mmol), guanidine hydrochloride (1.5 mmol), and sodium 
hydrogen carbonate (4 mmol). The mixture was irradiated for ten minutes in a 
microvave oven at 120°C. For compound N1  the reaction mixture was poured into 
cold water and left in the fridge for 30min until  complete precipitation of the 
product.  The solid formed was filtered, washed with cold water and finally triturated 
with diisopropyl ether. In the case of compound  N17 the mixture was filtered and 
the solvent  evaporated in vacuo, to give a  residue that was crystallized from AcOEt.  
 
Method C137
,166a:
 
2-thio-DHPM (1mmol) was dissolved in chlorobenzene in a sealed reaction tube, 
then methyl trifluoromethansulfonate was added to the solution at 0°C in one 
portion. The reaction was stirred at r. t. and monitored by 
1
H-NMR. After 
completation ammonium acetate (10mmol) was added to the mixture and ammonia 
gas was bubbled at 0°C for 30min, then the solution was heated at 100°C for 24h. 
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The sealed tube was cooled to r. t., opened and the suspension stirred in a current of 
argon to drive off the mercaptan by-product (take precautions). The solid was filtered 
and washed with water, then it was triturated with a NaOH solution (0.2M), left at 
0°C for one hour and refiltered, leading to N1.  
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6.8.3.1 3,4-dihydropyrimidin-2(1H)-imine N1-19 (Table 17) 
a
 R
3
= Phenyl 
Table 17 2-iminoDHPMs synthesized (R
3
= phenyl)
a 
R
1 
R
2
 Product name 
Phenyl EtO N1 
Benzothiophen-2-yl EtO N2 
2-Naphtyl EtO N3 
Phenyl MeO N4 
Phenyl i-PrO N5 
Phenyl BnO N6 
Methyl EtO N7 
Buthyl EtO N8 
4-fluoro-phenyl EtO N9 
1-Naphtyl EtO N10 
Biphenyl-4-yl MeO N11 
4-(pyridin-2-yl) phenyl MeO N12 
Benzyl EtO N13 
Phenyl EtO N14
a 
Phenyl NH2 N16 
Phenyl (CH2)5N N17 
Phenyl (-)MenthylO N18 
Phenyl (-)BorneylO N19 
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Synthesized by Method A unless otherwise stated. 
 
5-Ethoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-imine (N1) 
 
Method A: Yield 83.2%, white solid, mp 175-178°C.  
Method B: Yield 65%, white solid, mp 175-178°C.  
Method C: Yield 70%, white solid, mp 175-178°C.  
 
IR: 3285, 1713, 1665, 1612, 1093 cm
-1
. 
1
H-NMR (500 MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.3 Hz, CH2CH3), 2.17 (s, 3H, 
C(6)CH3), 3.89 (q, 2H, J = 7.3 Hz CH2CH3), 5.17 (s, 1H, C(4)H), 6.16 (br, 2H, 
N(3)H and C(2)=NH), 7.15-7.30 (m, 5H, Ph), 7.39 (s, 1H, N(1)H) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.8, 23.9, 53.2, 58.65, 97.9, 126.9, 127.6, 
128.8, 147.4,  155.9, 161.3, 166.9 ppm.  
ESI-MS, m/z: 260.4 [M+H]
+
. 
 
5-Ethoxycarbonyl-4-(benzo[b]thiophen-2-yl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-imine (N2) 
 
Yield 80%, light brown solid, mp 130-132 °C (dec). 
IR: 3340, 3112, 1710, 1559, 1244, 1096 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6): δ 1.16 (t, 2H, J = 7.2 Hz, CH3CH2), 2.18 (s, 3H, 
C(6)CH3), 4.02 (q, 3H, J = 7.2 Hz, CH3CH2O), 5.57 (s, 1H, C(4)H), 6.45 (bs, 2H, 
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N(1)H and C(2)=NH), 7.11(s, 1H, N(3)H), 7.22-7.35 (m, 2H, ArH), 7.65 (s, 1H, 
N(3)H), 7.74 (d, J = 7.8 Hz, 1H, ArH), 7.85 (d, J = 7.8 Hz,1H, ArH) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.5, 23.6, 48.8, 58.3, 97.0, 118.9, 122.5, 
123.2, 123.9, 124.2, 138.8, 139.1, 151.4, 155.5, 161.6, 165.7 ppm.  
ESI-MS, m/z: 316.4 [M+H]
+
. 
 
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-1-yl)-3,4-dihydropyrimidin-2(1H)-
imine (N3) 
 
Yield 71%, light brown solid, mp 165.2–167.3 °C. 
IR: 3350, 2923, 2854, 1703, 1661, 1602, 1094 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 1.06 (t, 3H, J = 7.4 Hz, CH3CH2), 2.24 (s, 3H, 
C(6)CH3), 3.92 (q, 2H, J = 7.4 Hz, CH3CH2O), 5.38 (s, C(4)H), 6.24 (s, 2H, N(1)H, 
C(2)=NH), 7.43-7.51 (m, 4H, ArH), 7.64 (s, 1H, ArH), 7.85 (m, 3H, ArH and 
N(3)H) ppm.
  
13
C NMR (125.68 MHz, DMSO-d6): δ 14.8, 23.6, 53.4, 58.7, 97.8, 124.7, 125.6, 
126.1, 126.6, 127.9, 128.2, 128.6, 132.7, 133.1, 144.1, 155.3, 160.3, 166.5 ppm.  
ESI-MS, m/z: 310.1 [M+H]
+
. 
 
5-Methoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-imine (N4) 
 
Yield 80%, yellow solid, mp 112-118°C. 
IR: 3030, 2950, 1697, 1626, 1557, 1495, 1431, 1345, 1238, 1188, 1087 cm
-1
.  
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1
H NMR (500 MHz, DMSO-d6): δ 2.20 (s, 3H, CH3), 3.46 (s, 3H, OCH3), 5.19 (s, 
1H, C(4)H), 6.21 (br, 2H, N(1)H) and C=NH), 7.21-7.30 (m, 5H, Ph), 7.41 (s, 1H, 
N(3)H) ppm. 
13
C NMR (125 MHz, DMSO-d6): δ 23.8, 49.9, 52.4, 96.7, 126.1, 126.9, 128.2, 146.5, 
155.45, 161.4, 166.6 ppm.  
ESI-MS, m/z: 246.4 [M+H]
+
. 
 
5-Isobutoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-imine (N5)  
 
Yield 73 %, yellow solid, mp 115-117 °C. 
IR: 3316, 2958, 1692, 1626, 1598, 1493, 1470, 1376, 1230, 1080 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 0.72 (d, J = 3.5 Hz, 3H, CH2CHCH3), 0.74 (d, J = 
3.5 Hz, 3H, OCH2CHCH3), 1.71 (m, 1H, CH(CH3)2), 2.20 (s, 3H, C(6)-CH3), 3.64 
(dd, J = 10.6, 6.3 Hz, 2H, OCH2CHCH3), 5.18 (s, 1H, C(4)H),6.13 (s, 2H, N(1)H and 
C(2)=NH),7.16-7.29 (m, 6H, N(3)H and Ph) ppm. 
 13
C NMR (125.68 MHz, DMSO-d6): δ 19.46, 19.49, 24.2, 27.9, 53.1, 68.9, 97.2, 
126.7, 127.4, 128.6, 146.9, 155.7, 161.9, 166.6 ppm. 
ESI-MS, m/z: 288.4 [M+H]
+
.  
 
5-Benzyloxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-imine (N6)
 
Yield 47 %, ocher solid, mp 142 – 145 °C. 
IR: 3435, 3359, 3030, 1701, 1629, 1454, 1376, 1232, 1076, 1028, 833, 732, 696 cm
-
1
.  
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1
H NMR (500 MHz, CDCl3): δ 2.31 (s, 3H, C(6)-CH3), 4.99 (d, 1H, J = 12.6 Hz, 
PhCH2), 5.07 (d, 1H, J = 12.6 Hz, PhCH2), 5.33 (s, 1H, C(4)H), 5.91 (bs, 2H, N(1)H 
and C(2)=NH), 6.95-7.45(m, 12H, 2xPh and N(3)H) ppm. 
13
C NMR (125.68 MHz, CDCl3): δ 22.6, 53.9, 65.8, 101.4, 126.6,127.9, 128.4, 
128.8, 136.1 143.4, 152.6, 165.5 ppm. 
ESI-MS, m/z: 322.5 [M+H]
+
. 
 
5-Ethoxycarbonyl-4, 6-dimethyl-3,4-dihydropyrimidin-2(1H)-imine (N7)  
 
Yield 40%, white solid, mp 195-197°C 
IR: 3392, 3305, 3090, 2977, 1663, 1587, 1228, 1156, 1094, 1067 cm
-1
 
1
H-NMR (500 MHz, DMSO-d6): δ 0.97 (d, 3H, J = 6.0 Hz, CH(4)CH3), 1.16 (t, 3H, 
J = 7.0 Hz CH2CH3), 2.10 (s, 3H, C(6)CH3), 3.99 (m, 2H, CH2CH3) 4.18 (q, 1H, J= 6 
Hz C(4)H), 6.05 (bs, 1H, N(3)H), 6.81 (s, 1H, N(1)H) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 15.0,. 23.8, 23.9, 45.4, 58.4, 98.7, 155.8, 
160.6, 166.5 ppm. 
ESI-MS: (m/z) 198 [M+H]
+
.  
 
5-ethoxycarbonyl-4-butyl-6-methyl-3,4-dihydropyrimidin-2(1H)-imine (N8)  
 
Yield 53%, light yellow solid, mp 110-115°C,  
IR: 3300, 1710, 1670, 1616, 1458, 1376, 1257, 1094 cm
-1
.  
1
H NMR (400 MHz, DMSO-d6): δ 0.85 (t, 3H, J = 7.2 Hz, CH3(CH2)3), 1.16 (t, 3H, J 
= 7.2 Hz, CH3CH2O), 1.17-1.35 (m, 6H, CH3(CH2)3), 2.10 (s, 3H, C(6)CH3), 3.90-
4.05 (m, 2H, CH3CH2O), 4.09 (d, 1H, J = 6.5 Hz, C(4)H), 6.01 (bs, 2H, N(1)H and 
C=NH,), 6.90 (bs, 1H, N(3)H) ppm. 
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13
C NMR (100 MHz, DMSO-d6): δ 14.0, 14.5, 22.0, 23.4, 25.8, 36.5, 48.9, 57.9, 
97.4, 155.6, 165.1, 166.1 ppm. 
ESI-MS, m/z: 240.1 [M+H]
+
. 
 
5-Ethoxycarbonyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidine-2(1H)-
imine(N9) 
 
Yield 70%, yellow solid, mp 113-115°C.  
IR: 3300, 1710, 1664, 1232, 1089, 832 cm
-1
.  
1
H-NMR (500 MHz, DMSO-d6): δ 1.07 (t, 3H, J = 7.3 Hz, CH2CH3), 2.20 (s, 3H, 
C(6)CH3), 3.91 (q, 2H, J = 7.3 Hz CH2CH3), 5.20 (s, 1H, C(4)H), 6.29 (br, 2H, 
N(3)H and C(2)=NH), 7.05-7.30 (m, 5H, Ph + N(1)H) ppm. 
13
C NMR (125 MHz, DMSO-d6): δ 14.3, 23.5, 52.0, 58.1, 97.1, 114.8 (d, 
2
J = 21.3 
Hz), 128.1 (d, 
3
J = 8.8 Hz), 143.0 (d, 
4
J = 2.5 Hz), 155.1, 161.1 (d, 
1
J = 236.0 Hz), 
166.1 ppm. 
ESI-MS, m/z: 278.4 [M+H]
+
. 
 
5-Ethoxycarbonyl-6-methyl-4-(naphthalen-1-yl)-3,4-dihydropyrimidin-2(1H)-
imine (N1O) 
 
Yield 76%, pale yellow solid, mp 165.2-167.3 °C. 
IR: 3380, 3187, 1652, 1585, 1071 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 0.82 (t, 3H, J = 7.4 Hz, CH3CH2), 2.32 (s, 3H, 
CH3), 3.77 (m, 2H, J = 7.4 Hz, CH3CH2O), 5.98 (bs, 1H, NH), 6.08 (s, 1H, C(4)H), 
7.24 (bs, 1H, NH), 7.35 (bd, 1H, J = 6.2 Hz, NH), 7.45 (t, 1H, J = 7.9 Hz, ArH), 7.52 
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(t, 1H, J = 7.1 Hz, ArH), 7.59 (t, 1H, J = 7.5 Hz, ArH), 7.81 (d, 1H, J = 7.9 Hz, 
ArH), 7.93 (d, 1H, J = 7.1 Hz, ArH), 8.35 (d, 1H, J = 7.5 Hz, ArH) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.2, 23.4, 48.7, 58.1, 96.4, 123.5, 124.4, 
125.5, 125.8, 126.2, 127.5, 128.6, 130.1, 133.6, 141.3, 154.7, 166.2 ppm. 
ESI-MS, m/z: 310.2 [M+H]
+
.  
 
5-Methoxycarbonyl-4-([1,1'-biphenyl]-4-yl)-6-methyl-3,4-dihydropyrimidine-
2(1H)-imine (N11) 
 
Yield 74%, orange solid, mp 152-157 °C. 
IR: 3289, 1698, 1651, 1598, 1463, 1342,  1234, 1085 cm
-1
. 
1
H-NMR (400 MHz, DMSO-d6): δ 2.26 (s, 3H, C(6)CH3), 3.50 (s, 3H, CH3O), 5.27 
(s, 1H, C(4)H), 7.30-7.36 (m, 3H, ArH, N(3)H), 7.42-7.50 (m, 3H, ArH), 7.57-7.72 
(m, 5H, ArH, N(1)H, C(2)=NH) ppm 
13
C-NMR ( 125.68 MHz, DMSO-d6): δ 22.4, 50.4, 52.2, 79.6, 98.2, 126.7, 126.8, 
126.9, 127.4, 128.9, 139.2, 140.0, 155.0, 166.4 ppm. 
ESI-MS, m/z: 322.1 [M+H]
+ 
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5-Methoxycarbonyl-6-methyl-4-(4-(pyridin-2-yl)phenyl)-3,4-dihydropyrimidine-
2(1H)-imine (N12)  
 
Yield 58%, light-orange solid, mp 137-142 °C. 
IR: 3288, 1710, 1668, 1464, 1377, 1242 cm
-1
.  
1
H-NMR (500 MHz, DMSO-d6): δ 2.22 (s, 3H, C(6)CH3), 3.48 (s, 3H, CH3O), 5.25 
(s, 1H, C(4)H), 6.23 (bs, 2H, N(1)H, C(2)=NH), 7.33 (d, 2H, J = 7.5Hz, ArH), 7.46 
(bs, 1H, N(3)H), 7.81 - 7.92 (m, 3H, ArH), 7.99 (d, 2H, J = 8.5 Hz, ArH), 8.64 (s, 
1H, NArH) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 23.3, 50.1, 52.8, 97.1, 120.2, 122.5, 126.6, 
126.6, 137.2, 149.5, 137.6, 147.0, 155.0, 155.9, 166.5 ppm. 
ESI-MS, m/z: 323.1 [M+H]
+ 
 
5-Ethoxycarbonyl-4-benzyl-6-methyl-3,4-dihydropyrimidine-2(1H)-imine(N13) 
 
Yield 69%, ocher solid, mp 125-130°C (dec). 
IR: 3385, 1702, 1661, 1494, 1456, 1377, 1239, 1089, 1030 cm
-1
. 
1
H-NMR (500 MHz, DMSO-d6): δ 1.95 (t, 3H, J = 7.1 Hz, CH3CH2O), 2.21 (s, 3H, 
C(6)CH3), 3.62-3.65 (m, 2H, CH3CH2O), 2.68-2.80 (m, 2H, CH2Ph), 4.50-4.54 (m, 
1H, C(4)H), 7.15-7.45 (m, 5H, ArH), 7.12 – 7.51 (s, 1H, N(1)H; s, 1H, C=NH; s, 1H, 
N(3)H) ppm. 
13
C-NMR (125.68 MHz, DMSO-d6): δ 20.6 23.1, 43.5, 50.9, 52.3, 71.2, 127.1, 128.9, 
130.4, 138.3, 148.9, 154.8, 166.8 ppm. 
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ESI-MS (m/z): 261.1 [M+H]
+ 
 
5-Ethoxycarbonyl-4,6-diphenyl-3,4-dihydropyrimidin-2(1H)-imine (N14) 
  
Yield 80%, solid, mp 242-245°C. 
IR: 3393, 1670, 1228, 1076, 760, 697cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 0.74 (t, 3H, J = 7.5 Hz, CH3CH2), 3.67 (m, 2H, J 
= 7.5 Hz, CH3CH2O), 5.30 (s, 1H, C(4)H), 6.31 (bs, 1H, NH), 7.30 (m, 11H, 2x Ph 
and NH) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 13.6, 52.9, 58.1, 97.6, 126.3, 126.8, 127.0, 
127.1, 128.1, 128.3, 142.4, 146.2, 155.3, 161.0, 166.2. ppm 
ESI-MS, m/z: 322 [M+H]
+
.  
 
2-Imino-6-methyl-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (N16) 
 
 
Method C: Yield 57 %, white solid. 
1
H NMR (500 MHz, DMSO-d6): δ 2.10 (s, 3H, C(6)CH3), 5.35 (s, 1H, C(4)H), 6.94 
(br, 2H, C(=O)NH2), 7.28-7.48 (m, 8H, Ph+ 3xNH) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 18.86, 56.75, 109.73, 130.14, 131.10, 139.24, 
131.15, 146.95, 155.73, 172.11, 179.80 ppm. 
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2-Imino-6-methyl-4-phenyl-5-( piperidin-1-carbonyl)-3,4-tetrahydropyrimidina 
(N17) 
 
 
Method B: Yield 60 %, white solid. 
1
H NMR (400 MHz, DMSO-d6): δ 1.13 (bs, 4H, CH2 piper), 1.35(bs, 4H, CH2 piper), 
1.56 (s, 3H, C(6)CH3), 3.00 (bs, 2H, pCH2piper), 5.11 (s, 1H, C(4)H), 5.50(br, 2H, 
2xNH), 6.80 (br, 1H, NH), 7.10-7.38 (m, 5H, Ph) ppm. 
13
C NMR (125.68 MHz, DMSO-d6): δ 14.1, 20.9, 24.0, 25.4, 59.6, 103.6, 126.1, 
127.1, 128.4, 145.8, 169.2, 170.3 ppm. 
 
(-)-Menthyloxycarbonyl-α-6-methyl-(4R,4S)-4-phenyl-3,4-dihydropyrimidin-
2(1H)-imine-5-carboxylate (N18) 
 
Yield 54%, white solid, d.e. 18% (major =M, minor= m).  
IR: 3324, 2954, 2925, 2869, 1694, 1652, 1622, 1494, 1456, 1373, 1231, 1080, 961 
cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 0.40 (d, M, 1.77H, J = 7.0 Hz, CHCH(CH3)2) 
0.52 (d, M, 1.77H, J = 7.0 Hz, CHCH(CH3)2, 0.69 (d, m, 1.23H, J = 7.0 Hz, 
CH(CH3)2),), 0.73 – 2.00 (m, m+M, 10H, CH and CH2 menthyl), 2.18 (s, m, 1.23H, 
C(6)-CH3), 2.23 (s, M, 1.77H, C(6)-CH3), 4.46 (m, m+M, 1H, OCH), 5.16 (s, M, 
0.59H, C(4)H), 5.18 (s, m, 0.41H, C(4)H ), 6.07 (s, M, 1H, N(1)H and C(2)=NH), 
6.13 (s, m, 1H, N(1)H and C(2)=NH), 7.24 (m, m+M, 6H, N(3)H and Ph) ppm.
  
13
C NMR (125 MHz, DMSO-d6): δ 15.9, 16.9, 21.1, 21.3, 22.37, 22.42, 22.8, 23.6 , 
23.8, 25.0, 26.5, 31.3, 31.4, 34.28, 34.31, 41.2, 41.8, 47.1, 47.3, 53.25, 53.30, 71.2, 
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71.6, 97.4, 98.0, 126.7, 126.8, 127.26, 127.29, 128.5, 128.6, 146.9, 147.1, 155.2, 
155.4, 160.2, 161.1, 165.9, 166.1 ppm.  
ESI-MS, m/z: 370.5 [M+H]
+
. 
 
(-)-Borneyloxycarbonyl 6-methyl-4-phenyl-1,2,3,4- tetrahydropyrimidine -2-imine-
5- carboxylate (N19) 
 
Yield 69%, light yellow solid, d.e. 9%(major =M, minor= m). 
IR: 3330, 2954, 1654, 1624, 1492, 1454, 1375, 1230, 1077 cm
-1
.  
1
H NMR (400 MHz, CDCl3): δ 0.41 (s, M, 1.62H, C(CH3)). 0.75 (s, m, 1.38H, 
C(CH3)), 0.77 (s, M, 1.62H, C(CH3)2), 0.79 (s, m, 1.38H, C(CH3)2), 0.80 (s, m, 
1.38H, C(CH3)2), 0.82 (s, M, 1.62H, C(CH3)2), 0.86 (m, m+M, 2H, CHCH2CH), 
0.90 – 2.20(m, m+M, 5H, CCH2CH2CH), 2.23 (s, M, 1.62H, C(6)-CH3), 2.24 (s, m, 
1.38H, C(6)-CH3), 4.61 (dt, m, 0.46H, J = 9.3, 2.3 Hz, OCH), 4.73 (dt, M, 0.54H, J 
= 9.3, 2.3 Hz, OCH), 5.24 (s, m, 0.46H, C(4)H), 5.25 (s, M, 0.54H, C(4)H), 6.12 (s, 
m+M, 1H, N(1)H), 7.00 – 7.34 (m, m+M, 7H, N(3)H, N(2)H and Ph) ppm.  
13
C NMR (100 MHz, CDCl3): δ 13.0, 13.5, 18.60, 18.63, 19.49, 19.52, 23.7, 26.8, 
27.2, 27.4, 27.7, 36.4, 37.0, 44.1, 44.2 , 47.2 , 47.3, 48.07, 48.15, 52.66, 52.69, 76.8, 
77.2, 126.3, 126.3, 126.9, 127.0, 128.2, 146,4, 155.0, 160.64, 161.5, 166.2 ppm. 
ESI-MS, m/z: 368.5 [M+H]
+
. 
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6.8.4 Hydrolysis of DHPMs  
6.8.4.1 3,4-Dihydropyrimidin-2(1H)-thione 
To a 0.34M ethanol solution of the 2-oxo or 2-thio-DHPM (1mmol) a 1M aqueous 
NaOH (5.88 mmol) was added. The resulting solution was refluxed under stirring 
and monitored by TLC (AcOEt 40% in hexane) till completion. The hot mixture was 
poured into fine crushed ice and acidified (pH~3). A solid precipitated that was 
filtered and dried.  
 
5-Carboxy-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-thione (S9) 
 
Yield 80%, orange solid, mp 145-148°C. 
IR: 3240. 1685, 1460, 1176, 689 cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 2.28 (s, 3H, C(6)CH3), 5.15 (s, 1H, C(4)H), 7.00-
7.50 (m, 5H, Ph), 9.57 (s, 1H, N(3)H), 10.22 (s, 1H, N(1)H) ppm.  
 
6.8.4.2 3,4-Dihydropyrimidin-2(1H)-one/imine 
The DHPM (1mmol) was dissolved in 2ml of MeOH. 10% Pd/C (10 wt % with 
respect of the substrate), and phenyl ethylamine (1mmol) were added to the solution 
under inert atmosphere. The reaction mixture was vigorously stirred at room 
temperature under 1atm H2 pressure for 24 h, then it was filtered and concentrated in 
vacuo to give N18. 
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5-Carboxy-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (O17) 
 
Yield 45%, white powder, mp 216-218°C 
IR: 3433, 3227, 1706, 1645 cm
-1
.  
1
H-NMR (500 MHz, DMSO-d6): δ 2.22 (s, 3H, C(6)CH3), 5.10 (d, J= 4 Hz, 1H, 
C(4)H), 7.18-7.34 (m, 5H, Ph), 7.64 (s, 1H, N(3)H), 9.05 (s, 1H, N(3)H), 11.83 (s, 
1H, OH).  
ESI-MS: (m/z) 233 [M+Na]
+
.  
 
5-Carboxy-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-imine (N15) 
 
Yield 50%, light yellow solid, mp > 320°C. 
IR: 3304, 2637, 1667, 1047, 833, 701cm
-1
.  
1
H NMR (500 MHz, DMSO-d6): δ 2.23 (s, 3H, C(6)CH3), 5.18 (d, 1H, J = 3.5 Hz, 
C(4)H), 7.21-7.65 (m, 5H, Ph), 7.65 (s, 1H, N(3)H), 9.05 (s, 1H, N(1)H), 13.12 (s, 
1H, OH), ppm. 
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6.8.5 Synthesis of 5-carboxamide dihydropirimidinone 
 
To a 1M DMF solution of O17 (2 mmol) TBTU ( 3 mmol) and DIPEA ( 4 mmol) 
were added, under inert  athmosphere . The reaction was stirred at 25°C for a few  
minutes, and then the appropriate amine (3mmol) was added  followed by a second 
amount of  DIPEA ( 4 mmol) The reaction was monitored by TLC (CHCl3/MeOH: 
9/1)until disappearance of the starting material.  Then, 50 ml of H2O was poured  
into the mixture, and the precipitated product was filtered and triturated with 
diisopropylether. 
 
6-Methyl-4-phenyl-5-(piperidine-1-carbonyl)-3,4-dihydropyrimidin-2(1H)-one 
(O18) 
 
Yield: 60%, white solid. 
1
H NMR (400 MHz, CDCl3): δ 1.10 (s, 2H, CH2), 1.33 (s, 2H, CH2), 2.95 (s, 4H, 
CH2NCH2), 5.17 (s, 1H, C(4)H), 7.19 - 7.35 (m, 5H, Ph), 8.44 (br, 1H, N(3)H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 15.73, 23.80, 25.16, 57.19, 100.81, 103.99, 126.34, 
127.61, 128.02, 128.69, 144.25, 152.71, 166.69 ppm. 
ESI-MS: m/z: 322.2 [M+Na]
+
. 
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6-Methyl-2-oxo-4-phenyl-N-propyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide 
(O19) 
 
Yield 40%, yellow solid.  
1
H NMR (400 MHz, CDCl3): δ 0.68 (t, 3H, J = 7.2 Hz, CH2CH2CH3), 1.20-1.32 (m, 
4H, CH2CH2), 1.96 (s, 3H, C(6)CH3), 5.22 (s, 1H, C(4)H), 7.13-7.35 (m, 5H, Ph), 
7.40 (s, 1H, N(1)H), 7.50(m, 1H, NHC(=O)), 8.45 (br, 1H, N(3)H) ppm. 
ESI-MS m/z: 296.2 [M+Na]
+
. 
 
6.8.6 Synthesis of 3,4-dihydropyrimidin-2(1H-pyrazol-1-yl)-imine derivatives 
(NP1-2)
164
 
 
R
1 
R
2
 Product name 
Phenyl Ethyl NP1 
2-Naphtyl Ethyl NP2 
 
0.7 M DMF solution of the appropriate aldehyde (1 mmol), β-ketoester (1.1 mmol), 
1H-pyrazole-1-carboxamide hydrochloride (1.1 mmol), and sodium hydrogen 
carbonate (4mmol) were added and the mixture stirred at 70°C for 48 hours. After 
cooling to room temperature, the mixture was poured into cold water, extracted with 
Et2O. The combined organic layer were dried over Na2SO4, filtered and concentrated 
in vacuo. The residue was purified by flash chromatography (siliga gel, Et2O (20% to 
45%) in hexane) as a mixture of tautomers, NP1-2.  
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5-Ethoxycarbonyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H-pyrazol-1-yl)-
imine (NP1) 
 
Yield 40%, pale yellow solid, mixture of tautomer (a and b).  
IR: 3381, 3334, 2932, 1717, 1703, 1630, 1532, 1263, 1240, 1175, 1154, 1093 cm
-1
. 
1
H-NMR (400 MHz, (CD3)2CO, mixture of tautomer): δ 1.16 (t, a, 1.65H, J = 7.5 
Hz, CH2CH3),1.18 (t, b, 1.35 H, J = 7 Hz, CH2CH3), 2.41 (s, a, 1.65 H, C(6)CH3), 
2.54 (s, b, 1.35 H, C(6)CH3), 4.07 (m, a and b, 2H, J = 7.3 Hz, CH2CH3), 5.71 (s, b, 
0.45 H, C(4)H), 5.75 (d, a, 0.55 H, J = 3.0 Hz, C(4)H), 6.48 (dd, b, 0.45H, J = 2.75 
and 2 Hz, CHCHN), 6.52 (dd, a, 0.45H, J = 2.75 and 2.0 Hz, CHCHN), 7.2-7.5(m, a 
and b, 10H, Ph), 7.69 (d, b, 0.45 H, J = 1.5 Hz, CHNN), 7.70 (d, a, 0.55 H, J = 1.0 
Hz, CHNN) 8.28 (d, b, 0.45 H, J = 3.0 Hz, CHNC(2)), (d, a, 0.45 H, J = 2.5 Hz, 
CHNC(2)), 8.60 (bs, a, 0.55H, NH), 8.78 (bs, a, 0.45H, NH) ppm. 
13C NMR (100 MHz, (CD3)2CO) all peaks from both tautomers δ14.53, 14.56, 
18.18, 18.25, 23.49, 54.58, 54.69, 59.62, 60.11, 60.17, 101.81, 101.77, 105.69, 
109.28, 109.64, 127.65, 127.84, 128.02, 128.14, 128.61, 129.11, 129.25, 129.33, 
142.17, 143.63, 142.18, 143.65, 157.28, 166.73, 166.90 ppm.  
ESI-MS, m/z: 333.2 [M+Na]
+
. 
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6.8.7 Derivatization of racemic DHPMs with chiral auxiliaries  
For the formation of the diasteroisomers, three chiral auxiliaries (8a, 8b, 8c) 
were taken into account with different DHPMs compounds. 
 
 
6.8.7.1 Formation of chloride:  
(2S)-3-phenyl-2-phthalimidylpropanoyl chloride (8a) 
 
  
Figure 46 Synthesis of 8a. 
Method A: 
To a solution of N-phthaloyl-L-phenylalanine (1mmol) in CH2Cl2 (0.1M), under 
inert atmosphere, cooled to 0°C, oxalylchloride (1.5mmol) and a cat. Amount of 
DMF were added. The reaction mixture was stirred at r.t. over night. The excess 
oxalylchloride was removed under reduced pressure, and the residue (8a) was used in 
the next step without purification. 
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Method B: 
N-phthaloyl-L-phenylalanine(1mmol) was mixed with thionyl chloride (1.2mmol) 
under inert atmosphere. The reaction mixture was stirred under heating at 60°C for 
1.30 h, then it was cooled down and concentrated in vacuo. The residue was used in 
the next step without further purification. 
 
(2S)-3-phenyl-2-phthalimidylpropanoyl chloride (8a) 
Spectral and analytical data in accordance with the literature.
178
 
 
 
Yield 99%, white solid, mp 83°C. 
1
H NMR (500 MHz, CDCl3): δ 3.63 (m, 1H, Ph(Phe)CH2), 3.73 (dd, 1H, J = 14.0, 
5.0 Hz, Ph(Phe)CH2), 5.43 (dd, 1H, J = 10.0, 5.0 Hz, PhCH2CH), 7.23 (m, 5H, 
Ph(Phe)), 7.80 (m, 2H, Ph), 7.90 (m, 2H, Ph) ppm. 
 
(S)-(+)-O-Acetyl mandelic chloride(8b) 
 
(S)-(+)-O-Acetyl mandelic acid (1mmol) was mixed with thionyl chloride (1.2mmol) 
under inert atmosphere. The reaction mixture was stirred under heating at 60°C for 4 
h, then it was cooled down and concentrated in vacuo. The residue was used in the 
next step without further purification. 
  
                                                 
178 S. Mallakpour, S. Sepehri Reactive & Functional Polymers 2008, 68, 1459. 
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(S)-(+)-O-Acetyl mandelic chloride(8b) 
 
Yield 98%, yellow solid. 
1
H NMR (270 MHz, CDCl3): δ 2.22 (s, 3H, CH3), 6.03 (s, 1H, CH), 7.45 (m, 5H, 
C6H5). 
 
 2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl chloride (8c) 
 
 
 
2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cianide (6.19 mmol), and conc. HCl (3 ml) in 
acetic acid (12 ml) was stirred at 100°C for 15 min. The solution was cooled to r.t. 
and poured into water (40 ml). The aqueous solution was extracted with ethyl acetate 
(40 ml) and the organic layer was washed with brine, dried over Na2SO4, and 
concentrated in vacuo to give a pale yellow oil, which was purified by flash 
chromatography on silica gel (gradient elution: 0–1% MeOH in DCM) to give 
the 2,3,5-tri-O-benzoyl-β-D-ribofuranosyl carboxylic acid as a colourless foam. 
The acid was dissolved in toluene (0,5M respect to the acid), and added of thionyl 
chloride (1,5 eq.) under inert atmosphere. The mixture was then stirred at 100°C for 
4 h. The solution was cooled down and concentrated in vacuo. The residue was used 
in the subsequent step without further purification. 
 
2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl acid 
 
Yield: 65%, incolor oil. 
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1
H NMR (500 MHz, CDCl3): δ 4.65 - 4.78 (m, 3H, H-5 and 2xH-6), 4.86 (d, 1H, H-
2), 5.73 (dd, 1H, H-4), 5.97 (dd, 1H, H-3), 7.30-7.60 (m, 9H, ArH)7.87 - 8.10 (m, 
6H, ArH). 
ESI-MS, m/z: 513.2 [M+Na]
+
. 
 
2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl chloride (8c) 
  
Yield: 70%, yellow oil. 
1
H NMR(400 MHz, CDCl3): δ 4.60-4.82 (m, 3H, H-5 e 2xH-6), 5.05 (d, 1H, J = 2.8 
Hz, H-2), 5.87 (dd, 1H, J = 6.8, 5.2 Hz, H-4), 6.10 (dd, 1H, J = 5.4, 2.8 Hz, H-3), 
7.30-7.60 (m, 9H, ArH), 7.90-8.05 (m, 6H, ArH) ppm. 
 
6.8.7.2 Derivatization of NP1 and N1 with 8a  
 
 
To a solution of compound N1or NP2 (1.1 mmol) in CH2Cl2 (0.07 M) under Ar, the 
chloride 8a (1mmol) and Et3N (1mmol) were added. The reaction mixture was stirred 
at room temperature and monitored by TLC (AcOEt (20 or 40%) in hexane) till 
completion. The reaction mixture was neutralized with saturated NaHCO3 solution, 
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and washed with water, brine, dried over Na2SO4, and concentrated in vacuo. The 
diasteroisomeric mixture was separated by flash chromatography (eluent AcOEt/ n-
Hexane from 10% to 30%). 
 
5 Ethoxycarbonyl-3-(2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanoyl)-6-methyl-4-
phenyl-3,4-dihydropyrimidin-2(1H)-imine (NCA1) 
 
Yield 80%, light yellow solid, d.e.0% (a and b).  
IR: 3233, 3062, 1774, 1713, 1634, 1281, 1072, 719 cm
-1
 
1
H NMR (400MHz, CDCl3): δ 1.09 (t, 3H, J = 7.5 Hz, CH3CH2), 2.31 (d, 2H, J = 2.0 
Hz, CH3CH2O), 3.37 (m, 1H, Ph(Phe)CH2), 3.62(m, 1H, Ph(Phe)CH2), 4.02 (m, 2H, 
CH3CH2), 4.93 (m, 1H, Ph(Phe)CH2CH), 5.49 (s, 1H, C(4)H), 7.10 (m, 4H, Ph), 7.30 
(m, 5H, Ph), 9.99(bs, 1H, C(2)=NH), 10.29 (bs, 1H, N(3)H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 13.98 (a), 14.00 (b), 17.46 (a and b), 34.20 (a), 
34.35 (b), 52.31 (a), 52.48 (b), 57.38 (a), 57.41 (b), 59.61 (a), 59.64 (b), 101.21 (a), 
101.36 (b), 126.41 (a), 126.53 (b), 127.73 (a), 127.79 (b), 128.28 (a), 128.29 (b), 
128.50 (a and b), 128.58 (a), 128.63(b), 131.08 (a), 131.09 (b), 134.59 (a and b), 
138.45 (a), 138.42 (b), 143.35 (a), 143.44 (b), 146.08 (a and b), 154.39 (a), 154.45 
(b), 164.67 (a), 164.71 (b), 167.59 (a), 167.60 (b) ppm. 
ESI-MS, m/z: 322 [M+H]
+
.  
HPLC (Lux5uCell3, IPA 19% in Hex, 39bar, 1ml/min) r.t.(min): 16.5(Area: 50%), 
37.4 (area 50%). 
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5-Ethoxycarbonyl 3-(2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanoyl)-6-methyl-4-
phenyl-2-(1H-pyrazol-1-yl)- 3,4-dihydropyrimidine(NPCA1) 
 
Yield 40 %, light yellow solid. 
IR: 3318, 1775, 1717, 1388, 1239, 1102, 719 cm
-1
.  
1
H-NMR (400 MHz, (CD3)2CO, mixture of diasteroisomers): δ 1.29 (dt, 3H, 
CH2CH3), 2.58 (s, 3H, C(6)CH3), 4.25 (m, 2H, J = 7.3 Hz, CH2CH3), 4.89 (m, 1H, 
Ph(Phe)CH2), 5.04 (m, 1H, Ph(Phe)CH2), 5.62 (s, 1H, C(4)H), 6.53 (dd, 1H, 
CHCHN), 6.73 (m, 1H, CHCHN),6.81 (dd, 1H, CHCHN), 7.0-7.45(m, 9H, Ph), 7.69 
(m, 1H, CHNN), 8.0 (m, 1 H, CHNN) 8.03 (m, 1H, CHNC(2)), 8.21 (bs, 1H, NH), 
8.38 (bs, 1H, NH) ppm. 
 
6.8.7.3 Derivatization of NP1 with 8b  
 
 
To a solution of compound NP1 (1mmol) in CH2Cl2, in a round bottomed flask, were 
added 8b (1 mmol), Et3N (1 mmol) and DMAP under an inert atmosphere. 
The mixture was left at r.t. 12-24h, and the reaction monitored by TLC (20-40 % 
AcOEt in hexane). H2O was added and the organic layer extracted with saturated 
NaHCO3, and brine, dried over Na2SO4 and evaporated to give an oily residue, 
identified as a 1:1 diastereoisomeric mixure of NPCA2. TFlash chromatography 
(eluent AcOEt/ n-Hexane from 10% to 30%) afforded  one diasteroisomer in a pure 
form ([α]20°C= 50.4). 
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5-ethoxycarbonyl 3-((S)-2-acetoxy-2-phenylacetyl)-6-methyl-4-phenyl-2-(1H-
pyrazol-1-yl)- 3,4-dihydropyrimidine(NPCA2) 
 
 
Yield:65%, white solid. 
1
H-NMR(400 MHz, CD3Cl3, single diasteroisomer): δ 1.25 (t, 3H, J = 7.3 Hz, 
CH2CH3), 2.12 (s, 3H, C(6)CH3), 2.14 (s, 3H, OCOCH3), 4.20 (m, 2H, CH2CH3), 
5.79 (s, 1H, N(3)C(=O)CH), 6.48 (dd, 1H, J = 2.4, 1.6Hz, CHCHN), 6.64 (s, 1H, 
C(4)H), 7,05 (dd, 1H, CHCHN), 6.98-7.48 (m, 10H, Ph), 7.83 (d, 1H, J = 1.2 Hz, 
CHN), 7.94 (m, 1H, J = 2.4 Hz, CHN) ppm. 
 
6.8.7.4 Synthesis of diasteroisomers derived from 2-thioDHPMs 
6.8.7.4.1 Synthesis of diasteroisomers with 8a 
Method A
138
: 
 
 
To a suspension of Thio-DHPM (1 mmol) in 10 ml dry THF under Ar, 1.6 N n-BuLi 
(1.1 mmol) was added drop wise at -78 °C, whereupon anion was formed. After the 
addition, reaction mixture was stirred at -78 °C for 30 min and quenched at -78 °C 
with enantiopure amino acid chloride 8a (1.5 mmol), dissolved in 10 ml dry THF. 
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The reaction was stirred at same low temperature till it was completed (TLC). A cold 
saturated aqueous solution of NH4Cl (30 ml) was introduced at the same low 
temperature. The reaction contents were extracted with ethyl acetate or chloroform 
(3x10 ml), washed with water (2x25 ml), treated with brine, dried over anhydrous 
Na2SO4, and concentrated under reduced pressure.  
 
Method B: 
 
To a suspension of Thio-DHPM (1 mmol) in toluene was added 8a (0.33mmol to 
1mmol). After the addition, reaction mixture was stirred at 100 °C. The reaction was 
stirred at same high temperature till it was completed (TLC). A cold saturated 
aqueous solution of NH4Cl (30 ml) was introduced. The reaction contents were 
washed with water (2x25 ml), treated with brine, dried over anhydrous Na2SO4, and 
concentrated under reduced pressure. 
 
6.8.7.4.2 Synthesis of diasteroisomers with 8c 
 
To a 0.5M toluene solution of 2,3,5-tri-O-benzoyl-β-D-ribofuranosyl chloride 8c (1 
mmol), S1 (0.3 mmol) was added.  The mixture was left  for 4h at 100°C and then it 
was concentrated in vacuo.  
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6.8.8 Enzymatic resolution 
6.8.8.1  With Subtilisine (from bacillius licheniformis)134, α- 
chymotrypsin and esterase from porcine liver 
A suspension of the racemic dihydropyrimidine (0.39mmol, 100mg), Trizma in 
water (0.044M, 8.75mL), and acetonitrile or DMSO (0.3M, 1.25mL) was heated to 
37°C, sometimes to help the dissolution of the DHPM was used acetone, 1 or 2 
drops. The enzyme (50mg, 12.45unit/mg solid) was added and the suspension was 
agitated. The pH was maintained at 7.8 with subtilisine, and 7.4 for chymotrypsin 
and esterase, with a solution of NaOH 1 M. The extent of the optical enrichment was 
followed by chiral HPLC: for N1 Lux5uCell 3, isocratic elution at ambient 
temperature with 10% isopropanol in hexanes, 0.5 mL/min, retention times: (+) and 
(–)-DHPM ester = 22.3 and 31.6 min, for O3 Lux5uCell 1 isocratic elution at 
ambient temperature with 20% isopropanol in hexanes, 0.8 mL/min, retention times: 
(+) and (–)-DHPM ester = 8.1 and 10.2 min. The reaction was stopped once the 
solution had been enriched with one of the two epimers. The batch was cooled to 
20°C, and then AcOEt (2x10mL) was added. The combined organic layers were 
washed with water (2x10mL) containing Na2CO3. The aqueous layers were acidified 
with HCl acq. and estracted with chloroform (2x10mL).The organic layers were 
concentrated to afford the products. The starting material was only extraxted till now.  
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6.9 Experimental conditions for the cell free BACE1 inhibition assay 
6.9.1 Intrinsic fluorescence spectra measurements.  
Starting from 10 mM in DMSO stock solutions of compounds O2-11, S1-7 and N1-
6, N8, N10-13, N14, 1 mM solutions in DMSO of each compound were prepared, 
and further diluted with a 20 mM acetate buffer soln. at pH = 4.5. to a final 10 µM 
concentration. The spectra were recorded in the range 450 to 600 nm with exc = 
345 nm. The excitation (Ex) and emission (Em) slits were set at 10 nm.  
 
6.9.2 Assay conditions  
The excitation and emission wavelengths were set respectively at 345 nm and 505 
nm, the excitation and emission slits were 10 nm, the emission intensity was 
recorded for 60 minutes at 0.01 seconds intervals. 
The Stock solution of the enzyme (human β-secretase) for the kinetic assay was 
composed of 5 µL of the commercial enzyme solution dissolved in 995 µL of 20 mM 
acetate buffer at pH = 4.5 in the presence of 4% of DMSO. This solution was stirred 
and left in the fridge for at least 2 hours to allow the protein folding. Then 200 µL 
was put in the quartz cell and allow the protein folding at r.t before the assay.  
Starting from stock DMSO 10mM solutions of each inhibitor O2-17, S1-7 and N1-6, 
N8-12, N14-N16, 1 mM, 0.1 mM, 0.5 mM, 50 μM, 25 μM solutions in DMSO were 
prepared.  
A 10 mM DMSO solution of the the substrate (Arg-Glu(EDANS)-(Asn⁶⁷⁰,Leu⁶⁷¹)-
Amyloid β/A4 Protein Precursor₇₇₀ (668-675)-Lys(DABCYL)-Arg trifluoroacetate 
salt) was used.  
In the enzymatic assay a mixture of the enzyme solution (200 µL), and the substrate 
solution (2 μL), in the quartz cell was shaked and then left on standing 5 minutes 
before recording the fluorescence emission. The enzyme solution (200 µL) was left 
at r.t. for 30 minutes before the substrate solution was added, in order to allow the 
protein folding. An increasing of fluorescence intensity vs time was observed, due to 
the releasing of the fluorescent portion  in the hydrolysis.  
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After few minutes, 2 μL of the 25 μM inhibitor solution was added in the cell, 
followed by the addition, at 5-10 min intervals, of 2 μL of the increasing 
concentration solutions of the inhibitor. 
The decrease of the slope was indicative of inhibitory activity.  
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6.9.3 Experimental data for the determination of IC50 for compounds: 
6.9.3.1 2-oxo-DHPMs (O2-O17)  
O2 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 2.26 ± 0.18µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 82.5 72.1 57.8 
3 5.0*10-5 7.3*10-7 60.8 52.7 57.0 
4 1.0*10-4 1.7*10-6 45.8 53.0 48.3 
5 5.0*10-4 6.4*10-6 42.2 44.9 38.5 
6 1.0*10-3 1.6*10-5 30.0 32.7 30.4 
7 1.0*10-2 1.1*10-4 30.0 23.8 20.8 
 
O3 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 2.8 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2,9*10-7 81,8 85,9 85,4 
3 5.0*10-5 7,6*10-7 70,8 55,4 53,0 
4 1.0*10-4 1,7*10-6 54,2 56,8 43,8 
5 5.0*10-4 6,4*10-6 41,1 43,6 30,7 
 
O4 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.3 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 5.0*10-8 72.0 66.8 80.9 
3 1.00*10-5 1.5*10-7 59.0 53.1 48.9 
4 2.50*10-5 3.9*10-7 47.1 53.6 47.9 
5 5.00*10-5 8.7*10-7 40.8  36.0 
6 1.00*10-4 1.8*10-6 32.4 31.2 38.6 
7 5.00*10-4 6.5*10-6 47.4 30.9 32.0 
8 1.00*10-3 1.6*10-5 27.8 27.1 18.3 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the enzyme solution; 1,2,3 (%) 
enzyme residual activity of each kinetics. 
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O5 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.72 ± 0.38µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 59.3 89.4 77.2 
3 5.0*10-5 7.3*10-7 44.1 74.1 59.6 
4 1.0*10-4 1.7*10-6 30.9 45.3 39.8 
5 5.0*10-4 6.4*10-6 27.4 2.7 38.1 
6 1.0*10-3 1.6*10-5 20.9 17.9 32.6 
 
O6 Add. 
N° 
[I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.65 ± 0.03µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 72.9 71.4 61.2 
3 5.0*10-5 7.3*10-7 39.1 41.1 16.9 
4 1.0*10-4 1.7*10-6 35.2 33.8 55.1 
5 5.0*10-4 6.4*10-6 31.1 24.5 23.1 
6 1.0*10-3 1.6*10-5 16.7 19.9 20.6 
7 1.0*10-2 1.1*10-4 22.4 5.3 16.3 
 
O7 Add. N° [I] [I]Int Test(%) 
 
IC50 : 46 µM 
1 0 0 100.0 
2 1*10-4 9.8*10-7 65.9 
3 3*10-4 3.9*10-6 70.0 
 5*10-4 8.7*10-6 56.2 
4 1*10-3 1.8*10-5 63.4 
5 5*10-3 6.5*10-5 51.5 
6 1*10-3 1.6*10-4 35.4 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the enzyme solution; 1,2,3 (%) 
enzyme residual activity of each kinetics. 
  
  
178 Experimental Part 
 
O8 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.4 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 4.9*10-8 73.2 78.8 88.5 
3 2.5*10-5 2.9*10-7 58.0 66.0 62.4 
4 5.0*10-5 7.7*10-7 45.2 57.4 60.3 
5 1.0*10-4 1.7*10-6 37.9 45.4 52.5 
6 5.0*10-4 6.4*10-6 30.9 47.0 52.0 
7 1.0*10-3 1.6*10-5 26.4 26.9 36.9 
 
O9 Add. N° [I] [I]Int test(%) 
 
IC50 : 71 µM 
1 0 0 100.0 
2 1*10-4 9.8*10-7 79.4 
3 3*10-4 3.9*10-6 63.5 
4 1*10-3 1.8*10-5 52.5 
5 5*10-3 6.5*10-5 55.0 
6 1*10-3 1.6*10-4 45.7 
 
O10 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.5 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 5.2*10-8 94.2 80.8 63.3 
3 1.0*10-5 1.5*10-7 93.1 79.7 61.8 
4 2.5*10-5 4.1*10-7 55.0 78.8 52.6 
5 5.0*10-5 9.1*10-7 32.5 41.8 31.3 
6 1.0*10-4 1.9*10-6 23.3 31.2 11.2 
7 5*10-4 6.8*10-6 21.2 42.9 22.9 
8 1.0*10-3 1.7*10-5 / / 4.3 
 
O11 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 3.1 ± 0.5µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 94.5 79.3 68.9 
3 5.0*10-5 7.3*10-7 62.7 65.6 73.9 
4 1.0*10-4 1.7*10-6 64.0 49.6 39.7 
5 5.0*10-4 6.4*10-6 47.3 49.4 38.1 
6 1.0*10-3 1.6*10-5 39.2 37.3 28.4 
7 1.0*10-2 1.1*10-4 32.7 36.3 15.0 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the enzyme solution; 1,2,3 (%) 
enzyme residual activity of each kinetics.  
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O12 Add. N° [I] [I]Int Test(%) 
 
IC50 : 2.2 µM 
1 0 0 100.0 
2 1*10-4 9.8*10-7 57.5 
3 3*10-4 3.9*10-6 45.2 
 5*10-4 8.7*10-6 37.4 
4 1*10-3 1.8*10-5 32.1 
5 5*10-3 6.5*10-5 28.9 
6 1*10-3 1.6*10-4 22.2 
 
O13 Add. N° [I] [I]Int Test(%) 
 
IC50 : 3.2µM 
1 0 0 100.0 
2 1*10-4 9.8*10-7 64.1 
3 3*10-4 3.9*10-6 45.9 
 5*10-4 8.7*10-6 38.7 
4 1*10-3 1.8*10-5 31.1 
5 5*10-3 6.5*10-5 25.9 
 
O14 Add. N° [I] [I]Int Test(%) 
 
IC50 : 1.2 µM 
1 0 0 100.0 
2 1*10-4 9.8*10-7 50.9 
3 3*10-4 3.9*10-6 46.6 
 5*10-4 8.7*10-6 44.9 
4 1*10-3 1.8*10-5 43.5 
5 5*10-3 6.5*10-5 45.3 
6 1*10-3 1.6*10-4 36.7 
 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the enzyme solution; 1,2,3 (%) 
enzyme residual activity of each kinetics. 
  
O16 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.60 ± 0.03µM 
1 0 0 100 100 100 
2 2.5*10-5 2.5*10-7 67.1 78.5 46.2 
3 5.0*10-5 7.3*10-7 55.2 52.2 90.0 
4 1.0*10-4 1.7*10-6 34.9 46.9 31.8 
5 5.0*10-4 6.4*10-6 37.2 36.8 24.8 
6 1.0*10-3 1.6*10-5 32.9 31.0 24.3 
  
180 Experimental Part 
O17 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 34 ± 8.2µM 
1 0 0 100 100 100 
2 2.5*10-5 2.5*10-7 86.9 100.3 66.8 
3 5.0*10-5 7.3*10-7 80.4 93.5 59.5 
4 1.0*10-4 1.7*10-6 80.4 80.2 45.8 
5 5.0*10-4 6.4*10-6 53.3 65.3 45.0 
6 1.0*10-3 1.6*10-5 50.6 58.8 36.9 
7 1.0*10-2 1.1*10-4 44.8 44.9 34.0 
 
O18 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 34 ± 8.2µM 
1 0 0 100.00 100.00 100.00 
2 2.5*10-5 2.5*10-7 72.2 73.2 89.3 
3 5.0*10-5 7.3*10-7 63.9 53.2 28.8 
4 1.0*10-4 1.7*10-6 47.5 51.6 13.3 
5 5.0*10-4 6.4*10-6 47.5 36.1 8.7 
6 1.0*10-3 1.6*10-5 42.6 36.1 25.6 
7 1.0*10-2 1.1*10-4 32.2 9.0 0.0 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the enzyme solution; 1,2,3 (%) 
enzyme residual activity of each kinetics. 
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6.9.3.2 2-thio-DHPMs (S1-2, S4-7) 
S1 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.5 ± 0.4µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 5.0*10-8 100.0 100.0 100.0 
3 2.5*10-5 2,9*10-7 100.0 48,0 91,4 
4 5.0*10-5 7,6*10-7 52,1 98,1 56,2 
5 1.0*10-4 1,7*10-6 45,7 69,8 46,1 
6 5.0*10-4 6,4*10-6 38,3 28,1 49,0 
 
S2 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
 
IC50 : 0.85 ± 0.03µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 5.0*10-8 81.7 92.7 98.0 
3 1.0*10-5 1.5*10-7 66.2 77.0 65.5 
4 2.5*10-5 3.9*10-7 58.6 61.2 60.4 
5 5.0*10-5 8.7*10-7 47.3 39.4 52.2 
6 1.0*10-4 1.8*10-6 27.2 31.1 41.0 
7 5.0*10-4 6.5*10-6 35.1 30.5 / 
8 1.0*10-3 1.6*10-5 27.1 24.5 29.8 
9 1.0*10-2 6.2*10-5 25.3 15.1 10.9 
 
S4 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.24 ± 0.05µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 41.3 46.4 53.2 
3 5.0*10-5 7.3*10-7 32.9 35.4 35.5 
4 1.0*10-4 1.7*10-6 35.9 26.6 38.2 
5 5.0*10-4 6.4*10-6 28.1 22.5 30.3 
6 1.0*10-3 1.6*10-5 6.6 21.1 18.8 
7 1.0*10-2 1.1*10-4 4.1 4.1 21.4 
8 1.0*10-2 1.9*10-4 / / 4.3 
 
S5 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.7 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 59.4 63.1 74.3 
3 5.0*10-5 7.3*10-7 41.8 54.6 37.3 
4 1.0*10-4 1.7*10-6 31.2 42.4 28.1 
5 5.0*10-4 6.4*10-6 28.8 26.8 24.0 
6 1.0*10-3 1.6*10-5 13.3 32.9 8.1 
7 1.0*10-2 1.1*10-4 5.9 24.6 20.0 
8 1.0*10-2 1.9*10-4 12.8 14.4 / 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the 
enzyme solution; 1,2,3 (%) enzyme residual activity of each kinetics  
  
182 Experimental Part 
S6 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
 
IC50 : 1.09 ± 0.04µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 64.6 59.7 79.1 
3 5.0*10-5 7.3*10-7 57.6 51.5 53.7 
4 1.0*10-4 1.7*10-6 46.5 32.5 32.8 
5 5.0*10-4 6.4*10-6 40.5 27.2 30.7 
6 1.0*10-3 1.6*10-5 9.3 21.2 22.2 
 
S7 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.3 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 56.2 50.5 59.3 
3 5.0*10-5 7.3*10-7 36.8 45.2 40.8 
4 1.0*10-4 1.7*10-6 31.1 31.0 27.3 
5 5.0*10-4 6.4*10-6 18.5 30.3 30.3 
6 1.0*10-3 1.6*10-5 18.4 17.3 34.2 
7 1.0*10-2 1.1*10-4 4.2 25.1 20.7 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the enzyme 
solution; 1,2,3 (%) enzyme residual activity of each kinetics. 
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6.9.3.3 2-iminoDHPMs (N1-6, N8-12, N14-16) 
N1 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.5 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 4.9*10-8 78.7 81.0 95.6 
3 2.5*10-5 2.9*10-7 50.8 51.5 72.1 
4 5.0*10-5 7.7*10-7 49.6 31.5 32.3 
5 1.0*10-4 1.7*10-6 32.8 27.4 37.8 
6 5.0*10-4 6.4*10-6 27.0 26.0 27.0 
 
N2 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.3 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 4.9*10-8 82.1 83.4 85.8 
3 1.0*10-5 1.5*10-7 81.7 58.7 68.4 
4 2.5*10-5 3.9*10-7 70.7 65.0 55.0 
5 5.0*10-5 8.6*10-7 55.1 38.3 55.0 
6 1.0*10-4 1.8*10-6 58.7 32.4 40.5 
7 5.0*10-4 6.5*10-6 40.9 22.1 51.6 
 
N3 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.2 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 4.9*10-8 64.3 88.0 / 
3 1.0*10-5 1.5*10-7 53.5 48.2 / 
4 2.5*10-5 3.9*10-7 51.1 41.2 43.2 
5 5.0*10-5 8.6*10-7 39.9 33.7 33.5 
6 1.0*10-4 1.8*10-6 37.7 33.5 18.5 
7 5.0*10-4 6.5*10-5 26.5 26.0 15.5 
 
N4 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.5 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 5.0*10-6 4.9*10-8 76.8 62.9 66.6 
3 2.5*10-5 2.9*10-7 60.8 51.0 54.0 
4 5.0*10-5 7.7*10-7 43.1 43.6 46.2 
5 1.0*10-5 8.6*10-7 51.8 55.2 58.4 
6 5.0*10-4 5.6*10-6 35.7 30.2 31.9 
7 1.0*10-3 1.5*10-5 32.7 23.6 25.0 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the enzyme 
solution; 1,2,3 (%) enzyme residual activity of each kinetics.  
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N5 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.06 ± 0.19µM 
1 0 0 100.0 100.0 100.0 
2 5.0* 10-6 5.18* 10-8 80.5 59.5 95.8 
3 1.0*10-5 1.54* 10-7 66.1 76.8 56.6 
4 2.5*10-5 4.06* 10-7 44.8 58.2 42.4 
5 5.0*10-5 9.05* 10-7 46.8 42.6  
6 1.0* 10-4 1.89* 10-6 46.7 39.8 44.6 
7 5.0*10-4 6.80* 10-6 43.1 28.0 32.2 
8 1.0* 10-3 1.65*10-5 39.0 13.1 54.7 
9 1.0* 10-2 1.13* 10-4 25.2 11.2 2.6 
 
N6 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : Inactive 
1 0 0 100.0 100.0 100.0 
2 5.0* 10-6 5.18* 10-8 100.0 100.0 100.0 
3 1.0*10-5 1.54* 10-7 96.9 82.2 83.6 
4 2.5*10-5 4.06* 10-7 205.1 63.5 90.6 
5 5.0*10-5 9.05* 10-7 71.0 27.4 117.5 
6 1.0* 10-4 1.89* 10-6 77.8 23.9 65.4 
7 5.0*10-4 6.80* 10-6 70.2 68.5 34.4 
8 1.0* 10-3 1.65*10-5 -180.7 -51.5 -96.3 
9 1.0* 10-2 1.13* 10-4 0 0 -378.1 
 
N8 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.06 ± 0.19µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 95.8 56.4 81.0 
3 5.0*10-5 7.3*10-7 48.8 46.6 67.9 
4 1.0*10-4 1.7*10-6 39.9 40.7 37.2 
5 5.0*10-4 6.4*10-6 36.3 27.7 29.8 
6 1.0*10-3 1.6*10-5 31.1 24.5 22.9 
7 1.0*10-2 1.1*10-4 33.8 18.5 18.0 
8 1.0*10-2 1.9*10-4 1.9 3.3 0 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the enzyme 
solution; 1,2,3 (%) enzyme residual activity of each kinetics. 
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N9 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.30 ± 0.14µM 
1 0 0 100.00 100.00 100.00 
2 2.5*10-5 2.5*10-7 76.6 37.1 54.4 
3 5.0*10-5 7.3*10-7 68.9 30.9 40.4 
4 1.0*10-4 1.7*10-6 58.4 27.8 27.6 
5 5.0*10-4 6.4*10-6 47.3 22.6 24.0 
6 1.0*10-3 1.6*10-5 36.2 15.6 16.6 
7 1.0*10-2 1.1*10-4 27.5 11.5 12.9 
 
N10 addition 
N° 
[I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 1.5 ± 0.1µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 77.9 66.2 74.1 
3 5.0*10-5 7.3*10-7 56.8 63.7 68.9 
4 1.0*10-4 1.7*10-6 43.4 41.6 47.2 
5 5.0*10-4 6.4*10-6 36.0 30.4 34.9 
6 1.0*10-3 1.6*10-5 26.5 39.3 10.7 
 
N11 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 4.65 ± 0.68µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 115.1 50.2 81.0 
3 5.0*10-5 7.3*10-7 75.7 39.6 56.4 
4 1.0*10-4 1.7*10-6 58.5 40.2 59.5 
5 5.0*10-4 6.4*10-6 50.4 11.8 49.5 
6 1.0*10-3 1.6*10-5 56.1 19.4 46.6 
7 1.0*10-2 1.1*10-4 48.5 15.8 / 
8 1.0*10-2 1.9*10-4 / 24.2 27.7 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the enzyme 
solution; 1,2,3 (%) enzyme residual activity of each kinetics. 
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N12 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.72 ± 0.13µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 66.1 68.6 65.5 
3 5.0*10-5 7.3*10-7 45.5 85.6 50.5 
4 1.0*10-4 1.7*10-6 36.8 61.2 43.4 
5 5.0*10-4 6.4*10-6 47.0 53.1 34.8 
6 1.0*10-3 1.6*10-5 74.5 36.0 26.3 
7 1.0*10-2 1.1*10-4 42.7 22.4 12.0 
 
N14 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.28 ± 0.19µM 
1 0 0 100.0 100.0 100.0 
2 2.5*10-5 2.5*10-7 53.6 57.0 52.6 
3 5.0*10-5 7.3*10-7 34.9 38.6 39.9 
4 1.0*10-4 1.7*10-6 26.2 23.8 25.3 
5 5.0*10-4 6.4*10-6 9.5 26.1 20.2 
6 1.0*10-3 1.6*10-5 17.0 21.6 13.5 
7 1.0*10-2 1.1*10-4 8.6 6.5 9.1 
 
N15 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 0.69 ± 0.19µM 
1 0 0 100 100 100 
2 2.5*10-5 2.5*10-7 63.5 83.3 55.3 
3 5.0*10-5 7.3*10-7 48.9 73.0 50.2 
4 1.0*10-4 1.7*10-6 42.4 74.3 42.9 
5 5.0*10-4 6.4*10-6 28.4 61.5 34.2 
6 1.0*10-3 1.6*10-5 21.2 41.0 23.7 
7 3.00*10-3 4.37*10-5 21.6 36.0 20.4 
 
N16 Add. N° [I] [I]Int 1 (%) 2 (%) 3 (%) 
 
IC50 : 2.15 ± 0.82µM 
1 0 0 100.0 100.00 100.00 
2 2.5*10-5 2.5*10-7 78.9 70.3 77.2 
3 5.0*10-5 7.3*10-7 70.4 39.3 62.5 
4 1.0*10-4 1.7*10-6 48.6 29.8 55.3 
5 5.0*10-4 6.4*10-6 37.2 30.2 42.8 
6 1.0*10-3 1.6*10-5 38.2 23.6 37.5 
7 1.0*10-2 1.1*10-4 34.1 24.0 25.6 
Legenda: [I] concentration of the starting inhibitor solution; [I]Int concentration of inhibitor in the quarz cell in the enzyme 
solution; 1,2,3 (%) enzyme residual activity of each kinetics.  
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6.10 CNS penetration: In vitro Parallel artificial membrane permeability 
assay (PAMPA)-Blood brain barrier (BBB). 
PAMPA assay (parallel artificial membrane permeability assay) was used as 
preliminary evaluation of the brain penetration. The PAMPA-BBB method was 
described by Di et al, which employed a brain lipid porcine membrane.
 170
 
Test compounds (1-2 mg of Atenolol, Caffeine, Desipramine, Enoxacin, 
Hydrocortisone, Ofloxacin, Piroxicam, Testosterone, Promazine and Verapamil) 
were dissolved in EtOH (1500 µL) and 3500 µL of PBS pH=7.4 buffer were added 
to reach 30% of EtOH concentration in the experiment. Meanwhile the compounds 
to be determined (O10, S6, N3) were also dissolved in 1500 µL of EtOH and 3500 
µL of PBS pH=7.4 buffer.  
These solutions were filtered. 180 μL of each test compound solution and O10, S6, 
N3 solution were added to a 96-well plate and the UV spetra were determined. 
Subsequently 180 μL of PBS/EtOH (70/30) were inserted in each plate of the 
acceptor 96-well microplate. The donor 96-well plate was coated with 4 µL of 
porcine brain lipid in dodecane (20 mg mL
-1
) and after 5 minutes, 180 μL of each test 
compound solution and compound to be tested solution were added. Then the donor 
plate was carefully put on the acceptor plate to form a “sandwich”, which was left 
undisturbed for 2h and 30 min at 25 °C.  
During this time the compounds diffused from the donor plate through the brain lipid 
membrane into the acceptor plate. After incubation, the donor plate was removed. 
UV plate reader determined the concentration of compounds and commercial drugs 
in the acceptor and the donor wells. Every sample was analyzed at three to five 
wavelengths, in 3 wells and in two independent runs. Results are given as the mean 
[standard deviation (SD)] and the average of the two runs is reported. 10 quality 
control compounds (previously mentioned) of known BBB permeability were 
included in each experiment to validate the analysis set. 
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6.10.1 In vitro PAMPA-BBB assay to determine compound penetration into 
the brain 
The in vitro permeabilities (Pe) of commercial drugs through lipid membrane extract 
together with different compounds were determined (Equation 2) and described in 
Table 18 
 
 
Equation 2 permeability (Pe) 
 
Compound Bibl.
b
 Pe (10
-6
 cm s
-1
)
c
 Prediction 
Atenolol 0.8 0.2  0.3 CNS - 
Caffeine 1.3 0.3  0.2 CNS - 
Desipramine 12 7.0  0.4 CNS + 
Enoxacin 1.6 0.4  0.1 CNS - 
Hydrocortisone 2.4 1.0  0.3 CNS - 
Ofloxacine 0.8 1.5  0.2 CNS - 
Piroxicam 2.5 3.4  0.4 CNS + 
Promazine 8.8 9.7  1.1 CNS + 
Testosterone 17 14.9  0.6 CNS + 
Verapamil 16 18.8  0.1 CNS + 
O10  8.3  0.3 CNS + 
S6  9.8  1.0 CNS + 
N3  6.9  3.5 CNS + 
Table 18 Permeability (Pe 10
-6
 cm s
-1
) in the PAMPA-BBB assay for 10 commercial drugs (used in 
the experiment validation) and different compounds with their predictive penetration in the CNS
a 
( 
a 
PBS:EtOH (70:30) was used as solvent. 
b
Reference Di et al. 
c
Data are the mean ± SD of 2 
independent experiments). 
 
Vd: donor plate volume (180 µL) 
Vr: acceptor plate volume(180 µL) 
S: area (0.266 cm
2
) 
t: incubation time (s) 
  
189 Experimental Part 
The correlation between experimental-described values was obtained (R
2
= 0.898) 
(Figure 47). From this equation and following the pattern established in the literature 
for BBB permeation prediction
171
 we could classify compounds as CNS+ when they 
present a permeability > 3.9·10
-6
 cm s
-1
 and CNS– when they present a permeability 
< 2.1·10
-6
 cm s
-1
.  
 
Figure 47 Linear correlation between experimental and reported permeability of commercial drugs 
using the PAMPA-BBB assay. 
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